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The major neuropathological feature associated with tauopathies is the aggregation of 
the microtubule associated protein tau within neurons. Aberrant phosphorylation events 
on tau contribute to the aggregation during disease. The kinases and the phosphorylation 
sites on tau responsible for the generation of pathogenic tau forms are still unclear. My 
thesis proposes to establish a Drosophila model to investigate the human kinases and 
phosphorylation sites responsible for the generation of human tau toxicity. Expression 
of human tau in the photoreceptors of transgenic Drosophila leads to a degenerative 
phenotype proportional to the transcriptional level of the transgene. Since the genomic 
position of the transgene influences its expression, I used a novel method of 
transgenesis to insert the human tau transgene in a reproducible position within the fly 
genome. Using this system, tau isoforms differing for the presence of two N-terminal 
domains were shown to generate the same level of toxicity in the fly eye. Moreover, in 
contrast with other studies, the tauopathy-associated mutation R406W on human tau did 
not cause an enhancement of tau-mediated degeneration of the fly eye. Selected human 
kinases relevant to tau pathology were tested for their ability to enhance tau toxicity in 
flies. Only human GSK3β showed a robust enhancement of tau-mediated eye 
degeneration. For the first time I showed that a human kinase, GSK3β, could 
specifically phosphorylate human tau in Drosophila on sites not targeted by endogenous 
fly kinases. In particular, tau phosphorylation of T181, S396 and S404 was found to 
significantly increase upon GSK3β expression. Site-directed mutagenesis on tau 
suggested that S404 might play a central role in mediating human tau toxicity in the fly 
eye. Finally this thesis demonstrates that the Drosophila model of tauopathy here 
created can be used to assess the importance of human kinases and of single 
phosphorylated sites in the generation of tau toxicity. 
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Dementia is a progressive terminal condition affecting the elderly that damages 
memory, thinking, behaviour as well as the ability to perform everyday activities. After 
the age of 65, the likelihood of developing dementia doubles every five years. Currently 
36 million people are affected by dementia worldwide and this figure is steadily 
increasing. The number of people affected by dementia in Europe and USA is estimated 
to be 9.95 million and 4.38 million respectively (Wimo & Prince, 2010). The assistance 
and medical care for dementia patients represent a true economic burden for 
governments worldwide, in particular in Europe and USA. In 2050, the incidence of 
senile dementia and its related costs are expected to triple (Thies et al, 2011). 
 
Dementia is a collection of disorders characterised by a progressive cognitive decline 
causing functional impairments and generally affecting the ageing population over 65 
years old. The diagnosis of dementia is formulated on the basis of several criteria 
published in the Diagnostic and Statistical Manual of Mental Disorders (1994). 
According to the manual, the symptoms of dementia include a progressive decline in 
memory and cognitive abilities severe enough to interfere with daily life. The cognitive 
abilities usually affected include generating coherent speech, understanding spoken or 
written language, recognising objects, executing motor activities, thinking abstractly, 
making judgments, and carrying out complex tasks. Dementia can be caused by various 
diseases and conditions, among which the neurodegenerative pathologies are 
characterised by the progressive and irreversible deterioration of brain cells and their 
interconnections (Dickson et al, 2011; Josephs et al, 2011). There are four major types 
of neurodegenerative dementia conditions associated with distinct symptomatic patterns 
and different brain abnormalities, including Alzheimer's disease (AD), vascular 
dementia (VaD), Lewy body dementia, and frontotemporal lobar degenerations 
(FTLDs). Ultimately, the gradual worsening course of neurodegeneration leads to death 
caused by neuronal loss. 
 
AD is the most common type of dementia accounting for an estimated 60% to 80% of 
cases (Thies et al, 2011). The most common pattern of disease begins with a slow 
progressive decline in memory and, in later stages, with confusion, disorientation, 
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impaired communication and loss of motor function. The neuropathological hallmark of 
AD is the deposition of amyloid plaques and neurofibrillary tangles (NFTs), composed 
of β-amyloid (Aβ) and tau proteins, respectively (Braak & Braak, 1996; St George-
Hyslop, 2000). Vascular dementia is considered the second most common type of 
dementia (Thies et al, 2011). During disease, a series of small strokes block the arteries 
causing a reduction of blood flow to parts of the brain. Symptoms often overlap with 
those of AD, although memory may not be as seriously affected. Importantly, vascular 
disease may predispose some individuals to acquire AD, or may exacerbate its clinical 
course (Iadecola, 2010). In dementia with Lewy bodies, the pattern of neurological 
decline may be similar to AD, including memory and judgment impairments and 
behavioural changes. However, the progression is more rapid and also includes visual 
hallucinations, muscle rigidity and tremors. The molecular hallmark of this type of 
dementia is the pathogenic deposition of the α-synuclein protein leading to the 
formation of Lewy bodies inside neurons (Sonnen et al, 2010). FTLDs are characterised 
by a slow progression of degeneration affecting mainly the frontal and temporal lobes of 
the brain. Typical symptoms include changes in personality and behaviour as well as 
difficulty with language. The neuropathological features of FTLDs are associated with 
three proteins that independently contribute to disease: tau, the transactive response 
DNA binding protein of 43 kDa (TDP-43) and the tumour-associated protein fused in 
sarcoma (FUS) (Hutton et al, 1998; Kwiatkowski et al, 2009; Neumann et al, 2006). 
The FTLDs associated with tau (FTLDs-tau) consist of a group of diseases in which the 
major pathogenic mechanism  is the precipitation of highly phosphorylated tau 
aggregates in the brain leading to cell death (Dickson et al, 2011; Josephs et al, 2011). 
Increasing evidence from long-term studies indicates that many people with dementia 
have brain abnormalities associated with more than one type of dementia. Mixed 
dementia is characterised by the hallmarks of AD and another type of dementia, most 
commonly vascular dementia or dementia with Lewy bodies (Table 1.1) (Jellinger & 
Attems, 2007). 
 
No treatment is available to prevent or slow the neurodegeneration occurring during 
dementia. Current drugs temporarily slow the worsening of symptoms, however they 
are effective for only about half of the patients. Therefore, understanding the underlying 




 Prevalence Clinical symptoms Neuropathological features Aggregated protein 
Alzheimer's disease 60-80% Memory loss, confusion, behavioral changes, language impairment 
Deposition of amyloid plaques and 
neurofibrillary tangles Aβ and tau proteins 
Vascular dementia 17% Mild memory loss, confusion, behavioral changes, language impairment Small strokes in the brain arteries - 
Lewy body dementia 10% 
Memory loss, confusion, behavioral 
changes, language impairment, visual 
hallucinations, muscle tremors 
Deposition of Lewy bodies α-synuclein 
FTLDs-tau 5% 
Psychosis, severe behavior and 
language disturbances, cognitive 
dysfunction, motor symptoms 
Deposition of tau aggregates Tau protein 
Mixed dementias 5% Alzheimer’s disease with Lewy bodies or vascular dementia 
Deposition of tau aggregates and Lewy 
bodies or strokes in the brain arteries 
Tau protein only 
or with α-synuclein 
 
 
Table 1.1 Neurodegenerative dementias. The main types of dementia with neurodegenerative pathologies are listed together with their 
prevalence, clinical symptoms, neuropathological features and types of protein aggregates present. 
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1.2 Protein aggregation and neurodegeneration 
 
Although dementia disorders affect different brain regions and lead to different 
symptomatic patterns, the neurodegenerative process presents common features 
(Jellinger, 2011). The cellular and molecular mechanisms in common between the 
dementia disorders are the toxic protein aggregation and inclusion body formation in 
selected areas of the brain. The pathologies characterised by protein aggregation and 
accumulation are also referred to as proteinopathies (Golde & Miller, 2009; McMillan 
& Leverenz, 2010). Accumulation of misfolded, aggregated proteins in the brain 
triggers a complex series of events that result in neuronal degeneration and death (Ross 
& Poirier, 2004). Although protein inclusions have been shown to contribute to 
neurodegeneration in dementia, the mechanisms leading to neuronal toxicity are still 
unclear. Proteins widely known to aggregate and accumulate in the brain of patients 
affected by dementia are Aβ, tau and α-synuclein. During AD, the deposition of the Aβ 
protein and tau has been demonstrated as key pathogenic triggers for neurodegeneration 
(Hardy & Allsop, 1991). Moreover, misfolding and subsequent aggregation of α-
synuclein play a central role in the pathogenesis of Lewy body dementia and other 
synucleinopathies (Uversky, 2007). Finally, the aggregation and precipitation of tau 
alone has been shown to be the major pathogenic event in the neurodegenerative 
process of FTLDs-tau (Lee et al, 2001). 
 
Proteins involved in neurodegenerative processes are natively unfolded, however, 
during disease they aggregate and precipitate. The protein deposits found in dementia 
brains are characterised by the same abnormal structural conformation including 
amyloid fibrils (Ross & Poirier, 2004). Amyloid fibrils consist of insoluble filamentous 
aggregates containing misfolded protein with β-sheet formation (Sunde & Blake, 1998). 
The most extensively characterised amyloid fibril is the one formed by the Aβ peptide 
implicated in AD (Török et al, 2002). During aggregation, tau often adopts higher 
structures, in particular β-structures, although it normally exists as an unstructured 
protein due to a high percentage of hydrophilic residues (Jeganathan et al, 2008). Also, 
similar fibrils are formed by α-synuclein (Der-Sarkissian et al, 2003). The detailed 
structure of amyloid fibrils and their assembly are still unknown, however it has been 
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noticed that the structures of different kinds of disease-related protein aggregates share 
considerable similarities. 
 
Protein aggregation is a complex process involving the formation of oligomeric 
intermediates that go on to form aggregated fibers. In many dementia disorders, 
aggregation intermediates have also been observed to confer toxicity in neurons. These 
small aggregated structures are known as oligomers and they are usually highly stable, 
diffusible and non-fibrillar (Gadad et al, 2011). Most commonly they initiate the 
impairment of neuronal transmission and functioning at the synaptic site (Schulz-
Schaeffer, 2010; Takahashi et al, 2010). It is thought that the toxic oligomers are 
sequestered in larger polymers leading to the formation of inclusion bodies and 
extracellular deposits (Lansbury & Lashuel, 2006). However, the role that the 
oligomeric intermediates and the large insoluble deposits play in synaptic and 
mitochondrial dysfunction, neuronal apoptosis and cell death is still debated (Jellinger, 
2011). These inclusions and aggregates result from a molecular cascade of events 
probably caused by an imbalance between protein synthesis, aggregation and clearance 
(Gadad et al, 2011). The pathogenic mechanism of the intermediate aggregation is still 
unclear, however, aggregated soluble non-fibrillar intermediates with similar size and 
morphology exist in Aβ, tau and α-synuclein pathologies. 
 
The initiation of protein misfolding in a cell may be a stochastic event, however, several 
factors may facilitate protein aggregation during dementia. Recent studies suggest that 
propagation of misfolded protein might occur in neurodegenerative diseases, including 
AD, Lewy body dementia and FTLDs-tau and this might contribute to the spreading and 
progression of the disease (Frost & Diamond, 2010; Jucker & Walker, 2011; Lee et al, 
2010). The formation of protein aggregates catalyses the structural conversion of the 
normally folded proteins into additional aggregates via a process of seeded 
polymerisation. For instance, extracellular Aβ and α-synuclein oligomers can induce 
intracellular aggregation of the same proteins (Danzer et al, 2009; Rosen et al, 2011). 
Moreover, also tau aggregates can induce normal tau to aggregate (Guo & Lee, 2011). 
Furthermore, post-translational modification of dementia proteins may facilitate their 
aggregation and precipitation. Oxidative stress causing protein modification is increased 
with age, one of the major risk factors for dementia (Sultana & Butterfield, 2010). For 
example, aggregation of α-synuclein has been shown to be facilitated by oxidative 
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modifications (Giasson et al, 2000). Another important post-translational modification 
promoting protein aggregation is phosphorylation. In Lewy body dementia, α-synuclein 
has been found to be extensively phosphorylated on S129 and this phosphorylation 
event appears to accelerate the formation of inclusions during disease (Iwatsubo et al, 
1996; Spillantini et al, 1997). Aberrant phosphorylation events are also implicated in 
AD and FTLDs-tau leading to tau hyperphosphorylation and aggregation in NFTs or 
other types of tau deposits (Lee et al, 2001). The pathological cascade of protein 
aggregation can also be triggered by mutations in a number of genes that increase the 
likelihood of accumulation of protein aggregates (Bertram & Tanzi, 2005). In AD, 
many genetic mutations have been identified to increase Aβ aggregation into amyloid 
plaques (Hashimoto et al, 2000). Moreover, several mutations in the tau gene have been 
associated with specific forms of FTLDs-tau and increase its likelihood to aggregate 
into filaments (Spillantini et al, 1998; van Swieten & Spillantini, 2007). 
 
Protein misfolding and aggregation represent important aspects of the 
neurodegenerative process that occur during the pathogenesis of dementia. Investigating 
common pathological mechanisms that underlie neurodegeneration in dementia could 
lead to the discovery of therapeutic targets common to several dementia conditions. The 
aggregation of the tau protein is a neuropathological feature of great importance in the 
pathogenic mechanisms underlying AD and FTLDs-tau. For this reason the subset of 
dementia disorders characterised by the deposition of tau aggregates are also known as 
tauopathies. Tau is a microtubule-associated protein (MAP) whose function is regulated 
by several post-translational modifications, including phosphorylation. However, in 
tauopathy brain aberrant phosphorylation events contribute to the formation of tau 
deposits in neurons and glia that lead to neurodegeneration and ultimately cell death. 
The full inventory of kinases involved in the hyperphosphorylation of tau, and their 
pathogenic sites of phosphorylation, is still unknown. In recent years, investigations 
have focused on identifying the pathogenic kinases involved in tau 
hyperphosphorylation, since these enzymes could be targets for new therapies that 





1.3 The structure of tau 
 
Tau proteins belong to the MAP family that binds to and stabilises microtubules. It was 
first described by Weingarten et al (1975) as a heat-stable protein essential for 
microtubule assembly. In porcine brain, tau was found to be present in association with 
tubulin and in vitro experiments showed that tau is necessary for tubulin assembly into 
microtubules (Weingarten et al, 1975). 
 
Tau is encoded by a single-copy gene located on the long arm of chromosome 17 
(17q21.1) in humans (Goedert et al, 1988; Himmler, 1989; Neve et al, 1986). The tau 
primary transcript contains sixteen exons, the majority of which are constitutively 
expressed, while exons 2, 3 and 10 are alternatively spliced (Figure 1.1). In adult human 
brain, alternative splicing generates six tau isoforms ranging from 352 to 441 amino 
acids in length. Exons 2 and 3 encode two amino (N)-terminal inserts in tau, each 
characterised by a highly acidic twenty-nine amino acid sequence. Alternative splicing 
generates tau isoforms carrying either no N-terminal insert (0N, exons 2 and 3 absent), 
one N-terminal insert (1N, exon 2 present) or two N-terminal inserts (2N, exons 2 and 3 
present). Exons 9, 10, 11 and 12 are responsible for encoding four repeated regions in 
the carboxy (C)-terminal half of tau, characterised by conserved repeats of eighteen 
amino acids separated by less well-conserved fourteen amino acid sequences. 
Alternative splicing of exon 10, encoding the second C-terminal repeat, generates tau 
isoforms carrying three (3R) or four (4R) C-terminal repeats (Andreadis, 2005; 
Andreadis et al, 1992; Buee et al, 2000; Goedert & Jakes, 1990; Goedert et al, 1988). 
 
The N-terminal region of tau functions as projection domain as it forms a link between 
the microtubule surface and the neural plasma membrane, other cytoskeletal elements 
and cytoplasmic organelles (Buee et al, 2000). Tau also binds to microtubules through 
its C-terminal repeats promoting their polymerisation and stabilisation. Splicing in of 
exon 10 creates tau isoforms with an extra microtubule-binding domain (4R tau) that are 
able to bind to microtubules more effectively than 3R tau, thereby stabilising them more 
effectively (Goedert & Jakes, 1990; Goode et al, 1997; Gustke et al, 1994). This is an 
important feature of tau because the differential stabilising abilities of 3R and 4R tau 
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isoforms are likely to contribute significantly to the level of plasticity in the brain 
(Ballatore et al, 2007; Buee et al, 2000). 
Tau alternative splicing is regulated during development such that only the shortest tau 
isoform (0N3R) is expressed in embryonic stages and this continues to be expressed 
during adulthood. During early development, the high requirement for plasticity enables 
the formation of the various brain regions and their connections. At this stage, exclusive 
expression of the weaker microtubule-binding 3R tau is an advantage (Buee et al, 2000; 
Takuma et al, 2003). In contrast, expression of the other five isoforms of tau (1N3R, 
2N3R, 0N4R, 1N4R and 2N4R) in the central nervous system (CNS) is specific to adult 
brain. During adulthood, the majority of tau isoforms contain a single N-terminal insert 
(1N), while the ratio of 3R:4R isoforms is approximately one. It is unclear how the 
different microtubule-binding affinities of the various tau isoforms affect their 







N-terminal domains Proline-rich region C-terminal repeats
Figure 1.1 Human tau isoforms. Alternative splicing generates six tau isoforms ranging 
from 352 and 441 amino acids in length in adult human brain. These variants differ from 
each other by the number of N-terminal domains (2N, 1N or 0N, shown in blue) or 
C-terminal repeats (3R or 4R, shown in red) present in the protein. The N-terminal part 
of tau includes highly acidic twenty-nine amino-acid inserts (N) and a proline rich region. 
The C-terminal part of tau is characterised by conserved eighteen amino acids repeats 
(R) separated by  fourteen amino acids fragments.
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1.4 Tau function 
 
In humans, MAPs are found in the majority of cell types, although tau is predominantly 
expressed in neurons (Buee et al, 2000). In glial cells, tau proteins are found mainly 
during pathological conditions, however, it is possible to detect tau mRNA and proteins 
in several peripheral tissues such as heart, kidney, lung, muscle, pancreas, testis, as well 
as in fibroblasts (Chin & Goldman, 1996; Ingelson et al, 1996; Vanier et al, 1998). 
Within neurons, tau is mainly localised to the axon where its primary function is to bind 
to and stabilise microtubules and to interact with other elements in the cell (Kanai et al, 
1992). 
 
The N-terminal inserts in tau are crucial for stabilisation and organisation of axons. 
These regions of tau extend from the microtubule surface to interact with other 
cytoskeletal elements forming the projection domain of the tau protein (Hirokawa et al, 
1988). Thus, alternative splicing of exons 2 and 3 produces projection domains 
characterised by different lengths. It has been suggested that the size of the projection 
domain determines spacing of axonal microtubules and hence axonal diameter (Chen et 
al, 1992). Peripheral neurons, that typically project long axons with a large diameter, 
carry an additional N-terminal tau sequence encoded by exon 4A (Andreadis et al, 
1992). The projection domain of tau protein also binds to spectrin and actin filaments 
(Carlier et al, 1984; Correas et al, 1990). This interaction allows microtubules to 
interconnect with other cytoskeletal components, such as neurofilaments, and may 
restrict the flexibility of the microtubules (Leterrier et al, 1982; Matus, 1994). 
Moreover, there is evidence that tau proteins interact with cytoplasmic organelles, such 
as mitochondria, endoplasmic reticulum, Golgi and the neural plasma membrane 
(Pooler et al, 2012). 
 
Finally, tau may also play a role in the signal transduction pathway, in particular src-
tyrosine kinase signalling. Tau protein can be phosphorylated by members of the src-
family of tyrosine kinases, such as fyn, syk, c-Abl, lck and arg (Lebouvier et al, 2009; 
Scales et al, 2011). Phosphorylation of tau on T231 has been shown to reduce tau 
binding to the SH3 domain of fyn (Lee et al, 1998; Lee et al, 2004; Reynolds et al, 
2008). 
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Through its C-terminal repeats, tau is able to bind to microtubules, to promote tubulin 
polymerisation, neurite outgrowth and axonal transport. The inter-region between the 
first and the second microtubule-binding region (R1-R2) is characterised by a high 
affinity for microtubule-binding and therefore it induces a high level of tubulin 
polymerisation. This R1-R2 inter-region is unique to 4R tau and confers a significantly 
increased microtubule-binding affinity to 4R tau compared to 3R tau (Goedert & Jakes, 
1990; Goode et al, 1997; Gustke et al, 1994). Moreover, tau is important for the 
generation and maintenance of neurites in vitro (Yoshizaki et al, 2004). The binding of 
tau to microtubules within neurites is a critical step in the formation of the axon since it 
may promote additional binding and lead to neurite elongation (Ferreira et al, 1989). 
Neurite growth is directly modulated by changes in tau expression in cerebellar rat 
neurons in vitro (Caceres et al, 1991). In addition, tau plays a role in inhibition of 
kinesin-dependent fast axonal transport. The interference of tau with the ability of the 
kinesin motors to attach to microtubules has been demonstrated to be mediated by 
phosphorylation (Cuchillo-Ibanez et al, 2008; Mandelkow et al, 2003; Stamer et al, 
2002). The microtubule-binding region may also be involved in functions other than 
microtubule assembly and growth. It might play an important role in development. In 
order to carry out this role, tau is specifically transported to the nucleus where it can 
bind RNA through its microtubule-binding domain (Brady et al, 1995; Kampers et al, 
1996; Thurston et al, 1996). 
 
 
1.5 Regulation of tau function by phosphorylation 
 
In order to carry out its physiological function, the tau protein undergoes several post-
translational modifications, in particular phosphorylation is known to regulate tau 
binding to microtubules (Lindwall & Cole, 1984). Phosphorylated tau reduces 
microtubule polymerisation compared to dephosphorylated tau. Inside neurons, tau 
exists in different phosphorylation states resulting from the activity of specific kinases 
and phosphatases. Although there are 85 sites that can be potentially phosphorylated on 
tau (45 serines, 35 threonines and 5 tyrosines), only 17 of these have been demonstrated 
so far to be phosphorylated on tau extracted from brain tissue from deceased healthy 
humans (Hanger et al, 2009). 
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Tau kinases phosphorylating serines and threonines can be broadly divided into two 
subgroups: the proline-directed kinases and the non-proline-directed kinases. Most of 
the kinases involved in tau phosphorylation are part of the proline-directed protein 
kinases targeting serine/proline and threonine/proline motifs on tau. These kinases 
phosphorylate tau at a large number of common residues and include mitogen activated 
protein kinase (MAPK), glycogen synthase kinase 3β (GSK3β) and cyclin-dependent 
kinases such as cdk5 (Baumann et al, 1993; Drewes et al, 1992; Hanger et al, 1992). 
The non-proline directed kinases phosphorylate tau within KXGS motifs present in the 
microtubule-binding domain. These kinases include microtubule affinity regulating 
kinase (MARK), Ca2+/calmodulin-dependent protein kinase II (CaMKII), cyclic-AMP-
dependent kinase (PKA) and casein kinase 1 (CK1) (Baudier & Cole, 1987; Drewes et 
al, 1997; Jicha et al, 1999; Singh et al, 1995). In addition fyn, syk, c-Abl, lck and arg 
are thought to be the kinase responsible for tyrosine phosphorylation of tau (Lebouvier 
et al, 2009; Scales et al, 2011). 
 
The activity of kinases is counterbalanced by phosphatases in the regulation of the 
phosphorylation status of tau. Protein phosphatases (PP) 1, 2A and 2B have been shown 
to dephosphorylate tau on different S/T residues in vitro (Liu et al, 2005; Yamamoto et 
al, 1988). In particular, PP2A activity on tau is much higher than the other phosphatases 





The term tauopathies refers to a collection of neurodegenerative disorders in which tau 
pathology is considered the major factor contributing to degeneration. In tauopathies, 
hyperphosphorylation of the tau protein leads to the formation of intraneuronal 
inclusions (Lee et al, 2001). The most common tauopathy is AD, while less frequent 






1.6.1 Alzheimer’s disease 
 
AD is the most common cause of senile dementia in humans. Patients affected by this 
pathology present symptoms characterised by progressive cognitive deterioration 
beginning with mild memory loss, behavioral changes and a decrease in everyday 
activities. With the progression of the condition, the clinical symptoms affect multiple 
cognitive and behavioral aspects such as language, learning, reasoning, attention, 
problem solving, emotion and memory (Walsh and Selkoe, 2004). 
 
Amyloid plaques and NFTs are now widely accepted as the main pathological features 
that contribute to the neurodegenerative process in AD. Amyloid plaques are 
extracellular accumulations of the Aß peptide produced by cleavage of the amyloid 
precursor protein (APP), while NFTs are composed of intracellular depositions of 
hyperphosphorylated tau protein (Braak & Braak, 1996; St George-Hyslop, 2000). The 
APP gene is located on chromosome 21 and encodes for a transmembrane protein 
comprising a large extracellular and a short intracellular domain (Thinakaran & Koo, 
2008). In healthy neurons the extracellular domain of APP undergoes a series of 
proteolytic cleavages by α-secretases, β-secretases and by the γ-secretase/presenilin 
complex (Wilson et al, 2003). During AD, the APP transmembrane protein undergoes 
an abnormal cleavage resulting in the release of Aβ1-40 and Aβ1-42. Aβ1-40 is the 
most common Aβ species, while Aβ1-42 is less abundant but the primary species found 
in Aβ plaques in AD brain (Evin et al, 2003). The formulation of the amyloid cascade 
hypothesis suggests that the aberrant processing of APP leading to the production of Aβ 
is the initial cause of the pathological processes in AD and that this precedes the 
formation of tau tangles. Abnormal processing of APP and subsequent elevated Aβ 
levels are thought to trigger NFT formation which then leads to terminal degeneration 
of the affected neurons, giving rise to the clinical symptoms (Hardy & Higgins, 1992; 
Selkoe, 1991). Mutations in the APP gene or in the presenilin genes affect the 
metabolism and production of Aβ1-42 and cause rare early-onset familial AD 
accounting for only 10% of cases (Hashimoto et al, 2000). Intracellular soluble Aβ 
species may also be important in the pathogenesis of AD. The release of toxic Aβ 
species can occur in the intracellular space since APP is found on the membrane of 
organelles such as the Golgi network, endoplasmic reticulum and lysosomal, endosomal 
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and mitochondrial membranes (Mizuguchi et al, 1992; Xu et al, 1995). 
 
The second neuropathological feature of AD is the deposition of intracellular NFTs 
made of hyperphosphorylated tau protein. These aggregated filaments are composed of 
an equimolar ratio of 3R and 4R tau isoforms (Goedert et al, 1992). These intracellular 
depositions can be distinguished as either paired helical filaments (PHFs) or straight 
filaments. PHFs are composed of two strands of filaments twisted around one another 
similar to a helix, while straight filaments lack the helical shape. Both of these 
intracellular inclusions are composed predominantly of insoluble, abnormally highly 
phosphorylated tau and are thought to be responsible for neuronal death (Crowther, 
1991; Iqbal et al, 1984; Mandelkow et al, 2007). Tau hyperphosphorylation occurs on 
many residues that are not phosphorylated in healthy neurons and also on usually 
phosphorylated residues at a much higher stoichiometry (Hanger et al, 2009). The 
abnormal phosphorylation of tau leads to neurodegeneration by deposition of NFTs, 




1.6.2 Frontotemporal lobar degenerations 
 
The frontotemporal lobar degenerations (FTLDs) are a group of dementia disorders 
sharing common clinical symptoms and molecular features of pathogenesis. In contrast 
with AD, which presents predominantly as memory loss, the clinical symptoms of 
FTLDs are associated with changes in personal and social conduct, severe behavioural 
and language disturbances, and motor symptoms with cognitive dysfunction appearing 
later (Neary et al, 1998). The neurodegeneration process in FTLDs affects the frontal 
and temporal lobes of the brain leading to cortex atrophy, neuronal loss and gliosis. The 
molecular pathogenesis is caused by an abnormal protein deposition that differs for 
protein type, inclusion morphology and distribution depending on the disease (Josephs, 
2008). Three proteins have been identified to be independently responsible for the 
mechanism of neurodegeneration in FTLDs: tau, the transactive response DNA binding 
protein of 43 kDa (TDP-43) and the tumour-associated protein fused in sarcoma (FUS) 
(Hutton et al, 1998; Kwiatkowski et al, 2009; Neumann et al, 2006). 
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The FTLDs associated with tau (FTLDs-tau) consist of a group of diseases in which the 
major pathogenic mechanism involves the microtubule-associated protein tau. The 
FTLDs-tau pathologies include frontotemporal degeneration with parkinsonism linked 
to chromosome 17 (FTDP-17), Pick’s disease (PiD), progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD), argyrophilic grains disease (AGD), sporadic 
multisystem tauopathy with globular inclusions (MST) and diffuse neurofibrillary 
tangle dementia with calcifications (DNTC) (Bigio et al, 2001; Braak & Braak, 1989; 
Dickson, 1999; Dickson, 2001; Kosaka, 1994; Wszolek et al, 2006). 
 
 
1.6.2.1 Frontotemporal dementia with parkinsonism linked to chromosome 17 
 
Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP- 17) is a 
form of dementia caused by autosomal-dominant mutations in the tau gene leading to 
the formation of abundant tau inclusions in neurons and/or glia cells. These exonic and 
intronic mutations in the tau gene were first identified by Hutton et al (1998) in FTDP-
17 patients. The pathogenic mutations identified in the tau gene can be grouped 
according to their positions in the gene, which also defines the resultant pathology. 
Moreover, depending on their nature, tau mutations can have multiple effects including 
alteration of microtubule assembly, promotion of tau filament formation and alteration 
of tau mRNA splicing and isoform expression. 
 
Tau gene mutations include missense, deletion and silent mutations and the majority of 
these are found in the coding region of tau. Most coding region mutations are located in 
the microtubule-binding region of tau and several of these lead to a reduction in the 
affinity of tau for microtubules, therefore decreasing the ability of mutant tau to 
promote microtubule assembly (Dayanandan et al, 1999; Hong et al, 1998). For 
example, the missense mutations P301L and P301S, are included in exon 10 encoding 
the second microtubule-binding region of tau. In particular, the P301L mutation causes 
the selective incorporation of 4R into tau inclusions only in brain regions affected by 
FTDP-17 (Hong et al, 1998). Other mutations are thought to introduce or remove 
potential phosphorylation sites that could lead to functional changes in the microtubule-
binding properties of tau (Hasegawa et al, 1998). In addition, a large number of 
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missense mutations are located outside exon 10, examples include G272V, V337M, 
G389R and R406W (Hutton et al, 1998). 
 
In contrast, intronic mutations in the tau gene are located close to the splice-donor site 
of the intron downstream of exon 10. These mutations affect exon 10 splicing, leading 
to an altered expression of 3R and 4R tau isoforms (D'Souza et al, 1999; Giaccone et al, 
2005; Hong et al, 1998; van Swieten et al, 2007). Importantly, several mutations result 
in increased expression of 4R tau and the formation of tau deposits consisting mainly of 
4R tau, such as N279K (Grover et al, 2003). The most prevalent familial tau mutation 
leading to FTDP-17 appears to be P301L (Bird et al, 1999; Kodama et al, 2000; Mirra et 
al, 1999; Rizzu et al, 1999; Tanaka et al, 2000; Zekanowski et al, 2003). Additional 
mutations have often occurred as independent events in several families, including 
R406W. The R406W mutations in tau leads to a slow rate of disease progression lasting 
up to 25 years, compared to an expected duration of illness of 10 years (Rademakers et 
al, 2003) seen for other mutant forms. 
 
 
1.6.2.2 Pick’s disease 
 
Pick’s disease (PiD) is a rare cause of frontal lobe dementia usually associated with a 
presenile dementia with age of onset younger than 65 years (Kertesz, 2010). The 
neuropathological feature characteristic of PiD is the presence of intra-neuronal 
inclusions enriched in hyperphosphorylated 3R tau, also known as Pick bodies (Buée & 
Delacourte, 1999; de Silva et al, 2006). These tau depositions are characterised by a 
rounded appearance and are localised in the cytoplasm of neurons (Dickson, 2001). 
Differences in the molecular composition of the tau deposits are linked to differences in 
their argyrophilic properties in reducing silver. The Pick bodies are strongly 
argyrophilic using the Campbell-Switzer method that is related to deposits containing 
3R tau, while those staining with Gallyas are linked to those containing 4R tau 
(Uchihara et al, 2005). Finally familial cases of PiD have been confirmed to be caused 
by mutations in the tau gene (Bronner et al, 2005; Murrell et al, 1999). In particular, the 
G272V mutation and other tau mutations in exons 9 and 11-13 cause hereditary Pick's 
disease and affect the biochemical composition of Pick bodies. 
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Levels of soluble tau are higher in PiD compared to AD, however, its phosphorylation 
levels are lower compared to AD (van Eersel et al, 2009). The two disorders also 
display a different phosphorylation profile on specific residues. In PiD, soluble tau is 
not highly phosphorylated on S396, S404 and S422 compared to AD, whereas the 
pT181 epitope displays more prominent phosphorylation in PiD compared to AD (van 
Eersel et al, 2009). In addition, PiD is characterised by dephosphorylation of S262 
(Bronner et al, 2005). 
 
 
1.6.2.3 Progressive Supranuclear Palsy and Corticobasal Degeneration 
 
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are 
associated with a variety of clinical symptoms arising from the different distribution of 
the pathology rather than different histopathologic appearance of the pathology.  
Both PSP and CBD present with neuronal, oligodendroglial, and astrocytic lesions 
characterised by the deposition of hyperphosphorylated 4R tau aggregates (Chambers et 
al, 1999). The differences in these two disorders are in the morphology and proportion 
of the toxic lesions (Dickson, 1999; Komori et al, 1998). The tau inclusions 
characterising PSP are large, globular deposits and the astrocytic lesions are represented 
by tuft-shaped aggregates (Yamada et al, 1992). In contrast, CBD pathology presents 
with fewer oligodendroglial inclusions and a specific type of astrocytic lesions, known 
as astrocytic plaques (Feany & Dickson, 1995). 
 
PSP and CBD show a differential production of low molecular weight tau fragments 
found in 4R tau isoforms only, suggesting the occurrence of different proteolytic events 
(Arai et al, 2004). A 35 kDa tau fragment lacking of the N-terminus region of the 
protein is predominant in PSP brains, while in CBD brains the 37 kDa tau species are 
more common (Arai et al, 2004; Wray et al, 2008). The number of phosphorylated 
residues on tau identified in PSP brains is substantially lower than that in AD brains 
(Table 1.3) (Wray et al, 2008). Genome-wide association analyses of PSP and CBD 
patients have demonstrated that these pathologies might have common genetic risk 
factors in the H1 haplotype, a region of complete linkage disequilibrium encompassing 
the entire coding sequence of tau and several other genes (Conrad et al, 1997; Di Maria 
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et al, 2000; Pittman et al, 2006; Pittman et al, 2004). Very recently novel genetic risk 
factors for PSP have been associated with the STX6 gene involved in the vesicle fusion 
at the Golgi, the EIF2AK3 gene for the endoplasmic reticulum unfolded protein 
response and the MOBP gene for a myelin structural component (Höglinger et al, 2011). 
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 Brain regions Clinical symptoms Tau aggregates Cell types Tau isoforms 
3R:4R 
ratio 
AD Cortex and limbic lobe Memory loss, confusion, behavioural 
changes, language impairment 
NFTs (helical or straight 
filaments) 
Neurons 3R, 4R 1:1 
FDTP-17 Fronto-temporal cortex, 
basal ganglia, brainstem 
Psychosis, severe behaviour and 
language disturbances, cognitive 
dysfunction, motor symptoms 
AD-like filamentous 
inclusions 
Neurons, glia 3R, 4R 1:2 
1:1 
2:1 
PiD Fronto-temporal cortex, 
limbic lobe 
Psychosis, severe behaviour and 




Neurons, glia 3R 3:1 
PSP Basal ganglia, 
brainstem, cerebellum 
Atypical motor dysfunction, vision 
impairment, mild cognitive 
dysfunction 







CBD Fronto-temporal cortex, 
basal ganglia 
Atypical motor dysfunction, language 
disturbances, mild cognitive 
dysfunction 









Table 1.2 Main tauopathies. The major types of tauopathies are listed together with the brain regions affected, their clinical symptoms, the 
types of tau aggregates present, the cell types affected, the tau isoforms composing the aggregates and the proportion of tau isoforms present 
in the brain. 
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1.7 Pathogenic tau post-translational modifications 
 
The physiological function of tau is predominantly regulated by post-translational 
modifications. Disruption to these modifications on tau might play a central role in tau 
dysfunction and aggregation in the tauopathies. Therefore, understanding the post-
translational regulation of tau may be essential to identify the origin of tau aggregate 
formation (Buee et al, 2000). 
 
 
1.7.1 Tau hyperphosphorylation 
 
The normal physiological activity of tau to bind microtubules within neurons is 
regulated by specific phosphorylation events (Lindwall & Cole, 1984). However, there 
is growing evidence that during tauopathies the normal regulatory role of 
phosphorylation may be disrupted leading to disease. It is thought that a series of 
aberrant phosphorylation events contribute to the formation of tau aggregates which 
sequester tau  away from its physiological function and allow precipitation in  neurons 
leading to toxicity (Alonso et al, 2001; Ballatore et al, 2007; Lauckner et al, 2003). 
Whether hyperphosphorylation of tau is due to an increase of tau kinase activity or to a 
decrease in the activity of tau phosphatases is still debated. It is unclear if the 
pathological tau kinases correspond to those regulating the physiological function of tau 
or if new kinases participate in the aberrant tau phosphorylation in disease. In addition, 
previous work demonstrates that phosphatase activity, in particular PP2A, is decreased 
in AD brains (Gong et al, 1993; Liu et al, 2005). Another possibility is that tau might 
become a better substrate for phosphorylation through an altered conformation or 
mislocalisation. In healthy neurons tau is localised to the axon, however in brains 
affected by tau pathology tau is mislocalised to the somatodendritic compartments 
(Hoover et al, 2010). 
 
The pathogenic hyperphosphorylation events on tau result in the attachment of 3 to 5 
times more phosphate compared to tau in physiological condition (Ksiezak-Reding et al, 
1992). This difference plays a critical role during pathogenesis because it alters the 
microtubule-binding affinity of tau. Indeed, the tau protein becomes 
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hyperphosphorylated often within its microtubule-binding domains, reducing the ability 
to bind to microtubules (Amniai et al, 2009; Ballatore et al, 2007; Iqbal et al, 2009). 
During pathogenesis, the aberrant phosphorylation events lead to the formation of tau 
depositions that precipitate in neurons. There are a number of ways in which these 
neuronal deposits may cause cell death. The intracellular deposition of tau filaments 
may form a physical impediment that compromises cellular functions including 
distribution and number of organelles as well as proteasome activity (Ballatore et al, 
2007; Iqbal et al, 2009). In addition, the sequestration of tau into aggregates causes the 
destruction of the microtubule network and consequently affects axonal transport and 
synaptic integrity (Morfini et al, 2009; Terry et al, 1991). Phosphorylation of tau is 
known to decrease the affinity of tau for microtubule-binding resulting in the 
detachment of tau from microtubules that no longer polymerise (Amniai et al, 2009). 
Microtubules together with kinesins are essential in the anterograde axonal transport 
that enables essential components to travel from their sites of synthesis in the cell body 
to synaptic locations along the axon (Dixit et al, 2008). As shown by cell culture 
studies, phosphorylated tau leads to the inhibition of anterograde axonal transport due to 
interference with kinesins (Stamer et al, 2002). Therefore, the relationship between 
axonal transport and tau is closely associated with the phosphorylation status of tau. 
Moreover, expression of tau in cultured neurons causes drastic changes in dendritic 
spine morphology leading to synapse loss and cell death (Hall et al, 2000). In vivo 
experiments have shown that human tau aggregation results in an age-dependent 
perturbation in basal synaptic transmission in areas of the brain associated with 
neurodegeneration (Polydoro et al, 2009). 
 
 
1.7.2 Other post-translational modifications of tau 
 
Beyond phosphorylation, the tau protein also undergoes other post-translational 
modifications, some of which have been postulated to have roles in the formation of 
pathogenic tau tangles (Buee et al, 2000; Gong et al, 2005). 
 
Firstly, tau glycosylation is implicated in PHF formation and stabilisation during 
disease. N-glycosylation of tau occurs only during disease and leads to the stabilisation 
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of the PHF conformation of tau (Wang et al, 1996). In contrast, O-glycosylation is 
thought to modulate tau function in healthy neurons by the addition of an O-linked N-
acetylglucosamine residue on serines or threonines in the proximity of proline residues 
(Haltiwanger et al, 1992). O-glycosylation of tau has been suggested to mediate the 
interactions between tau and tubulin, leading to an opposite effect to tau 
phosphorylation (Liu et al, 2004). Finally O-glycosylation has been reported to be 
upregulated in pathogenesis (Griffith & Schmitz, 1995). 
Moreover, when assembled into PHFs, tau has been shown to be ubiquitinated. The 
attachment of ubiquitin is a signal for degradation of short-lived, abnormal or damaged 
proteins. Tau ubiquitination probably suggests an attempt by the cell to eliminate the 
toxic PHFs species (Bancher et al, 1991). 
 
It has also been suggested that PHF insolubility may be related to glycation of tau, the 
reaction between the N-terminal group of an amino acid side chain and the carboxyl end 
of reducing sugars. Tau glycation occurs specifically during pathogenesis and leads to a 
cross-linking reaction causing the formation of insoluble aggregates of proteins (Ko et 
al, 1999; Liu et al, 2002). On PHF-tau thirteen residues of lysine are found to be 
glycated in one of the microtubule-binding domains, therefore their modification could 
result in a decreased interaction of tau with tubulin (Ledesma et al, 1995). 
 
Finally, tau has been shown to undergo cleavage by a number of proteases such as 
caspases, thrombin and calpain. The resulting fragments appear to have a higher 
propensity for aggregation when compared to full-length tau (Hanger & Wray, 2010; 
Novák, 1994). Whereas, PHF-tau has been demonstrated to be extremely resistant to 
degradation by the calcium-dependent protease calpain compared to normal tau protein. 
Only a partial proteolysis was obtained with a higher concentration of calpain forming 
mainly N-terminal tau fragments. The resistance of abnormal filaments to proteolysis is 
thought to be associated with the conformation of tau proteins into PHF, rather than 
with hyperphosphorylation (Litersky & Johnson, 1992). In particular, calpain-digestion 
sites might be buried in the core of filaments and could become inaccessible to the 
protease (Yang & Ksiezak-Reding, 1995). Beyond exhibiting strong aggregation 
properties, tau fragments are capable of seeding the aggregation of both cleaved and 
full-length tau (Kovacech & Novak, 2010). 
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1.8 Tau kinases as major contributors to pathogenesis 
 
Hyperphosphorylation of tau is thought to be one of the major contributors leading to 
tau aggregation and toxicity during tauopathies (Alonso et al, 2001; Ballatore et al, 
2007; Lauckner et al, 2003). Potential therapeutic strategies against tauopathies have 
focused on reducing tau phosphorylation through inhibition of specific protein kinases 
(Lau et al, 2002). This approach aims to reduce tau aggregation and associated neuronal 
loss slowing neurodegeneration (Churcher, 2006). Recently, the validity of this 
approach has been demonstrated by successful experiments in transgenic animals. In 
fact, it has been demonstrated that tau kinase inhibitors can reduce tau 
hyperphosphorylation and prevent motor deficits in transgenic mice over-expressing 
human tau (Lewis et al, 2000). Calpain inhibitor prevents cdk5 activation and decreases 
tau phosphorylation improving neuronal function in a rat model of tau 
hyperphosphorylation (Hung et al, 2005). Furthermore, inhibition of GSK3β by lithium 
ions correlates with reduced tauopathy and neurodegeneration in vivo (Munoz-Montano 
et al, 1997; Nakashima et al, 2005; Noble et al, 2005). Therefore, it is crucial to identify 
the protein kinases and phosphatases that regulate tau phosphorylation in order to find 
further targets and optimise current therapeutic approaches. 
 
There is no in vivo evidence of which kinases are involved in the production of 
pathogenic tau hyperphosphorylation in AD brains. However, many kinases have been 
shown to phosphorylate tau in vitro (Anderton et al, 2001; Cruz & Tsai, 2004; Feijoo et 
al, 2005; Hanger et al, 2009; Hanger et al, 2007; Mandelkow et al, 2004). The potential 
major protein kinases that mediate pathological phosphorylation of tau include GSK3β, 
cdk5, MAPK, PKA and CK1δ (Hanger et al, 2009). In vitro phosphorylation studies 
with purified protein kinases and recombinant tau have shown that GSK3β can 
phosphorylate at least 37 of the identified tau phosphorylation sites, PKA up to 27 sites 
and CK1δ at least 39. A combination of GSK3β, PKA and CK1δ can phosphorylate 38 
sites known to be phosphorylated in PHF-tau extracted from AD brains (Hanger et al, 
2009; Hanger et al, 2007). 
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1.8.1 Glycogen synthase kinase 3β 
 
GSK3β is an evolutionary conserved S/T protein kinase initially described for its role to 
phosphorylate and inhibit glycogen synthase (Rylatt et al, 1980). It is an important 
component of signalling systems and targets a large number of substrates, including 
metabolic proteins, growth factors, cytoskeletal proteins, transduction and transcription 
factors and other signaling molecules (Medina et al, 2011). Expressed in all tissues, 
GSK3β is abundant in the brain, in particular in neurons, where it plays a fundamental 
role in neuronal signaling pathways (Leroy & Brion, 1999). Different aspects of 
neuronal and glial development are regulated by GSK3β, such as morphogenesis, 
axonal polarity, synaptogenesis and cell survival (Grimes & Jope, 2001). Among the 
processes controlled by GSK3β, regulation of cytoskeletal dynamics is one of the most 
critical since it is involved in neuronal plasticity (Cohen & Frame, 2001; Frame & 
Cohen, 2001). 
 
GSK3β phosphorylates several proteins that are critical components of the cytoskeleton 
and tau was found to be one of them (Hanger et al, 1992). A link between GSK3β and 
the major neuropathological mechanisms associated with AD and tauopathies has been 
suggested (Hanger & Noble, 2011). In particular, GSK3β may contribute to the 
abnormal phosphorylation of tau observed in NFTs (Hanger et al, 1992). Furthermore, 
GSK3β has been shown to phosphorylate tau both in vitro and in cultured cells at 
epitopes known to be phosphorylated in post-mortem AD brain tissue (Hanger et al, 
2007; Hanger et al, 1992; Lovestone et al, 1994b). In particular, over-expression of 
GSK3β in cells causes a dramatic change in tau phosphorylation at a number of residues 
such as pS202/T205  (Lovestone et al, 1996; Wagner et al, 1996). Transgenic mice 
over-expressing an inducible form of GSK3β show a higher level of tau 
phosphorylation and neurodegeneration than control brains (Lucas et al, 2001). In 
contrast, tau phosphorylation and tangle load are reduced in neurons exhibiting 
neurofibrillary pathology after lithium-induced inhibition of GSK3β in vitro and in vivo 
(Lovestone et al, 1999; Munoz-Montano et al, 1997; Noble et al, 2005). Finally, GSK3β 
has been demonstrated to be present at increased levels in AD brains where it has been 
found to co-localise with NFTs (Pei et al, 1999; Yamaguchi et al, 1996). 
 
 37 
All together this evidence suggests that GSK3β is a significant contributor to tau 
toxicity and is an excellent target for the development of inhibitors of tau 
hyperphosphorylation. Indeed, several pharmaceutical companies now have inhibitors 
of GSK3β under development as therapeutic agents for tauopathies. However, it is not 
clear whether inhibition of GSK3β alone would be sufficient to alleviate disease and it 
is necessary to identify further kinases that contribute to tau pathology since they may 
be considered as additional therapeutic candidates (Hanger et al, 2009). 
 
 
1.8.2 Cyclic-AMP-dependent kinase 
 
The cAMP-dependent protein kinase PKA is part of a family of enzymes whose activity 
is dependent on cellular levels of cyclic AMP (cAMP). PKA is a holoenzyme composed 
of two regulatory and two catalytic subunits. An increased level of cAMP leads to the 
activation of the kinase. Binding of cAMP to the regulatory subunits alters their affinity 
for the catalytic subunits that are released as two active monomers (Taylor et al, 1990). 
PKA is expressed in kidney, liver, muscular system and CNS where it is mainly 
involved in the regulation of glycogen, sugar, and lipid metabolism. 
 
Several studies have shown that the tau protein is also a substrate for PKA (Litersky & 
Johnson, 1992; Pierre & Nunez, 1983). In vitro phosphorylation of recombinant human 
tau by PKA results in decreased electrophoretic mobility of tau on SDS-PAGE and in a 
92% decrease in the rate of tau-induced microtubule assembly (Robertson et al, 1993; 
Scott et al, 1993; Singh et al, 1994). Tau phosphorylation by PKA occurs in three 
sequential stages characterised by increased phosphorylation and decreased 
electrophoretic mobility of tau (Scott et al, 1993). Up to 27 phosphorylation sites were 
identified as PKA targets on recombinant tau, two of which were located within 
microtubule-binding domains: S214, S324, S356, S409, and S416 (Scott et al, 1993). 
Moreover, it has been shown that PKA phosphorylation of tau on S356 and S409 
induces the PHF kinase associated with tau filaments to sequentially phosphorylate 
recombinant tau in vitro (Jicha et al, 1999; Vincent & Davies, 1992). 
 
Furthermore, PKA has been demonstrated to be involved in the regulation of tau 
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degradation. In particular, tau proteolysis by calpain is significantly reduced by PKA 
phosphorylation, possibly on specific sites (Litersky & Johnson, 1992). During 
tauopathies, abnormal phosphorylation could result in a protease-resistant tau 
population that may contribute to the formation of PHFs. 
 
 
1.8.3 Casein kinase 1δ 
 
Casein kinase 1 (CK1) encompasses a large family of evolutionary conserved S/T 
protein kinases found in a variety of subcellular locations (Vielhaber & Virshup, 2001). 
In vitro studies have revealed that CK1 proteins phosphorylate substrates with a 
negatively charged region N-terminal to the site of phosphorylation, in particular 
substrates containing the recognition motifs S/T(P)-X-X-S/T (Flotow & Roach, 1991). 
The CK1 family is involved in regulating a large number of cellular processes, 
including cell cycle progression in oocytes, RNA metabolism and synaptic vesicle 
formation. In particular, CK1δ may regulate the cell response to DNA damage 
(Vielhaber & Virshup, 2001). 
 
The CK1 family has been shown to phosphorylate the tau protein and it is thought to be 
one of the principal families of phosphotransferases associated with tau filaments in 
tauopathies (Hanger et al, 2007; Singh et al, 1995). Evidence in cultured cells shows 
that over-expression of CK1δ significantly increases tau phosphorylation of S202, 
T205, S396 and S404 and reduces the fraction of tau bound to microtubules. These 
results suggest that CK1δ can phosphorylate tau at sites that modulate its binding to 
microtubules (Li et al, 2004). Moreover, members of the CK1 family correlate spatially 
with neurofibrillary lesions in tauopathies (Kuret et al, 1997). In particular, one isoform, 
CK1δ, shows particularly robust co-localisation with granulovacuolar degeneration 
bodies in the hippocampus (Ghoshal et al, 1999; Schwab et al, 2000). Furthermore, 
CK1 levels are elevated in the hippocampus of AD brains, with CK1δ being elevated 
over thirty fold (Ghoshal et al, 1999; Yasojima et al, 2000). The localisation and 
expression pattern of the CK1 protein kinase family leads to the hypothesis that CK1δ 
has a key role in the hyperphosphorylation of tau and in the formation of tau pathology 
in vivo. 
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1.8.4 Dual-specificity tyrosine-regulated protein kinase 1A 
 
DYRK1A belongs to a family of dual-specificity tyrosine-regulated protein kinases 
(DYRKs) that possess dual substrate specificities. They are characterised by S/T 
phosphorylation activity as well as auto-phosphorylation activity on tyrosine residues 
(Y321 residue for self-activation) with a preferred phosphorylation consensus motif of 
RPX(S/T)P (Kentrup et al, 1996; Marti et al, 2003). In humans DYRK1A is highly 
expressed at embryonic stages and also during adulthood in the CNS, suggesting an 
involvement in the physiology of the CNS. It has been suggested that DYRK1A may 
control proliferation and maturation events during development and motor function in 
the adult (Marti et al, 2003). DYRK1A knockout mice show a general delay in foetal 
development and are embryonic lethal suggesting vital and non-redundant biological 
function of DYRK1A (Fotaki et al, 2002). DYRK1A has also been identified as 
regulator of microtubule stability in growing axons via a priming action on GSK3β 
phosphorylation of MAP1B (Scales et al, 2009). 
 
Importantly, it has been shown that Down syndrome (DS) patients constantly suffer 
early-onset AD and that the DYRK1A gene is localised on the human chromosome 21 
within the DS critical region (Altafaj et al, 2001; Ryoo et al, 2007). This chromosomal 
region is relatively small but when present in three copies it is sufficient to produce DS, 
the major cause of mental retardation in humans. Therefore, the position of the 
DYRK1A locus makes this kinase a good candidate gene to contribute to the aberrant 
brain development underlying mental retardation in DS and a factor that may cause AD. 
The CNS of DS patients shows a large number of alterations, including a reduction of 
brain size, abnormal neuronal migration, differentiation and density, affecting several 
brain regions (Altafaj et al, 2001). Both DS and AD have common pathological 
hallmarks such as amyloid plaques and NFTs. Higher levels of DYRK1A have been 
found in DS brains and its presence has been detected in NFTs from patients with 
sporadic AD (Liu et al, 2008; Wegiel et al, 2008). 
 
Transgenic mice over-expressing DYRK1A show specific motor and cognitive defects 
similar to those seen in DS patients (Altafaj et al, 2001; Marti et al, 2003; Ryoo et al, 
2007). Moreover, in neuronal cultures over-expression of DYRK1A has been shown to 
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contribute to synaptic dysfunction reducing synaptic vesicle endocytosis (Kim et al, 
2010). DYRK1A has been shown to phosphorylate the tau protein in vivo mainly in its 
proline-rich region. The known phosphorylation sites on tau in vitro that may play a key 
role in the loss of microtubule assembly and in the formation of NFTs are S202, T205, 
T212 and S404 (Hanger et al, 2009; Liu et al, 2008; Ryoo et al, 2007). There is also 
evidence suggesting that over-expression of DYRK1A in DS brain induces tau 
hyperphosphorylation. In particular, DYRK1A phosphorylation of T212 residue 
promotes GSK3β-mediated phosphorylation of tau that ultimately leads to tau lesions in 
the brain (Woods et al, 2001). In conclusion, DYRK1A could be a novel potential 
therapeutic target for the treatment of AD in both DS and AD patients. 
 
 
1.8.5 Multiple kinases 
 
It is becoming clear that no single kinase or phosphatase is responsible for all of the 
abnormal tau phosphorylation observed in tauopathies. Recent in vitro studies have 
suggested that multiple kinases are likely to be involved in tau phosphorylation and that 
specific kinases may prime tau for phosphorylation by others inducing a kinase cascade. 
Indeed, CK1, DYRK1A and cdk5 have been suggested to prime tau for subsequent 
phosphorylation by GSK3β (Hanger et al, 2007; Li et al, 2006; Woods et al, 2001). 
Therefore, targeting the inhibition of a priming kinase may be another promising 
therapeutic strategy to reduce the overall level of tau phosphorylation. 
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1.9 Phosphorylation sites on tau contributing to disease 
 
During disease, hyperphosphorylation of tau results in the loss of its physiological 
function and in the gain of a toxic function (Alonso et al, 2001; Ballatore et al, 2007; 
Lauckner et al, 2003). The mechanisms by which tau kinases and their phosphorylation 
sites lead to neuronal toxicity are still debated. Importantly, the phosphorylation sites 
that are crucial for the physiological and pathological role of tau in vivo remain 
unknown. 
 
An increase of phosphorylation of residues in the microtubule-binding domains of tau 
and the flanking regions is reported to have a large effect on the ability of tau to bind to 
microtubules (Amniai et al, 2009). Hyperphosphorylation of sites usually involved in 
the regulation of the microtubule-binding activity causes the loss of physiological 
function of tau. Thus, defects in microtubule assembly and polymerisation lead to 
axonal transport impairment and synaptic loss (Morfini et al, 2009; Terry et al, 1991). 
On the other hand, phosphorylation at specific residues not normally phosphorylated in 
physiological conditions may cause conformational changes of tau (Jeganathan et al, 
2008). Indeed, recent studies have identified 45 phosphorylated sites on tau extracted 
from AD brains in contrast with only 17 extracted from healthy brains (Table 1.3) 
(Hanger et al, 2009; Hanger et al, 2007; Lebouvier et al, 2009; Morishima-Kawashima 
et al, 1995). The conformational changes on tau might lead to inaccessibility for 
phosphatases, to increased affinity for kinases or to impaired tau physiological functions 
(Fischer et al, 2009). 
 
In conclusion, the hyperphosphorylation process that occurs on tau during pathogenesis 
includes an increased phosphorylation of residues of tau that normally participate in the 
physiological role of tau, but also includes the phosphorylation of additional sites that 
are not involved in the microtubule-binding function. However, the role that specific 








PHF-tau PSP tau MAPK GSK3β PKA CK1δ 
T17       ★ Y18  A      Y29        T30        T39        S46 ★ A ★ ★ ★  ★ T50     ★  ★ T52        S56        S61        T63        S64        S68  ★      T69  ★  ★ ★   T71  ★      T76        T95       ★ T101       ★ T102       ★ T111        S113  ★     ★ T123  A      S129        S131       ★ T135        S137        T149     ★  ★ T153  A   ★   T169       ★ T175  ★  ★ ★   T181 ★ ★ ★ ★ ★   S184  ★   ★  ★ S185  ★  ★    S191  ★      S195     ★ ★  Y197  ★      S198 ★ ★   ★ ★ ★ S199 ★ ★   ★ ★  S202 ★ ★ ★ ★ ★ ★  T205 ★ A A ★ ★ ★  S208  ★     ★ S210  ★   ★ ★ ★ T212 ★ ★ A ★ ★ ★ ★ 








PHF-tau PSP tau MAPK GSK3β PKA CK1δ 
S293      ★  S305    ★ ★ ★ ★ Y310        S316        T319        S320    ★  ★  S324     ★ ★  S341       ★ S352     ★ ★ ★ S356  ★  ★ ★ ★ ★ T361       ★ T373     ★  ★ T377        T386       ★ Y394  ★      S396 ★ ★ ★ ★ ★  ★ S400 ★ ★ ★  ★   T403  ★ ★     S404 ★ ★ ★ ★ ★  ★ S409  ★ A ★ ★ ★  S412 ★ ★    ★ ★ S413 ★ ★ A  ★ ★ ★ T414 ★ ★     ★ S416 ★ ★    ★ ★ S422  ★ A ★  ★  T427  ★      S433  ★     ★ S435  ★    ★ ★ 
 
 
Table 1.3 Phosphorylated sites on human tau. The phosphorylation sites on human 
tau extracted from control brains, AD brains and PSP brains are listed together with 
those by major S/T tau kinases MAPK, GSK3β, PKA and CK1δ. The residue 
numbering refers to the 2N4R human tau isoform. The star indicates sites identified by 
direct means (mass spectrometry or Edman degradation) and "A" indicates sites 




1.10 Drosophila melanogaster to study neurodegeneration 
 
Most work investigating the phosphorylation of tau has been performed in vitro with 
purified proteins; in vivo validation of these findings is required. Therefore, it is 
essential to understand the importance of the candidate kinases that produce tau toxicity 
and their activity on the predicted sites in vivo. Drosophila melanogaster has emerged 
as an excellent model system for studying human neurodegenerative disease (Moloney 
et al, 2010; Muqit & Feany, 2002). Beyond the short lifespan and the useful genetic 
tools available, Drosophila has a complex nervous system and clear orthologs exist for 
70% of the disease-related loci found in humans (Reiter et al, 2001). 
 
Meaningful fly models of tauopathy have been created by expressing human tau in the 
Drosophila photoreceptor neurons (Bonini & Fortini, 2003). Examination of the 
degeneration in the Drosophila eye has numerous advantages including dispensability 
for fly viability and ease of use in degeneration screens due to loss of crystalline-like 
eye structure. Therefore, the Drosophila eye represents a quick readout of 
neurodegeneration that can be applied in large-scale screenings. Moreover, expression 
of human tau in Drosophila photoreceptor neurons results in neurodegeneration that 
bears many of the hallmarks of tauopathies including age dependency, presence of 
abnormally phosphorylated tau and in some cases tau aggregates (Jackson et al, 2002; 
Nishimura et al, 2004).  
 
The Drosophila models produced so far have focused on identifying Drosophila genes 
that can modify human tau toxicity (Chatterjee et al, 2009; Chau et al, 2006; Jackson et 
al, 2002; Shulman & Feany, 2003; Steinhilb et al, 2007a; Steinhilb et al, 2007b; 
Wittmann et al, 2001). To date there has been little work on understanding the causes of 
human tau-induced neurodegeneration in Drosophila.  However, it appears that the 
sequential activation of the TOR signalling pathway enhances tau-induced 
neurodegeneration and drives cell cycle activation leading to apoptosis in fly cells 
expressing human tau (Khurana et al, 2006). A genetic screen for modifiers of tau-
induced neurodegeneration revealed endogenous Drosophila genes, primarily kinases 
and phosphatases that enhance or suppress human tau toxicity (Shulman & Feany, 
2003; Steinhilb et al, 2007b). Wittmann et al (2001) first created an in vivo model of 
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tauopathy that showed neurodegeneration without the formation of NFTs. Indeed, this 
study also demonstrated that expression of human 0N4R tau in the fly CNS led to 
progressive vacuolisation and degeneration of neurons in the cortex without the 
formation of tau aggregates. Moreover, the FTDP-17 associated tau mutations R406W 
and V337M, increased human tau toxicity in flies, showing more severe 
neurodegeneration in the fly brain (Wittmann et al, 2001). The R406W mutation also 
resulted in increased eye degeneration and phosphorylation of tau by endogenous 
kinases on residues T181, S202, T205, T231 and S235 (Chau et al, 2006). However, it 
is not clear how the R406W mutation influences tau-mediated toxicity in flies. It was 
also shown that human 0N4R tau expressed in the fly CNS or eye is phosphorylated by 
endogenous Drosophila kinases on epitopes directly associated with tauopathies, 
including T181, S199, S202, T205, T212, S214, T217, T231, S235, S396 and S404 
(Steinhilb et al, 2007a; Wittmann et al, 2001). As the fly ages, tau phosphorylation 
increases and accumulates in areas of degeneration (Wittmann et al, 2001). 
 
The ease of genetic manipulation on Drosophila allows investigation of the effects of 
tau mutations on phosphorylation and toxicity of human tau in flies. For example, 
individual point mutations in 0N4R tau that inhibit phosphorylation do not affect the 
neurodegeneration caused by wild type tau in the fly eye. However, when human tau 
carries multiple mutations at the majority of the phosphorylation sites, tau toxicity is 
abolished. Thus, this suggests that no single phosphorylation site alone contributes to 
human tau toxicity in flies. The S/P and T/P sites on tau are suggested to co-operate 
together to mediate neurotoxicity in vivo (Steinhilb et al, 2007a; Steinhilb et al, 2007b). 
In contrast, site-specific mutations in tau have demonstrated that phosphorylation of 
S396 and S404 might contribute substantially to tau phosphorylation in vivo (Steinhilb 
et al, 2007a). Moreover, it has been confirmed that some Drosophila protein kinases are 
necessary for tau-mediated neurodegeneration, including shaggy and PAR-1, the fly 
orthologs of GSK3β and MARK, respectively. These kinases are each capable of 
increasing the toxicity produced by human 2N4R tau and 0N4R tau R406W in the fly 
eye. Shaggy increased tau phosphorylation of S202, T212, S214, T231, S235, S396 and 
S404, while PAR-1 also targeted S262. Through analysis of mutant forms of tau, S262 
and S396 were found to be the major phosphorylation sites targeted by PAR-1 (Jackson 
et al, 2002; Nishimura et al, 2004). Furthermore, expression of Drosophila cdk5, JNK 
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kinase and murine PKA enhanced the fly eye toxicity caused by human 0N4R tau and 
phosphorylation was increased (Steinhilb et al, 2007b). 
 
Other studies demonstrated that human tau toxicity in Drosophila is not only 
determined by phosphorylation or formation of insoluble tau, but also by the alteration 
of the microtubule-binding properties of tau. As previously mentioned, phosphorylation 
regulates the microtubule-binding of tau. When phosphorylation is inhibited, tau has an 
increased affinity for microtubules. A study by Chatterjee et al (2009) showed that 
human 2N4R tau carrying eleven S/T mutations to alanine resulted in an enhanced eye 
phenotype upon PAR-1 and shaggy expression. This was explained by the fact that the 
tau protein was no longer able to detach from microtubules leading to toxicity. 
Moreover, it has been shown in Drosophila larvae that human 0N4R tau carrying 
fourteen S/T mutations, disrupts axonal transport, reducing the number of motile 
vesicles within axons as well as their mobility. As seen before, this is due to an 
increased ability to bind microtubules when tau is dephosphorylated (Talmat-Amar et 
al, 2011). 
 
In conclusion, using Drosophila is likely to provide a sensitive and accurate biosensor 




My thesis aims to establish a Drosophila model of tauopathy to monitor human tau 
toxicity and to evaluate the role of human kinases during neurodegeneration. Several 
methods of Drosophila transgenesis are analysed to find the optimal conditions to create 
the animal model. The purpose of this fly model of tauopathy is to gain a greater insight 
into the role of human kinases in the generation of tau toxicity. Human kinases are 
tested for their contribution to confer tau toxicity in the fly eye and those generating the 
most pathogenic tau forms are identified. Selected human kinases relevant to tau 
pathology are studied, including GSK3β, PKA, CK1δ and DYRK1A. In addition, this 
work aims to use this in vivo model to determine which of the phosphorylation sites on 
tau is responsible for increased toxicity giving rise to neural degeneration. Ultimately, I 
aim to establish a Drosophila model of tauopathy that is able to provide an optimal tool 
to identify therapeutic targets and biomarkers of tauopathies such as pathogenic tau 













2.1.1 Drosophila stocks and husbandry 
 
Flies were maintained on standard cornmeal agar medium (0.8% w/v agar, 2% w/v 
cornmeal, 8% w/v glucose, 5% w/v Brewer’s yeast, 2% v/v ethanol, 0.22% v/v methyl-
4-hydroxybenzoate, 0.38% v/v propionic acid) at either 18°C or room temperature. 
Crosses were maintained at 18°C or 25°C on rich food (0.8% w/v agar, 6% w/v glucose, 
3% w/v sucrose, 8% w/v Brewer’s yeast, 2% w/v yeast extract, 2% w/v peptone, 1% v/v 
methyl-4-hydroxybenzoate, 0.6% v/v propionic acid, 0.05% w/v magnesium sulphate, 
0.05% w/v calcium chloride). In all cases w1118 were used as wild type. Genetic markers 
and balancer chromosome are described in Lindsley & Zimm (1992) and Flybase 
(www.flybase.org).(Lindsley & Zimm, 1992) 
 
 
2.1.2 Production of transgenic flies 
 
Transgenic flies were generated by standard embryonic injection and P-element 
mediated transgenesis or phiC31-mediated transgenesis by BestGene Inc. (Chino Hills, 
CA, USA) or GenetiVision (Houston, TX, USA). The mini-white (w+) marker 
contained in the expression plasmids was used to map the insertion into the 
chromosomes using standard mating schemes (Greenspan, 2004). Adult males with 
P[w+] insertions were selected by eye colour and the insertions were mapped and 
balanced using a w- stock with balancers on the second and third chromosomes. The 
insertions of all transgenic flies produced were confirmed by DNA sequencing. 
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Name Genotype Source 
Balancer line w1118; If/CyO; MKRS,Sb /TM6B,Hu Bloomington 
GFP line w1118; P{UAS-mCD8::GFP}/CyO Bloomington 









w1118; GMRGAL4/CyO; UAS-2N4RtauIII-1/TM6B,Hu 
R. Tuxworth 
This study 
2N4Rtau#2 w1118; UAS-2N4RtauII-2/CyO R. Tuxworth 
2N4Rtau#3 w1118; UAS-2N4RtauIII-3/TM6B,Hu R. Tuxworth 
2N4Rtau#4 w1118; UAS-2N4RtauIII-4/TM6B,Hu R. Tuxworth 
2N4Rtau#5 w1118; UAS-2N4RtauII-5/CyO R. Tuxworth 
2N4Rtau#51C w1118; UAS-2N4RtauII-51C/CyO R. Tuxworth 
2N4Rtau#68A 
w1118; UAS-2N4RtauIII-68A/UAS-2N4RtauIII-68A 
w1118; GMRGAL4/CyO; UAS-2N4RtauIII-68A/TM6B,Hu 
This study 
2N4Rtau#68E w1118; UAS-2N4RtauIII-68E/TM6B,Hu This study 
2N4Rtau#86F w1118; UAS-2N4RtauIII-86F/UAS-2N4Rtau This study 


































Name Genotype Source 
0N4Rtau 
w1118; UAS-0N4RtauIII-68A/TM6B,Hu 







Shaggy w1118; P{UAS-sgg.B}MB5 Bloomington 
GSK3β#1 w1118; UAS-GSK3β-Myc/CyO R. Tuxworth 
GSK3β#2 w1118; UAS-GSK3β-Myc/TM6B,Hu R. Tuxworth 
GSK3β#3 w1118; UAS-GSK3β-Myc/CyO R. Tuxworth 
GSK3β#4 w1118; UAS-GSK3β-Myc/TM6B,Hu R. Tuxworth 
PKA w1118; UAS-PKAcatα/CyO R. Tuxworth 
CK1δ w1118; UAS-Flag-CK1δΔ317/CyO R. Tuxworth 
DYRK1A w1118; UAS-Flag-DYRK1A/TM6B,Hu This study 
2N4Rtau + GSK3β w1118; 2N4Rtau,GSK3β-Myc/TM6B,Hu This study 
GSK3β + CK1δ w1118; UAS-Flag-CK1δΔ317/CyO; GSK3β-Myc/TM6B,Hu This study 
GSK3β + DYRK1A w1118; UAS- GSK3β-Myc,Flag-DYRK1A/TM6B,Hu This study 
 
 


















Chromosome Cytological location Company 
II 51C BestGene 
III 68A GenetiVision 
III 68E BestGene 
III 86F BestGene 
III 96E BestGene 
 
 
Table 2.2 Sites used for the phiC31-mediated transgenesis. Chromosomes and 





2.2.1 Light microscopy for adult eyes 
 
Flies were placed in 1.5 ml tubes and snap-frozen in liquid nitrogen. After thawing, the 
flies were photographed using an Olympus DP71 camera mounted on a Leica MZ16 
stereo microscope using ambient light to minimise glare. 
 
 
2.2.2 Fly fixation for scanning electron microscopy 
 
Whole flies were immersed in EM fixative solution (Appendix) for 2 hours and rinsed 
twice with distilled water. Flies were dehydrated by replacing the water with 30%, 50%, 




2.2.3 Scanning electron microscopy 
 
Scanning electron microscopy (SEM) was performed in the Centre for Ultrastructural 
Imaging at King’s College London. Samples were fixed and critical point dried as 
described in Wolff (2000), then sputter-coated in gold and imaged using an FEI Quanta 
200F microscope operated at 5 kV in high vacuum mode. (Wolff, 2000) 
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2.3 Histological techniques 
 
2.3.1 Adult eye embedding in epoxy resin 
 
Adult flies were anesthetised, heads were cut and one eye was gently removed using a 
scalpel. Wounded heads were fixed in 0.1 M sodium phosphate buffer (Appendix) 
supplemented with 1% v/v glutaraldehyde on ice for 30 minutes, then incubated in a 1:1 
solution of OsO4 (Electron Microscopy Sciences) (Appendix) and 0.2 M sodium 
phosphate buffer (Appendix) for 2 hours on ice. Heads were dehydrated in ethanol 
washes (30%, 50%, 70%, 90% and 100%), each incubated for 5 minutes on ice. Heads 
were infiltrated with propylene oxide (BDH and Prolabo) for 10 minutes at room 
temperature and incubated overnight in a 1:1 mix of propylene oxide and epoxy resin 
(Fluka, Sigma). Finally, heads were embedded in the pure epoxy resin and polymerised 
overnight at 80°C. 
 
 
2.3.2 Adult eye sectioning 
 
Semi-thin 1 µm eye sections were cut with a Leica UltraCut microtome using a 
diamond Diatome knife and post-stained with 1% v/v toluidine blue (Sigma). 
Examination was performed with a Zeiss Axioplan 2 Imaging microscope. Images were 
captured using a SpotInsight FireWire camera (Diagnostic Instruments). 
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2.4 Molecular biology 
 
2.4.1 Polymerase chain reaction 
 
Polymerase chain reaction (PCR) was performed using Go Taq DNA Polymerase 
(Promega) or Phusion High Fidelity DNA Plymerase (Finnzymes). Amplification 
reactions were carried out in a MWG-Biotech Primus thermal cycler programmed using 
the following steps: 2 minutes at 94°C, then 30 cycles of 15 seconds at 94°C, 30 
seconds at temperature depending on the set of primers used, 1 minute/kb at 72°C and 
finally stored at 8°C. PCR amplifications were confirmed by standard agarose gel 












Table 2.3 Sequencing primers. The primers UAS2/3 were used to sequence across 
the multiple cloning site of the pTW (inducible UASt promoter) expression constructs. 
The primer sequences of Tau_F and Tau_R correspond to the 5’ and 3’ end of the 
human tau cDNA sequence respectively. 
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2.4.2 DNA gel electrophoresis and fragment purification 
 
DNA gel electrophoresis was conducted in TAE buffer (Appendix) using a 1% w/v 
agarose gel containing 0.003% v/v GelRed (VWR). DNA samples were supplemented 
with DNA loading buffer (Appendix) and run alongside 3 µl of 1 kb DNA ladder (New 
England Biolabs) at 100 V constant voltage. DNA bands were visualised under UV 
light. For cloning purposes, bands were excised from agarose gels and purified using 
Geneclean Turbo Kit (MP Biomedicals). 
 
 
2.4.3 Cloning techniques and DNA preps 
 
Standard cloning techniques were used according to Sambrook et al (1989). DNA 
digestions were performed using restriction enzymes from New England Biolabs 
following manufacturer’s instructions. Linearised DNA vectors were dephosphorylated 
using Rapid Alkaline Phosphatase (Roche) and insertions were ligated using T4 DNA 
ligase (Roche). The ligation mixture was transformed into Subcloning Efficiency DH5α 
chemically competent cells (Invitrogen). Positive colonies were selected using 
resistance to the appropriate antibiotic on Luria Bertani (LB) agar plates (Appendix). 
Single colonies were transferred into 2 ml starter cultures of LB (Appendix) containing 
the appropriate selective antibiotic. DNA was extracted using QIAprep Spin MiniPrep 
kit (Qiagen) following manufacturer’s instructions. Presence of the correct insert was 
confirmed by PCR using one primer located in the insert and one in the vector. DNA 
sequencing was performed by Source Bioscience (lifesciences.sourcebioscience.com). 
The QIAFilter MidiPrep kit (Qiagen) was used for large scales plasmid purification 
required for sub-cloning, generation of transgenic flies and transfections. 
 
 
2.4.4 Genomic DNA isolation 
 
Genomic DNA was isolated from single flies snap-frozen in liquid nitrogen in 1.5 ml 
tubes. Each fly was grounded using a micropestle in DNA prep buffer (Appendix) 
supplemented with 200 µg/ml proteinase K (Sigma). The samples were incubated at 
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56°C for at least 30 minutes and at 100°C for 5 minutes, then spun for 1 minute at 
maximum speed using a bench top centrifuge to pellet debris. The supernatant was 
transferred to a new tube and stored at -20°C. 
 
 
2.4.5 Splinkerette PCR 
 
Splinkerette PCR was used to identify genomic DNA region flanking P-element 
insertions as described in Potter & Luo (2010). Genomic DNA was extracted as 
described on the Berkeley Drosophila Genome Project website 
(www.fruitfly.org/about/methods/inverse.pcr.html). Thirty flies were homogenised in 
400 µl of splinkerette DNA prep buffer (Appendix) supplemented with 200 µg/ml 
proteinase K (Sigma). Samples were incubated at 65°C for 30 minutes. Eight hundred 
µl of LiCl/KAc solution (Appendix) were added and the samples were incubated on ice 
for at least 30 minutes, then spun for 15 minutes at maximum speed using a bench top 
centrifuge. The supernatant was transferred to a new tube and 600 µl of isopropanol 
were added. The mixture was spun for 15 minutes at maximum speed using a bench top 
centrifuge. The pellet was washed with 75% ethanol and air-dried. The DNA was 
resuspended in 70 µl TE buffer (Appendix) and stored at -20°C.  0.5-1 µg of genomic 
DNA were digested with BglII (New England Biolabs, UK). The splinkerette 
oligonucleotides (Splnk_top and Splink_bottom) were annealed at 95ºC for 3 minutes 
and subsequently ligated to the digested genomic DNA at room temperature for at least 
2 hours in a volume of 50 µl using T4 DNA ligase (Roche). The mixture for the first 
round PCR was set up using 10 µl of ligated DNA. The two sets of primers used were 
specific for the 5’ and 3’ ends of PZ-elements respectively: Splnk#1/5’Splnk#1 and 
Splnk#1/3’Splnk#1. Amplification reactions were carried out in a MWG-Biotech 
Primus thermal cycler programmed using the following steps: 1.15 minutes at 98°C, 
then 2 cycles of 20 seconds at 98°C and 15 seconds at 64°C, 30 cycles of 20 seconds at 
98°C, 15 seconds at 61°C, 2 minutes at 72°C and finally store at 8°C. The mixture for 
the second round PCR was set up using 0.5 µl of the previous PCR reaction. The two 
sets of primers used were specific for the 5’ and 3’ ends of PZ-elements respectively: 
Splnk#2/5’Splnk#2 and Splnk#2/3’Splnk#2. Amplification reactions were carried out in 
a MWG-Biotech Primus thermal cycler programmed using the following steps: 1.15 
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minutes at 98°C, then 2 cycles of 20 seconds at 98°C and 15 seconds at 58°C, 30 cycles 
of 20 seconds at 98°C, 15 seconds at 61°C, 2 minutes at 72°C and finally store at 8°C. 
The resulting DNA bands were purified using Geneclean Turbo Kit (MP Biochemicals) 
and sequenced by Source Bioscience (www.lifesciences.sourcebioscience.com). (Potter 
































Table 2.4 Primers used for the splinkerette PCR. 
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2.4.6 Expression constructs 
 
To make expression constructs, the ORF of the cDNA of interest was amplified by PCR 
using Platinum Pfx polymerase (Invitrogen) and cloned into pENTR cloning vectors 
(Invitrogen). The correct insertion was verified by sequencing. Error-free clones were 
transferred to the expression vectors pAW (actin promoter) or pTW (inducible UASt 
promoter) according to manufacturer’s instructions (Murphy collection of Gateway-
equipped expression vectors, supplied by the Drosophila Genetic Resource Centre, 
University of Indiana) using LR Clonase II (Invitrogen). The pUAStattB expression 
vector allowed phiC31-mediated transgenesis and was a kind gift of the Basler group 





Name Vector Insert Tag Source 
pRIT373 pUASt 2N4R tau - R. Tuxworth 
pRIT376 pUAStattB 2N4R tau - R. Tuxworth 
pRIT291 pUASt GSK3β Myc R. Tuxworth 
pRIT353 pUASt PKAcatα - R. Tuxworth 
pRIT293 pUASt CK1δΔ317 Flag R. Tuxworth 
pGEP12 pUASt DYRK1A Flag This study 
pGEP22 pAMW GSK3β Myc This study 
pGEP20 pAMW PKAcatα Myc This study 
pGEP19 pAFW CK1δΔ317 Flag This study 
pGEP18 pAFW DYRK1A Flag This study 
pGEP31 pUAStattB 2N4R tau R406W - This study 
pGEP32 pUAStattB 0N4R tau - This study 
pGEP34 pUAStattB 0N4R tau R406W - This study 
 
 
Table 2.5 Expression constructs used in this study. 
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2.4.7 Site-direct mutagenesis 
 
Template for site-directed mutagenesis was the full-length ORF of 2N4R human tau 
cloned into the UASt cassette of the pTW expression vector. Point mutations were 
generated using the QuikChange Multi site-directed mutagenesis kit (Stratagene) 













S202A TCC GCC TACAGCAGCCCCGGCGCCCCAGGCACTCCCGG 
T205A ACT GCT CCGGCTCCCCAGGCGCTCCCGGCAGCCGCTCC 
T212A ACC GCC GGCAGCCGCTCCCGCGCCCCGTCCCTTCCAAC 
S404A TCT GCT GTGTCTGGGGACACGGCTCCACGGCATCTCAG 
 
 
Table 2.6 Mutagenic primers used on 2N4R human tau. Amino acid change, codon 
change and primer sequence used for site-specific mutagenesis of four S/T sites on 
2N4R human tau. Point mutations are shown in red in each sequence. 
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2.4.8 RNA extraction from adult heads 
 
RNA was extracted from 5 to 10 adult heads. Heads were placed in a sterile 1.5 ml tube 
and homogenised in 500 µl of Tri reagent (Sigma) using a micropestle. The lysate was 
incubated at room temperature for 5 minutes and subsequently 100 µl chloroform 
(Sigma) were added. After shaking vigorously for 15 seconds, the mixture was 
incubated for 15 minutes at room temperature and spun at maximum speed for 15 
minutes at 4°C. The upper aqueous phase was transferred to a fresh sterile tube and 250 
µl of isopropanol were added. After vortexing for 10 seconds, the sample was incubated 
at room temperature for 10 minutes and spun at maximum speed for 10 minutes at 4°C. 
The pellet was washed 3 times with ethanol and resuspended in 20 µl nuclease-free 
water (Promega). RNA samples were immediately used for cDNA synthesis and then 
stored at -80°C. RNA quality controls, including RNA integrity and RNA purity were 
performed by QStandard (www.qstandard.co.uk). 
 
 
2.4.9 Complementary DNA synthesis 
 
Complementary DNA (cDNA) samples were synthesised using ImProm-II™ Reverse 
Transcription System (Promega) following manufacturer’s instructions. The reactions 
were set up using 500 ng of RNA. The cDNA synthesis was carried out in a 
Termocycler Rotor-Gene 6000 (Corbett Research) programmed using the following 
steps: 5 minutes at 25°C, 1 hr at 42°C, 15 minutes at 70°C. The cDNA samples were 
stored at -20°C. 
 
 
2.4.10 Quantitative PCR 
 
Quantitative PCR (qPCR) was performed by QStandard (www.qstandard.co.uk) using 
Termocycler Rotor-Gene 6000 (Corbett Research). The cDNA samples were assessed 
for the transcript levels of the following genes: Drosophila actin, Drosophila GAPDH, 



























Table 2.7 Primers used to perform qPCR. 
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2.4.11 Fly decapitation	  
 
Flies were placed in 2 ml screw cap tubes, snap-frozen in liquid nitrogen and 
decapitated using a FastPrep24-Instrument (MP biomedical) at 6.5 m/s for 20 seconds. 
Heads were then separated from thoraces and abdomens using a sieve and transferred to 
a clean 2 ml tube for homogenisation. 
 
 
2.4.12 Fly head homogenisation 
 
A volume of 100 µl of cold homogenisation buffer (Appendix) at pH 6.8 supplemented 
with protease and phosphatase inhibitors (Calbiochem) and garnet beads (MP 
Biomedical) were added to 20 adult heads. Tubes were shaken twice at 6.5 m/s for 20 
seconds and then spun for 10 minutes at 20,000 g at 4°C. The supernatant was 
transferred to a clean tube and stored on ice. A second homogenisation was then 
performed by adding 100 µl of cold homogenisation buffer at pH 9.2 to the garnet beads 
and the cellular matter remaining from the first homogenisation. The tubes were then 
shaken twice at 6.5 m/s for 20 seconds and then spun for 10 minutes at 20,000 g at 4°C. 
The second supernatant was combined with the first, obtaining a final pH of 8. The 
lysate was spun for 30 minutes at 20,000 g at 4°C and the supernatant was transferred in 
a clean tube. Finally the sample was stored at -80°C. 
 
 
2.4.13 Sarcosyl-solubility protocol 
 
A volume of 60 µl of cold solubility buffer (Appendix) supplemented with protease and 
phosphatase inhibitors (Calbiochem) and garnet beads (MP Biomedical) were added to 
30 heads. Tubes were shaken three times at 6.5 m/s for 20 seconds and then spun for 5 
minutes at 1,000 g at 4°C. The supernatant was transferred to a clean tube and stored on 
ice. The mixture was brought to 1% v/v N-lauroylsarcosinate (Sigma) and incubated for 
1 hour at room temperature with shaking. Samples were spun for 1 hour at 100,000 g at 
4°C. The sarcosyl-soluble supernatant was transferred to a new tube, while the sarcosyl-




This procedure was carried out according to Laemmli (1970) and Sambrook et al 
(1989). Protein samples were separated on 10% w/v polyacrylamide gels using a 
BioRad mini-protean II gel electrophoresis apparatus. Kaleidoscope pre-stained 
standard markers were obtained from Biorad. Protein samples were mixed in SDS 
loading buffer (Appendix) and boiled for 3 minutes before loading onto the gel. The 
samples were run at 90 V constant voltage through the stacking gel and 150 V constant 
voltage through the separating gel in ultra pure tris-glycine-SDS buffer (National 
Diagnostics). (Laemmli, 1970) 
 
 
2.4.15 Western blotting 
 
Western blotting was performed according to Sambrook et al (1989). After separation 
on a 10% acrylamide SDS-PAGE, proteins were transferred on nitrocellulose membrane 
(Biorad) by electrophoretic transfer for 1 hour at 100 V constant voltage in ultra pure 
tris-glycine buffer (National Diagnostics). The membrane was blocked in 5% w/v non-
fat dried milk in TBS (Appendix). Primary and secondary antibodies were individually 
diluted in 5% w/v non-fat dried milk in TBS-T (Appendix) and incubated with the 
membrane overnight and for 45 minutes respectively at 4°C. Membranes were washed 
with TBS every 10 minutes for 1 hour and then scanned by an Odyssey machine (Li-
Cor Biosciences) using 169 µm of resolution and 5 arbitrary units of channel intensity. 
Fluorescent images were analysed by Odyssey Infrared Imaging System 3.0 software 
(Li-Cor Biosciences) applying a median top/bottom background method. Protein levels 
were quantified as intensities of the fluorescent signals drawing a box of constant area 
around the bands of interest. The images were converted to black and white and then 












Antibody Epitope Host species Source Dilution 
Total human tau 243-441 Rabbit Dako 1:10,000 
PHF1 human tau pS396/pS404 Mouse P. Davies 1:5,000 
AT8 human tau pS202/pT205 Mouse Innogenetics 1:2,000 
Tau1 human tau 195-205 Mouse Chemicon 1:1,000 
AT100 human tau pT212/pS214 Mouse Innogenetics 1:1,000 
AT270 human tau pT181 Mouse Innogenetics 1:1,000 
Human PKA, α chain 330-350 Rabbit Santa Cruz 1:200 
Human GSK3β-pS9 pS9 Rabbit Cell Signaling 1:1,000 
c-Myc EQKLISEEDL Mouse Santa Cruz 1:1,000 
Flag M2 DYKDDDDK Mouse Sigma 1:1,000 
β-Actin - Mouse Calbiochem 1:5,000 
Mouse IgG 680 - Goat Invitrogen 1:15,000 
Mouse IgM 800 - Goat Rockland 1:15,000 
Rabbit IgG 800 - Goat Rockland 1:15,000 
 
 
Table 2.8 Primary and secondary antibodies used in this study. Each antibody is 
described by name, epitope, source and dilution used on western blot. The epitope 
description includes numbers to define the amino acid position of the epitope or letters 
to define its sequence. 
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2.5 Tissue culture 
 
All tissue culture experiments were carried out using Drosophila Schneider 2 (S2) cells. 
 
2.5.1 S2 cell maintenance 
 
Cells were maintained in Insect Express Sf9-S2 medium (PAA) supplemented with 
penicillin-streptomycin (Gibco) and kept in 25 cm2 tissue culture flasks (Nunc) at 25°C. 




2.5.2 Transfection of S2 cells 
 
Cells were split in 6 well plates so that each well contained 2 x 106 cells in a total 
volume of 2 ml and incubated at 25°C overnight. The medium was substituted with 
Insect Express Sf9-S2 medium (PAA) without antibiotic. Cells were transfected using 
Cellfectin II (Invitrogen) following manufacturer’s instructions. The total amount of 
plasmid DNA transfected was 1.5 µg. After 5 hours of incubation at 25°C, the medium 
was substituted with Insect Express Sf9-S2 medium (PAA) supplemented with 
penicillin-streptomycin (Gibco). The transfected cells were left to recover at 25°C 
overnight. When necessary, induction was performed by adding 100 µM of CuSO4 
solution to the cells. 
 
 
2.5.3 Cell lysis 
 
Cells were washed with PBS (Appendix) and harvested in 250 µl of cold lysis buffer 
(Appendix) supplemented with protease and phosphatase inhibitors (Calbiochem). The 
cell lysate was spun at maximum speed for 10 minutes at 4°C and the supernatant was 
stored at -80°C. 
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2.6 Statistical data analysis 
 
In this study all statistical analyses were performed using the software Prism 4.0 
GraphPad. Transcript and protein quantification data were analysed using one way 
Anova analysis of variance and a parametric post-test (p<0.05). The data on 
photoreceptor counting were analysed using a Pearson’s chi-square analysis and a 







PBS buffer 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.2 
TBS buffer 50 mM Tris-HCl, 150 mM NaCl, pH 7.6 
TBS-T buffer TBS, 0.1% v/v Tween 20 
TAE buffer 40 mM Tris-HCl, 20 mM acetic acid, and 1mM EDTA 
TE buffer 10 mM Tris-HCl (pH 8), 1 mM EDTA 
6X DNA loading buffer 30% v/v glycerol, 0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol FF 
LB medium 1% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract, 1% w/v NaCl (pH 7) 
LB agar LB medium containing 1.5% w/v agar 
1 M sodium phosphate 
buffer 72% v/v 1 M Na2HPO4, 28% v/v 1 M NaH2PO4 
EM fixative solution 50% Na-cacodylate (pH 7.2), 1% v/v glutaraldehyde, 1% v/v formaldehyde, 0.5% v/v Triton X-100 
Homogenisation buffer 50 mM Tris-HCl (pH 6.8 or pH 9.2), 0.3 M NaCl, 1% v/v β-mercaptoethanol 
Solubility buffer 10 mM Tris pH 7.5, 0.8 M NaCl, 1 mM EGTA pH 8, 10% w/v sucrose 
DNA prep buffer 10 mM Tris-HCl (pH 8), 25 mM KCl, 1 mM EDTA, 0.1% v/v Triton X-100  
Splinkerette DNA prep 
buffer 
100 mM Tris-HCl (pH 7.5), 100 mM NaCl, 100 mM EDTA, 
0.5% v/v sodium dodecyl sulfate 
S2 cell lysis buffer 20 mM HEPES (pH 7.4), 100 mM NaCl, 1 mM NaCL, 1 mM EDTA, 0.5% v/v Triton X-100 
4x SDS loading buffer 200 mM Tris-HCl (pH 6.8), 6.4% v/v SDS, 5 mM EDTA, 16% v/v glycerol, 0.25% w/v bromophenol blue 
 
 
Table 2.9 Formulation of solutions and media. All chemicals and reagents used in 









Human tau expression in 




Tauopathies are a collection of neurodegenerative diseases characterised by the 
distinctive accumulation of tau aggregates in neurons. The best known of these 
pathologies is AD, but tauopathies also include FTDP-17, Pick’s disease, progressive 
supranuclear palsy and corticobasal degeneration. Tau aggregates are composed 
predominantly of insoluble highly phosphorylated tau protein and are likely to be 
responsible for the neuronal loss (Ballatore et al, 2007; Bouchard & Suchowersky, 
2011; Buee et al, 2000; Hanger et al, 2009; Iqbal et al, 2009; Lee et al, 2001). Human 
tau is a microtubule-associated protein that stabilises microtubules and promotes 
microtubule polymerisation in neurons. It is involved in regulation of the cytoskeleton 
and vesicle transport along axons. In adult human brains, alternative splicing generates 
six different tau isoforms that differ in the number of amino-terminal and carboxyl-
terminal domains (Figure 1.1) (Buee et al, 2000; Burbank & Mitchison, 2006; Goedert 
et al, 1988; Takuma et al, 2003).  
 
Drosophila is as an excellent model system for studying human neurodegenerative 
diseases (Bonini & Fortini, 2003; Muqit & Feany, 2002; Reiter et al, 2001). In 
particular, expression of human tau in Drosophila results in neurodegeneration that 
bears many hallmarks of the tauopathies including age-dependency, presence of 
abnormally phosphorylated tau and in some cases neurofibrillary tangles (Chatterjee et 
al, 2009; Jackson et al, 2002; Nishimura et al, 2004; Steinhilb et al, 2007a; Steinhilb et 
al, 2007b; Wittmann et al, 2001). The Drosophila eye has been extensively used to 
investigate neurodegeneration thanks to its richness in neurons and dispensability for fly 
viability. Moreover, the fly eye provides a rapid readout of degeneration (Bonini & 
Fortini, 2003; Muqit & Feany, 2002). Expression of human tau in the Drosophila eye 
has been shown to cause loss of the crystalline-like structure of ommatidia characteristic 
of wild type flies. In particular, the eye degeneration is observable from the 
disorganisation of the ommatidial arrangement on the external surface of the optic lobe 
and loss of photoreceptor neurons inside each ommatidium (Chatterjee et al, 2009; 
Jackson et al, 2002; Nishimura et al, 2004; Steinhilb et al, 2007a; Steinhilb et al, 2007b; 
Wittmann et al, 2001). 
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Many successful fly models of tauopathy have been created to investigate the toxicity of 
human tau. The main differences between these Drosophila models are the human tau 
isoforms studied and the genetic background of the transgenic flies created (Chatterjee 
et al, 2009; Jackson et al, 2002; Nishimura et al, 2004; Steinhilb et al, 2007a; Steinhilb 
et al, 2007b; Wittmann et al, 2001). Firstly, human tau-mediated degeneration in flies 
has been studied using several different tau isoforms, often exhibiting different levels of 
toxicity. In the majority of cases, the human tau isoform with all four C-terminal repeats 
that are responsible for the microtubule-binding activity has been used. To evaluate the 
role of specific sites to the production of tau toxicity, transgenic flies carrying mutated 
forms of the human tau gene were created. The most common types of point mutations 
tested are those thought to either inhibit hyperphosphorylation or to be associated with a 
specific tauopathy in human patients (Chatterjee et al, 2009; Jackson et al, 2002; 
Steinhilb et al, 2007b). Secondly, differences in genetic background among the fly 
tauopathy models derive from the method of transgenesis used. The human tau 
transgene is inserted into the fly genome using standard P-element mediated 
transgenesis. An early stage Drosophila embryo is injected with two vectors, one 
containing the transgene of interest and the other one encoding for a transposase. The 
transgene is integrated in the fly germ cells at a random chromosomal site (Rubin & 
Spradling, 1982; Spradling & Rubin, 1982). P-element mediated transgenesis is a 
powerful genetic tool in Drosophila research, however one of the major drawbacks 
concerns the genomic position of the transgene insertion. In particular, the chromosomal 
insertion site of the transgene occurs at random leading to two major consequences. 
Firstly, there is a risk that the inserted transgene will disrupt essential genes and 
secondly, the levels of the transgene expression will differ depending on the genomic 
position. In addition, the insertion site of the transgene cannot be reproduced, meaning 
that it is impossible to replicate the insertion event of a transgene in a specific 
chromosomal site. 
 
Previous studies investigating the variability in toxicity mediated by different wild type 
or mutated isoforms of human tau have used transgenic Drosophila carrying various 
human tau transgenes inserted at random at different genomic positions. Since 
expression of the transgene can vary due to positional effects, these fly tauopathy 
models are characterised by a diverse genetic background and by a variable level of tau 
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expression. No documentation on the phenotypic reproducibility and transgene 
expression levels in these tauopathy models has been described. 
 
My thesis aims to establish a Drosophila tauopathy model to investigate the 
contribution of individual human kinases and their phosphorylation sites to the 
generation of toxic forms of human tau. To be able to define their role, it is important to 
control for the expression level of the transgenes. The aim of this chapter is to 
characterise the toxicity levels mediated by human tau in several transgenic Drosophila 
lines made via standard P-element mediated transgenesis. In this chapter, I investigated 
human tau toxicity using the full-length isoform, characterised by two N-terminal 
inserts (2N) and four repeated regions at the C-terminal (4R) (Buee et al, 2000; Goedert 
et al, 1988; Takuma et al, 2003). In particular, the reproducibility of the fly eye 
degeneration caused by the human tau gene was evaluated in fly lines carrying the same 
human tau transgene inserted in different genomic positions. To define the effects on 




3.2.1 Drosophila models of tauopathy created via P-element mediated 
transgenesis 
 
I utilised a similar animal model for tauopathies as previous investigations, where 
human tau was expressed in the Drosophila eye using GMRGAL4 that drives 
expression of the transgene in the eye, including the photoreceptor neurons (Brand & 
Perrimon, 1993; Duffy, 2002). In order to monitor the reproducibility of the phenotypic 
effect mediated by human tau expression in Drosophila, transgenic lines were created 
via P-element mediated transgenesis carrying the full-length human 2N4R tau 
transgenes. The same UAS-human 2N4R tau transgene was inserted at random in five 
different genomic positions. Expression was induced throughout development at 25ºC 
and flies were collected between 0 to 5 days post-eclosion. The eye phenotypes caused 
by expression of human tau were examined by scanning electron microscopy. Control 
flies expressing GMRGAL4 alone were monitored to identify any background 
phenotype caused by the expression of the driver. Control eyes are characterised by an 
oval optic lobe and a regular arrangement of ommatidia (Figure 3.1A). In contrast, 
when human 2N4R tau is expressed in the fly eye (2N4Rtau#1-5), a disruption of the 
eye architecture is observed. The degenerative phenotype is characterised by an 
alteration of eye shape caused by loss of tissue, the disarrangement of the regular 
pattern of ommatidia caused by cell fusion and occasionally the presence of necrotic 
tissue consistent with cell death (Figure 3.1B-F). Examination of the phenotypes caused 
by expression of human 2N4R tau reveals different levels of degeneration in lines 
carrying the same human transgene inserted in different genomic positions. Lines 
2N4Rtau#1 and 4 show a weak disruption of ommatidial patterning concentrated in the 
posterior part of the eye, while the oval eye shape is conserved (Figure 3.1B and E). 
Line 2N4Rtau#2 is characterised by a more disorganised structure of ommatidia and a 
mild loss of tissue in the posterior part of the eye compared to control (Figure 3.1C). 
Line 2N4Rtau#3 exhibits severe eye degeneration characterised by a strong 
disorganisation of the ommatidial architecture extending to the whole eye surface. In 
addition, the presence of necrotic ommatidia and substantial loss of tissue are 
observable (Figure 3.1D). Line 2N4R#5 shows mild to strong eye degeneration 
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characterised by ommatidial disarrangement and loss of tissue in the anterior and 
posterior part of the eye (Figure 3.1F). 
 
The individual transgenic lines have a reproducible phenotype, with exception for line 
2N4Rtau#5 that over time has shown some variability in the amount of degeneration. 
For the most part, the human tau expression phenotype was restricted to the eye only. 
However, when human tau is over-expressed from line 2N4Rtau#3, the flies suffer from 
a reduced viability. The number of 2N4Rtau#3 flies hatching from a standard cross with 
the GMRGAL4 driver was approximately half compared to any other 2N4R tau lines 
(data not shown). 
 
Human tau expression causes eye degeneration in the fly models created in this study as 
expected. However, a large variation in the level of phenotype is observable among 




Figure 3.1 Expression of human 2N4R tau in the Drosophila eye during 
development. Scanning electron microscopy pictures of eyes from 0-5 days old flies. (A) 
Control eyes carrying the eye specific GMRGAL4 driver show a regular array of 
ommatidia. (B-F) Different degrees of ommatidial disruption result from expression of 
human 2N4R tau in the eye using GMRGAL4. Each Drosophila line has the tau 
transgene inserted in a different genomic position. Inserts show higher magnification of 
the central area of the eye. Scale bar: 100 µm (panel) and 25 µm (insert). Dorsal is top 





The transgenic flies over-expressing the same human 2N4R gene created in this study 
exhibit different levels of degeneration. To identify whether the differences in eye 
degeneration is a combined result of tau expression and effects on endogenous genes at 
the insertion sites, the genomic position of the transgene was mapped. 
Splikerette PCR is an alternative approach for mapping insertion sites that has been 
recently developed by Potter and Luo (2010). This technique was originally developed 
to amplify the genomic DNA between a known restriction site and a target gene, and 
then it was adapted to map the insertion sites of viral integrating gene traps in the mouse 
genome. Mapping transposable elements in Drosophila using splinkerette PCR is highly 
efficient. The genomic regions flanking the human tau transgene insertions were 
sequenced and aligned against the whole Drosophila genome. 
 
The locations of the transgenes are shown in figure 3.2A. Lines 2N4Rtau#1, 3 and 4 
have the tau transgene inserted on chromosome III, while lines 2N4Rtau#2 and 5 have 
insertions on chromosome II. In line 2N4Rtau#1, the human tau gene is inserted 300 bp 
downstream of the first exon of the neurotactin gene (CG9704). The gene neurotactin 
encodes a surface glycoprotein with homology to serine esterases highly expressed 
during embryogenesis. It is thought to be a cell adhesion molecule and it is involved in 
the central nervous system development including axon guidance, axonal fasciculation, 
heterophilic cell adhesion and axonogenesis (de la Escalera et al, 1990; Hortsch et al, 
1990). Line 2N4Rtau#2 has the transgenic insertion in a non-coding region of 
chromosome II. In line 2N4Rtau#3, the genomic position of human 2N4R tau is 100 bp 
downstream of the 5’ end of the l(3)87Df gene (CG7620) in its second exon. Its 
molecular function is unknown, however the loss-of-function phenotype affects the 
longer fly bristles on the notum, known as macrochaetae. Loss of the l(3)87Df gene 
results in homozygous lethality, in fact transgenic flies homozygous for 2N4Rtau#3 
insertion are not viable. In line 2N4Rtau#4, the human 2N4R tau gene is inserted in the 
central intronic region of the CG7381 gene on chromosome III. The molecular function 
of CG7381 and the biological processes that rely on the gene are unknown. The human 
tau transgene insertion in line 2N4Rtau#5 is at the 5’ end of the MrgBP gene 
(CG13746) in its first exon. Although MrgBP is thought to be involved in transcription 
and neurogenesis, its molecular function is unknown (Jin et al, 2005). 
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Line 2N4Rtau#3 exhibits the strongest degree of eye degeneration, reduced viability 
upon human tau expression and it is homozygous lethal, suggesting a potential 
contribution to the degenerative phenotype due to an effect on the endogenous gene 
l(3)87Df. Therefore, I investigated whether disruption of the l(3)87Df gene only could 
contribute to the phenotype of line 2N4Rtau#3. 
 
An independent allele of l(3)87Df was obtained (Bloomington no. 1670) to test whether 
functional reduction in this gene actively contributed to the phenotype caused by 2N4R 
tau expression in the fly eye. When the l(3)87Df allele was combined with GMRGAL4, 
the eye morphology appeared similar to control (Figure 3.2D). One of the tau transgenic 
lines exhibiting a mild phenotype was crossed with the l(3)87Df allele to see whether 
the tau-mediated phenotype would be affected. When 2N4R tau was expressed from 
line 2N4Rtau#1 with GMRGAL4 in the background of the disrupted l(3)87Df gene, the 
eye phenotype was comparable to line 2N4Rtau#1 expressed in a wild type background 
(Figure 3.2C and E). This result suggests that the disruption of l(3)87Df is not 
responsible for the eye degeneration observed in 2N4Rtau#3. 
 
None of the transgenic Drosophila lines has the human 2N4R tau transgene inserted in a 
gene known to be responsible for fly eye development. In particular, line 2N4Rtau#3 
with the strongest phenotype does not disrupt an endogenous gene that contributes to 
the phenotype. All the transgenic lines in the absence of the genetic driver have an eye 
morphology similar to control (data not shown). Together this evidence suggests that 
the phenotypic differences in eye degeneration in lines 2N4R#1-5 are not due to effects 
on endogenous genes disrupted by the insertion. 
B Control DC EGMR>2N4Rtau#1 GMR>2N4Rtau#1+ l(3)87Dfl(3)87Df / +
A Fly line Chromosome Gene Description 
1 III Neurotactin 
- Unkown molecular function 
- Involved in CNS development, axon guidance, 
axonal fasciculation, axonogenesis 
- Phenotypes annotated with: commissure, ventral 




3 III l(3)87Df 
- - Unknown molecular function 
- - Phenotype annotated with macrochaeta 
- - Homozygous lethal 
4 II CG7381 - - Unknown molecular function 
- - No phenotypic data available 
5 III MrgBP 
- Unknown molecular function 
- - Involved in regulation of transcription, DNA-
dependent 
 
Figure 3.2 Genomic insertion sites of the human tau transgene. (A) Table listing the 
chromosome where the human tau gene is inserted, the gene nearest the insertion site 
and a brief description of the gene function (adapted from flybase.com). (B-E) Light 
micrographs of eyes from 0-5 days old flies. (B) Control eyes carrying the eye specific 
GMRGAL4 driver show a regular array of ommatidia. (C) Representative example of the 
disarrangement of ommatidia generated by expression of the human tau gene in the 
Drosophila line 2N4Rtau#1. (D) Flies heterozygous for l(3)87Df do not exhibit any 
ommatidial disruption. (E) The human tau-mediated eye phenotype in 2N4Rtau#1 is not 
enhanced by the loss of l(3)87Df. Scale bar: 100 µm. Dashed lines indicate the area of 
degeneration. Dorsal is top and anterior is left.
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To investigate the causes of the variation in eye phenotype upon human 2N4R tau 
expression from different insertion sites in Drosophila, the levels of human tau protein 
expressed were analysed for each transgenic line. 
 
Human 2N4R tau was expressed throughout development at 25ºC using the eye-specific 
GMRGAL4 driver. Protein extracts were prepared from heads of flies collected 0 to 5 
days post-eclosion (Chapter 2). Expression of human tau was detected by western 
blotting (Figure 3.3A). An anti-human tau antibody supplied by Dako was used to 
recognise an epitope on tau independent from its phosphorylation state. The lanes from 
control flies carrying only the GMRGAL4 driver show no tau expression, suggesting 
that the anti-human tau antibody is specific and does not cross-react with endogenous 
Drosophila proteins. Following expression driven by GMRGAL4, human tau is 
detected in all transgenic lines (2N4Rtau#1-5) as a single band at an apparent molecular 
weight of 65 kDa. The migration of human tau expressed in the flies corresponds to that 
of recombinant 2N4R tau, suggesting that the phosphorylation state of human tau by 
endogenous kinases does not lead to a significant change in mobility. Expression levels 
of human tau were quantified using actin levels to normalise for gel loading. Although 
the level of tau expression in line 2N4Rtau#3 appears to be much lower compared to the 
other lines, parametric statistical analysis show that the levels of human tau expression 
are not significantly different among the transgenic lines (Figure 3.3B). This suggests 
that the expression levels of human tau protein from the different transgenes do not 
correlate with the severities of eye degeneration observed in figure 3.1. In particular, 
despite showing the most severe eye degeneration, line 2N4Rtau#3 has a similar level 
of human tau expression compared to the other transgenic lines with a milder 
phenotype. 
 
In conclusion, the levels of human tau protein driven in the tau transgenic lines are 
similar and do not correlate with the intensity of the degenerative phenotypes, although 
















Figure 3.3 Total levels of human tau protein expression in transgenic Drosophila 
lines. (A) Human 2N4R tau and actin expression were detected on western blot of head 
homogenates from flies expressing the transgene using the eye-specific driver 
GMRGAL4. Total tau was detected as single band using the phospho-independent 
antibody Dako (65 kDa) and β-actin was used as loading control (42 kDa). Recombinant 
human 2N4R tau (rTau) was loaded as positive control for tau and flies carrying 
GMRGAL4 alone were analysed as negative control. Only the transgenic lines 
(2N4Rtau#1 to 5) show human tau expression. (B) Protein levels for each transgenic line 
were normalised to actin. Values correspond to the mean and SEM of 3 replicates of 
independent experiments. The levels of total tau expression in the transgenic fly lines 
are non significantly different (p>0.05).
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The difference in toxicity may be determined by a variation in the solubility of the tau 
protein. Alterations in tau solubility properties have been shown to be associated with 
toxic functions of tau (Hirata-Fukae et al, 2009). Sarcosyl fractionation is a widely used 
method to determine the solubility of human tau. Sarcosyl-insoluble tau has been found 
to be hyperphosphorylated in AD mouse models (Ishihara et al, 2001; Lewis et al, 2000; 
Zhukareva et al, 2002). Protocols to isolate PHF-tau from brains of AD patients are 
based on their insolubility in 1% Sarcosyl (Greenberg & Davies, 1990; Lee et al, 1999). 
More importantly, it has also been shown that Sarcosyl-soluble and insoluble forms of 
human tau are produced in Drosophila models of tauopathy (Chau et al, 2006). Since 
the total level of human tau did not correlate with the variations in eye degeneration 
displayed by the five transgenic Drosophila lines created in this study, the Sarcosyl-
soluble and insoluble tau levels were analysed. 
 
Protein homogenate obtained from fly heads was resuspended in 1% Sarcosyl and 
insoluble tau separated by centrifugation at 100,000g (Chapter 2). Human 2N4R tau 
was expressed throughout development at 25ºC using GMRGAL4. Protein extracts 
were prepared from heads of flies collected 0 to 5 days post-eclosion. Human tau in the 
extracts was successfully detected by western blotting using the a phospho-independent 
tau antibody (Figure 3.4A). Control flies carry the GMRGAL4 driver only and show no 
tau expression in the soluble or insoluble fraction (data not shown). Following 
expression using GMRGAL4, human tau is detected in all transgenic lines (2N4Rtau#1-
5) in the soluble and insoluble fractions. Human 2N4R tau was represented as a single 
band at an apparent molecular weight of 65 kDa corresponding to recombinant 2N4R 
tau. There is no shift in the mobility of either the soluble or insoluble fractions 
compared to recombinant 2N4R tau, suggesting that the phosphorylation state of human 
tau by endogenous kinases is not significant in both fractions. 
 
Expression levels of human tau were quantified using actin to normalise for gel loading. 
As previously seen in figure 3.3, the levels of expression of total human tau are not 
significantly different between each transgenic line (Figure 3.4B). More importantly, 
the quantification reveals that the levels of insoluble tau produced are significantly 
lower than the levels of soluble tau in all transgenic lines. Among each fly line the 
proportion of tau in the insoluble fraction is similar. 
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These results show that Sarcosyl-soluble and insoluble human tau forms are produced in 
the transgenic Drosophila models created in this study, however their levels do not 
correlate with the severity of eye degeneration as seen for the levels of total tau. One of 
the possible causes of lack of correlation could be related to the loss of eye tissue 
observed in some of the lines with strongest phenotypes, including lines 2N4Rtau#3 and 
5. The normalisation of protein levels in these experiments was conducted using the 
actin expression of the whole head. There is a possibility that using actin as loading 




























































Figure 3.4 Levels of Sarcosyl-soluble and insoluble human tau in transgenic flies 
generated via P-element mediated transgenesis. (A) Sarcosyl-soluble and insoluble 
human 2N4R tau and actin expression were detected on western blot of head 
homogenates from flies expressing the transgene using the eye-specific driver 
GMRGAL4. Total tau was detected as single band using the phospho-independent 
antibody Dako (65 kDa) and β-actin was used as loading control (42 kDa). Recombinant 
human 2N4R tau (rTau) was loaded as positive control for tau and flies carrying 
GMRGAL4 alone were analysed as negative control. Only the transgenic fly lines 
(2N4Rtau#1 to 5) show human tau expression in the soluble and insoluble fractions. (B) 
Soluble (white) and insoluble (blue) tau protein levels for each transgenic were 
normalised to actin. Values correspond to the mean and SEM of 3 replicates of 
independent experiments. The amount of insoluble tau is less than that of soluble tau in 
each transgenic fly line. The levels of soluble and insoluble tau expression are non 
significantly different between the transgenic fly lines (p>0.05).
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Previous experiments show that the expression of human 2N4R tau at the protein level 
does not correlate with the intensity of eye phenotype. Here the levels of human tau 
protein were normalised against the levels of actin expressed in the whole fly head. 
Since the expression of human tau was driven only in a subset of cells of the eye, it 
would be more accurate to use an independent marker expressed within the eye 
alongside tau for normalisation. Therefore, I included the expression of a reporter gene 
in the eye together with human tau. 
 
The transcript level of human tau was quantified via qPCR in order to see whether there 
was a correlation with the variation in intensities of eye phenotype shown in figure 3.1. 
The experimental design was planned in order to account for loss of eye tissue in the 
transgenic fly lines, in particular 2N4Rtau#3. Flies were raised at 18ºC and after 
eclosion they were aged for three days at 25ºC. At lower temperatures the level of 
GAL4 expression decreases, thus leading to a reduced amount of transgene expression 
(Duffy, 2002). In this way, transgenic flies expressed a low level of human tau during 
development at 18ºC to reduce the loss of tissue that occurs when flies were raised at 
25ºC (Figure 3.1). After development, the human tau expression was restored raising 
the temperature to 25ºC. Secondly, the human tau transgene was expressed alongside a 
reporter gene using the same genetic driver. The spatial and temporal control of the 
reporter gene is the same as of the human tau transgene. In all Drosophila transgenic 
lines, human 2N4R tau was expressed together with a UAS-CD8::GFP reporter driven 
by GMRGAL4. The transcript level of human 2N4R tau in each transgenic Drosophila 
line was quantified using actin, GAPDH and the transcriptional factor eIF-­‐4a	   as 
reference genes. The copy number of CD8::GFP was used to normalise for the actual 
number of eye cells expressing human tau. Flies carrying only the eye specific driver 
GMRGAL4 and reporter UAS-CD8::GFP were used as negative control. There is no 
expression of human tau in those flies suggesting that the primers designed for qPCR 
are specific for human tau (Figure 3.5). All transgenic Drosophila lines (2N4Rtau#1-5) 
carry the human tau transgene inserted in different genomic positions and UAS-
CD8::GFP expressed using GMRGAL4. As expected, the external ommatidia 
arrangement of all lines was disrupted by human tau expression compared to control. 
However, the eye phenotype was overall milder than the one shown in figure 3.1 since 
flies were raised at lower temperature and thus protein expression was decreased (data 
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not shown). Upon expression, the transgenic fly lines produce different levels of human 
tau transcript. To enable a better comparison between the different lines, the transcript 
levels were expressed in percentage relative to the highest mean. The qPCR result 
shows that line 2N4Rtau#3 expresses a significantly higher level of human tau 
transcript compared to all other Drosophila tau lines. Lines 2N4Rtau#1, 2, 4 and 5 
express an equal amount of human tau transcript that is approximately half of that 
produced by line 2N4Rtau#3. 
 
These results suggest that the eye degeneration observed in transgenic flies 
overexpressing human tau correlates with the level of tau transcript expressed. In 
particular, line 2N4Rtau#3 exhibits the strongest tau-mediated eye degeneration and it is 
characterised by the highest level of human tau transcript production within the eye 
compared with the other transgenic lines. 
 
Since my research aim was to examine the role of specific kinases and the sites they 
phosphorylate on tau, I needed to identify a mechanism that allowed me to control for 
expression levels of the transgene to allow comparison between wild type and mutant 
forms of tau. A new approach has been developed to target transgenes to specific 
insertion sites, thus I examined whether this system could be used in my experiments.  
Figure 3.5 Transcript levels of human 2N4R tau are proportional to the level of 
degeneration caused by expression of the transgene in the Drosophila eye. 
Human 2N4R tau expression was driven together with UAS-CD8::GFP using the eye 
specific driver GMRGAL4. To enable comparison between samples, the transcript levels 
were expressed as relative copy number to the highest mean. Tau copy numbers were 
normalised to 3 reference genes and to UAS-CD8::GFP. Values correspond to the mean 
and SEM of 3 to 5 replicates from independent experiments. Asterisks indicate 
statistically significant differences of tau transcript. Control flies carrying the eye specific 
GMRGAL4,UAS-CD8::GFP driver show no human tau transcript expression. Transgenic 
flies (2N4Rtau#1 to 5) expressing the 2N4R human tau gene using the eye specific 
GMRGAL4,UAS-CD8::GFP driver show different tau transcript levels depending on the 
genomic position of the transgene. All transgenic lines display a highly significant level of 
tau transcript compared to control. Only line 2N4Rtau#3 shows a significantly higher tau 
copy number compared to other transgenic lines (p<0.001).
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3.2.2 Drosophila models of tauopathy created via phiC31-mediated 
transgenesis 
 
An alternative approach has been successfully developed in Drosophila to allow the 
insertion of transgenes in specific genomic loci. This system utilises an integrase 
derived from phage phiC31 to catalyse a stable recombination between the bacterial 
attachment site attB and the phage attachment site attP. In Drosophila, the phiC31 
integrase is used to efficiently integrate attB-containing plasmids into attP landing sites 
within the fly genome (Bischof et al, 2007; Groth et al, 2004). One of the advantages of 
using this technique is reproducibility: transgenic Drosophila lines can be created 
carrying transgenes inserted in the same genomic position and thus the same expression 
levels. This study intends to use this technique to solve the issue related to phenotypic 
variations of eye degeneration due to positional effects and expression levels of the 
human tau transgene. 
 
Several transgenic Drosophila lines were created carrying the human 2N4R tau 
transgene inserted in different genomic positions using the phiC31 site-specific 
integration. The genomic sites used are located on chromosome II and III: 51C, 68A, 
68E, 86F and 96E. These cytological positions were chosen due to their availability at 
the time the transgenic lines where produced. Human tau was over-expressed from these 
insertion sites throughout fly development at 25ºC using the eye specific driver 
GMRGAL4. The eye phenotypes caused by expression of human tau were examined 
using a light microscope. Figure 3.6 shows the eye degeneration phenotype of 
transgenic fly lines carrying the same human 2N4R tau gene inserted in specific 
genomic positions. Control flies expressing GMRGAL4 alone were used to monitor the 
background phenotype caused by the expression of the GAL4 driver. Control eyes are 
characterised by an oval optic lobe and a regular arrangement of ommatidia (Figure 
3.6A). Not all transgenic Drosophila lines exhibited a tau-mediated degeneration of the 
eye when tau expression was driven from the targeted insertions. When 2N4R tau was 
expressed from insertions 2N4Rtau#51C and 68E, the flies have a regular eye 
morphology similar to control (Figure 3.6B and D). In contrast, the other fly lines over-
expressing human 2N4R tau exhibit a disruption of the eye architecture. In particular, 
lines 2N4Rtau#68A, 86F and 96E are characterised by a weak disarrangement of the 
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ommatidial pattern compared to control (Figure 3.6C, E and F). No alteration of eye 
shape or necrotic tissue is present. 
 
The level of eye degeneration caused by human tau in Drosophila eyes is proportional 
to the transcript level of the transgene as shown above. Therefore, the weak level of eye 
degeneration shown by 2N4Rtau#68A, 86F and 96E could be explained by a low level 
of expression of human 2N4R tau. Lines 2N4Rtau#68A and 86F were considered for 
further investigations. Line 2N4Rtau#96E was discarded because over time it has 






Figure 3.6 Expression of human 2N4R tau from transgene inserted at 
phiC31-specific sites causes a mild phenotype in the Drosophila eye. Light 
micrographs of eyes from 0-5 days old flies. (A) Control eyes carrying the eye specific 
GMRGAL4 driver show a regular array of ommatidia. (B-F) The human 2N4R tau 
transgene was inserted in 5 different genomic positions via phiC31-mediated 
transgenesis. When human 2N4R tau is inserted in the cytological position 51C (B) or 
68E (D), its expression in the eye does not cause significant disarrangement of 
ommatidia. When the same human transgene is inserted in the cyto-sites 68A (C) or 86F 
(E) or 96E (F) and expressed in the eye, a weak ommatidial disruption is observed. 
Scale bar: 100 µm. Dorsal is top and anterior is left.
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To examine the reasons for the weaker eye phenotype, the expression level of tau 
transcript from the lines created using the phiC31-specific integration was examined. 
The characterisation of the phiC31 transgenic lines included the quantification of the 
human tau transcript levels via qPCR. The experimental protocol follows that used in 
the previous experiment conducted using lines 2N4Rtau#1-5 (Figure 3.5). 
 
Human 2N4R tau was driven in the eye by the GMRGAL4 driver together with a UAS-
CD8::GFP reporter line. Flies were raised at 18ºC and subsequently aged for three days 
at 25ºC. In order to be able to compare the transcript levels of lines 2N4R#68A and 86F 
with the random insertion lines 2N4Rtau#1-5, three cDNA samples produced during the 
previous experiment were analysed alongside the samples from 2N4Rtau#68A and 86F 
to monitor reproducibility. The transcript level of human 2N4R tau was quantified in 
each transgenic Drosophila line using actin, GAPDH and the transcriptional factor eIF-
4a	   as reference genes. The copy number of CD8::GFP was used to normalise for the 
actual number of eye cells expressing human tau. To enable a better comparison 
between the transgenic lines generated with the phiC31-mediated system and the P-
element mediated transgenesis, the transcript levels were expressed in percentage 
relative to line 2N4Rtau#3 as done for figure 3.5. Flies carrying the GMRGAL4 driver 
together with the UAS-CD8::GFP reporter were used as negative control and they do 
not show transcription of human tau (Figure 3.7). Lines 2N4Rtau#68A and 86F produce 
levels of human tau expression that are not significantly different to one another. Lines 
2N4Rtau#68A and 86F express a significantly lower level of human tau transcript 
compared to 2N4Rtau#3. In particular, the lines generated using the phiC31 site-specific 
integration produce 80% less human tau transcript compared to 2N4Rtau#3. 
 
This evidence suggests that the weak eye degeneration observed following human tau 
expression in 2N4Rtau#68A and 86F might be due to the very low level of human tau 
expressed. Moreover, this study shows that all transgenic lines created with the P-
element mediated transgenesis express a significantly increased level of human tau 
transcript (at least 50%) compared to the lines generated using the phiC31-mediated 
transgenesis. 
Figure 3.7 Drosophila lines generated via phiC31-mediate transgenesis express 
low transcript levels of human tau in the eye. Human 2N4R tau expression was 
driven together with UAS-CD8::GFP using the eye specific driver GMRGAL4. To enable 
comparison between samples, the transcript levels were expressed as relative copy 
number to the 2N4Rtau#3 mean (Figure 3.5). Tau copy numbers were normalised to 3 
reference genes and to UAS-CD8::GFP. Values correspond to the mean and SEM of 5 
replicates from independent experiments. Asterisks indicate statistically significant 
differences of tau transcript. Control flies carrying the eye specific 
GMRGAL4,UAS-CD8::GFP driver show no human tau transcript expression. The tau 
transcript levels of the transgenic flies generated via phiC31-mediated transgenesis 
(2N4Rtau#68A and 86F) are not significantly different (ns). The 2N4Rtau#3 line 




The transgenic lines created using the phiC31-specific integration were further 
characterised at the protein level. Human 2N4R tau was expressed throughout 
development at 25ºC using the GMRGAL4 driver. Protein extracts were prepared from 
heads of flies collected 0 to 5 days post-eclosion (Chapter 2). Expression of human tau 
was successfully detected on a western blot using a phospho-independent tau antibody 
(Figure 3.8A). Control flies with the GMRGAL4 driver only show no tau expression. 
Following expression driven by GMRGAL4, human tau is detected in lines 
2N4Rtau#68A and 86F as a single band at an apparent molecular weight of 65 kDa 
corresponding to recombinant tau. Expression levels of human tau were quantified 
using actin to normalise for protein loading. The levels of expression of human tau are 
non-significantly different between lines 2N4Rtau#68A and 86F (Figure 3.8B). 
 
This result shows that the levels of human tau protein expressed in the lines created 
using the phiC31-mediated transgenesis are similar between each other as previously 





















Figure 3.8 Total levels of human tau protein expression in fly lines generated via 
phiC31-mediated transgenesis. (A) Human 2N4R tau and actin expression were 
detected on western blot of head homogenates from flies expressing the transgene 
using the eye-specific driver GMRGAL4. Total tau was detected as single band using the 
phospho-independent antibody Dako (65 kDa) and β-actin was used as loading control 
(42 kDa). Recombinant human 2N4R tau (rTau) was loaded as positive control for tau 
and flies carrying GMRGAL4 alone were analysed as negative control. Only the 
transgenic lines (2N4Rtau#68A and 86F) show human tau expression. (B) Protein levels 
for each transgenic line were normalised to actin. Values correspond to the mean and 
SEM of 3 replicates of independent experiments. The levels of total tau expression in the 
transgenic fly lines are non significantly different (p>0.05).
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The transgenic Drosophila models previously created in this study produce Sarcosyl-
soluble and insoluble forms of human tau as shown in figure 3.4. To investigate whether 
the transgenic lines created using the phiC31-specific integration produced similar 
amounts of soluble and insoluble tau, the amount of human tau solubilised by 1% 
Sarcosyl was assessed (Chapter 2). Human 2N4R tau was expressed throughout 
development at 25ºC using GMRGAL4. Protein extracts were prepared from heads of 
flies collected 0 to 5 days post-eclosion and human tau was successfully detected by 
western blotting using a phospho-independent tau antibody (Figure 3.9A). Control flies 
carry the GMRGAL4 driver only and show no tau expression in the soluble or insoluble 
fraction. Following expression using the GMRGAL4 driver, human tau is detected on 
the blot in lines 2N4Rtau#68A and 86F in the soluble and insoluble fractions. Human 
2N4R tau was detected as a single band at an apparent molecular weight of 65 kDa 
corresponding to recombinant 2N4R tau. As seen for lines 2N4Rtau#1-5 (Figure 3.4), 
these results confirm that Sarcosyl-soluble and insoluble human tau forms are also 
produced in lines created using the phiC31-mediated transgenesis. Expression levels of 
human tau were quantified using actin as normalisation value. The levels of expression 
of total human tau in lines 2N4R#68A and 86F are not significantly different between 
each other, consistent with the values in figure 3.7 and 3.8. The quantification reveals 
that the levels of insoluble tau are significantly lower than the levels of soluble tau. 
However, the levels of soluble and insoluble tau in lines 2N4R#68A and 86F are similar 
to that seen for lines 2N4Rtau#1-5 (Figure 3.4). 
 
These results suggest that Sarcosyl-soluble and insoluble tau forms are produced at 
similar levels in transgenic Drosophila created with the site-specific integration system. 
The amount of soluble tau is greater than insoluble tau as previously observed for the 
transgenic lines created with P-element mediated transgenesis. Very little insoluble tau 
is produced from the various Drosophila transgenic lines. 
 
The low level of 2N4R tau expression and resultant eye degeneration produced from the 
GAL4 driven expression of human tau in these lines is advantageous for the 
identification of enhancers of tau-mediated toxicity. The aim of my thesis is to identify 
the human kinases generating toxic forms of tau in Drosophila, thus an initial low level 
of tau-mediated toxicity might be useful in determining the nature of the genetic 



















Figure 3.9 Levels of Sarcosyl-soluble and insoluble human tau in fly lines 
generated via phiC31-mediated transgenesis. (A) Sarcosyl-soluble and insoluble 
human 2N4R tau and actin expression were detected on western blot of head 
homogenates from flies expressing the transgene using the eye-specific driver 
GMRGAL4. Total tau was detected as single band using the phospho-independent 
antibody Dako (65 kDa) and β-actin was used as loading control (42 kDa). Recombinant 
human 2N4R tau (rTau) was loaded as positive control for tau and flies carrying 
GMRGAL4 alone were analysed as negative control. Only the transgenic fly lines 
(2N4Rtau#68A and 86F) show the human tau protein in the soluble and insoluble 
fractions. (B) Soluble (white) and insoluble (blue) tau protein levels for each transgenic 
were normalised to actin. Values correspond to the mean and SEM of 3 replicates of 
independent experiments. The levels of soluble and insoluble tau expression are non 
significantly different between the transgenic fly lines (p>0.05).
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3.2.3 Investigating the photoreceptor degeneration caused by human 
tau in Drosophila 
 
The Drosophila eye is a widely used experimental system to identify factors that cause 
loss of neural tissue. In the previous experiments, human 2N4R tau was expressed in the 
fly eye throughout development. It is still unclear whether cell death is due to a defect 
during development of the eye or to the progressive degeneration of differentiated cells, 
specifically photoreceptor neurons. 
 
To identify if human tau can cause degeneration of differentiated cells, human 2N4R 
tau was expressed in the fly eye only during adulthood. In order to modulate the 
temporal expression of human tau, the GMRGAL4 driver was recombined with a GAL4 
repressor, GAL80TS. The expression of active GAL80TS occurs at 18ºC leading to the 
sequestration of GAL4 and therefore no transgene is transcribed. When the temperature 
is increased to 29ºC, GAL80TS is no longer active and transgene expression can occur. 
Human 2N4R tau was expressed in the fly eye driven by GMRGAL4 in the presence of 
GAL80TS. Embryonic and larval development proceeded at 18ºC in order to prevent 
human 2N4R tau transcription during development. After eclosion, flies were moved to 
29ºC to allow induction of human tau expression. Transgenic Drosophila lines were 
analysed after 1 day or 21 days of human 2N4R tau expression at 29ºC. To investigate 
the neurodegeneration of photoreceptor neurons, 1 µm sections of fly eyes were 
produced and membranes were stained with toluidine blue (Chapter 2). 
 
The cells forming the ommatidium are characterised by a concentric organisation. The 
core of the ommatidium contains eight photoreceptor cells, six of which are organised 
in an asymmetrical trapezoidal pattern and two lie in the middle. The central 
photoreceptors develop above one another, therefore only seven photoreceptors are 
visible on the apical surface. Each photoreceptor is associated with a rhabdomere, a 
rhodopsin-loaded cell with photosensitive microvilli (Figure 3.10A). The photoreceptor 
core is surrounded by two cone cells and two primary pigment cells. The outer layer is 
composed of six secondary pigment cells alternated by three tertiary pigment cells and 
three bristles. The cells of the outer layer are shared by adjacent ommatidia and together 
define their hexagonal shape (Ready et al, 1976).  
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Control flies carry the GMRGAL4 together with GAL80TS alone in order to monitor the 
background phenotype caused by the expression of the genetic driver. The eye sections 
of the control flies at 1 day and 21 days of age at 29ºC reveal a very organised eye 
architecture characterised by a regular pattern of ommatidia each one displaying 7 
photoreceptor neurons (Figure 3.10B and F). The transgenic flies analysed include the 
random insertion line with the highest human tau expression, line 2N4Rtau#3, and the 
two lines generated using the phiC31 site-specific integration system, 2N4Rtau#68A 
and 86F. Human 2N4R tau was expressed in the fly eye using the GMRGAL4 driver in 
the presence of GAL80TS. In flies where human tau was induced for 1 day after 
eclosion, the morphology of all transgenic lines is similar to control, characterised by a 
regular arrangement of ommatidia displaying 7 photoreceptor neurons (Figure 3.10C-
E). When human 2N4R tau expression is induced for 21 days after eclosion, line 
2N4Rtau#3 displays a disorganised eye morphology compared to control. In particular, 
the rhabdomeres are characterised by irregular size and position compared to control 
(Figure 3.10G). In contrast, after 21 days of human tau induction, lines 2N4Rtau#68A 
and 86F show a regular arrangement of ommatidia similar to control (Figure 3.10H-I). 
 
In order to measure the degeneration of photoreceptor neurons caused by the expression 
of human 2N4R tau, the number of photoreceptors per ommatidium was counted in flies 
over-expressing human tau for 1 day and 21 days after eclosion. The results were 
plotted on bar graphs showing the percentage of ommatidia displaying the numbers of 
photoreceptor in each transgenic line (Figure 3.10J and 3.10K). After 1 day of human 
tau expression, 100% of the ommatidia in the control flies exhibit seven photoreceptors, 
while 3 to 6% of the ommatidia in lines 2N4Rtau#3, 68A and 86F display six 
photoreceptors. Following a chi-squared distribution test, all transgenic Drosophila 
lines are characterised by a non-significant difference in photoreceptor number 
compared to control (Figure 3.10J). After 21 day of human tau expression, between 1 
and 2% of the ommatidia display six photoreceptors and 1% displays five 
photoreceptors in all fly lines. The statistical analysis confirmed that the distribution of 
photoreceptors in the transgenic lines 2N4Rtau#3, 68A and 86F is not statistically 
different from the control. 
 
This result suggests that adult onset of human 2N4R tau expression does not lead to 
photoreceptor neurodegeneration in the transgenic fly lines created in this study. In 
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addition, it is not possible to detect a difference in eye degeneration that could be 
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Figure 3.10 Expression of human 2N4R tau during adulthood does not induce 
photoreceptor degeneration in the fly eye. Human 2N4R tau was overexpressed in 
the fly eye using the GMRGAL4,GAL80TS inducible driver and induced after eclosion for 
1 or 21 days at 29ºC. (A) Schematic structure of an ommadium showing rhabdomeres 
(1-7) and photoreceptors (black dots). (B-I) Micrographs of eye sections from control 
flies carrying the GMRGAL4,GAL80TS driver alone and ﬂies expressing human 2N4R 
tau from transgenes inserted in different genomic positions. Inserts show higher 
magnification of single representative ommatidia. Scale bar: 10 µm (panel) and 5 µm 
(insert). (B-E) After 1-day induction of tau expression, the fly lines exhibit an ommatidial 
structure similar to control. (F-i) After 21-day induction of tau expression, in the 
2N4Rtau#3 line a mild disarrangement of the ommatidial structure can be observed 
compared to 2N4Rtau#68A, 2N4Rtau#86F and control. (J-K) Histograms showing the 
number of photoreceptors in flies expressing human 2N4R tau inserted in different 
genomic positions using GMRGAL4,GAL80TS and aged for 1 or 21 days. On average 
>100 ommatidia were counted coming from 3-5 independent flies. Human tau 





Neurofibrillary tangles containing high levels of hyperphosphorylated tau are one of the 
main pathological features that contribute to the neurodegenerative process in 
tauopathies. Drosophila is now a well-established model for tauopathies where it is 
possible to investigate human tau toxicity (Bonini & Fortini, 2003; Muqit & Feany, 
2002). Transgenic Drosophila models of tauopathy have shown key features of the 
human disorders including human tau-driven neurotoxicity. In particular, it has already 
been demonstrated that expression of human tau during the development of the 
Drosophila eye is toxic and causes photoreceptor degeneration (Jackson et al, 2002; 
Khurana et al, 2010; Shulman & Feany, 2003; Steinhilb et al, 2007a; Steinhilb et al, 
2007b; Wittmann et al, 2001). These fly models were created using standard P-element 
mediated transgenesis that allows the integration of the transgene in random 
chromosomal sites (Rubin & Spradling, 1982; Spradling & Rubin, 1982). As a 
consequence, the fly models are characterised by different genetic backgrounds and by a 
different expression level of the transgene. However, no clear evidence has been shown 
on the phenotypic reproducibility and transgene expression levels in the fly models 
created to investigate tauopathies. The aim of my thesis is to characterise the 
contribution of individual sites in human tau toxicity. To do this I need to establish a 
model where the transgenes have a uniform level of expression. This chapter 
investigated the reproducibility of the eye degeneration mediated by human tau in 
Drosophila and characterised the fly models of tauopathy generated in this study by 
quantifying the transgene expression levels and the neurodegeneration levels. 
 
 
3.3.1 Variability of tau transgene expression from P-element insertions 
 
Expression of human tau in the Drosophila eye produced a degenerative phenotype as 
previously demonstrated (Jackson et al, 2002; Nishimura et al, 2004; Wittmann et al, 
2001). Several transgenic Drosophila lines were created via P-element mediated 
transgenesis carrying the same human 2N4R tau construct. When expressed in the eye 
photoreceptor neurons, human tau causes several different amounts of degeneration that 
varies between the transgenic lines carrying the human tau inserted at different genomic 
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positions at random. The level of tau-mediated degeneration is not reproducible when 
the same construct is inserted at different sites via P-element mediated transgenesis. 
 
The transgenic flies created in this study differ only by the genomic position of the 
human 2N4R tau. The variation in the intensity of the eye phenotype upon tau 
expression could potentially be explained if the chromosomal sites of the transgene 
interfere with endogenous genes required for eye development. The genomic positions 
of the human tau transgene were mapped in all transgenic lines. None of the tau 
insertions disrupts fly genes known to be involved in eye development. Thus, the 
variation of eye degeneration is not likely due to the alteration or mutagenesis of genes 
playing a key role in fly eye development. In order to establish the basis of the variation 
in tau-mediated eye degeneration, a biochemical characterisation of the fly models of 
tauopathy created in this study was performed. All transgenic lines expressed an equal 
amount of total 2N4R tau protein in the fly eye, suggesting that the different intensities 
of eye degeneration is not determined by the levels of expression of human 2N4R tau 
protein. 
 
The formation of insoluble aggregates of tau is one of the main cellular features of 
tauopathies. Tau hyperphosphorylation and detachment from microtubules produces 
species of human tau with altered solubility properties in humans and fly models (Chau 
et al, 2006; Hirata-Fukae et al, 2009). Wittmann et al, (2001) have shown that in flies 
expressing human tau neurodegeneration occurs without the formation of neurofibrillary 
tangles, characteristic of human pathologies. However, tau aggregates have been found 
in the retina of transgenic Drosophila over-expressing human tau, suggesting the 
possible presence of pre-tangle tau forms (Chatterjee et al, 2009; Jackson et al, 2002). 
Human tau hyperphosphorylation has been shown to correlate with an alteration of tau 
protein solubility in flies (Chau et al, 2006; Wittmann et al, 2001). In this investigation, 
the levels of soluble and insoluble tau were quantified in all transgenic lines expressing 
2N4R tau in the fly eye. The majority of the human 2N4R tau expressed was found in a 
soluble state in each individual transgenic line. However, levels of soluble and insoluble 
tau did not change when the fly lines where compared to each other. As a conclusion, 
no direct correlation was found between the levels of insoluble human tau and the 
severity of toxicity in the eye. Although these results confirm that human tau protein 
exists in different solubility states in Drosophila models of tauopathy as previously 
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shown (Chau et al, 2006). Finally, qPCR analysis revealed that levels of human tau 
transcript correlate to the intensities of eye degeneration exhibited by transgenic fly 
lines carrying the human 2N4R tau transgene inserted in different genomic positions. 
Potentially, the line exhibiting the strongest eye degeneration was also characterised by 
the highest tau transcript level. The transcript analysis allowed a more accurate 
quantification of human tau expression compared to the protein analysis. 
 
This study shows that the human tau-mediated toxicity in the Drosophila eye 
corresponds to the level of transcription expression of the human transgene, but not to 
the protein level. This discrepancy might be due to two factors. Firstly, the sensitivity 
between the techniques used is different. The transcript quantification via qPCR is more 
sensitive than the protein quantification via western blotting and it is not affected by any 
possible post-translational modification of the protein. Secondly, when analysing the 
transcript level, a reporter protein was expressed together with human tau in the eye to 
allow a more precise normalisation. On the other hand, the protein analysis was 
conducted using actin from the whole head as normalisation factor. 
 
Furthermore, the genomic position of the transgene influences this expression level. The 
same transgene inserted in different chromosomal sites can be expressed at significantly 
different levels and ultimately lead to variations in phenotype intensity. These findings 
agree with recent studies focused on measuring the positional effect of transgenes 
across different genomic loci in Drosophila. Using the GAL4 system Markstein et al 
(2008) found that the positional effect causes a large variation in the transgene 
expression from tissue to tissue and therefore there is no single locus that permits 
optimal gene expression in all tissues. Moreover, the results presented show that the 
genomic position of the insertion and the expression level of the transgene contribute to 
determine the intensity of phenotype in a specific tissue in Drosophila (Markstein et al, 
2008). 
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3.3.2 Low level of human tau expression from phiC31 insertions 
 
To date, many studies have investigated the effect that single point mutations in human 
tau might have in modulating tau toxicity in flies induced by endogenous kinases. The 
mutated tau constructs were inserted via P-element mediated transgenesis at random in 
the fly genome. The phenotypes observed upon expression of various tau isoforms were 
compared between the different fly lines in order to compare the toxicity levels. 
However, the possible phenotype variation caused by the genomic positional effect of 
the human tau transgene was not considered. One of the aims of this work is to 
investigate the phenotypic effect of several mutations in human tau, therefore a novel 
method of transgenesis was used to standardise the transgene expression level and the 
genetic background of the tauopathies models created. 
 
Recently an alternative approach of transgenesis in Drosophila has been developed that 
allows the integration of transgenes in specific and reproducible genomic loci. This 
novel method exploits the ability of the phiC31 integrase to mediate recombination 
between the bacterial and phage attachment sites, attB and attP (Bischof et al, 2007; 
Groth et al, 2004). A collection of fly lines is available with attP attachment sites 
located in different non-coding genomic positions. One of the first lines to be described 
contained the attachment site located in the cytological position 68A flanked by the 
CG6310 and MocsI genes on the third chromosome (Groth et al, 2004). It has been 
shown that a luciferase reporter transgene inserted in 68A is optimally regulated using a 
GAL4 system - it is nearly silent under basal conditions and strongly induced under 
activating conditions (Markstein et al, 2008). Moreover, since the position of the 
transgenic insertion within the genome affects its expression and the effects are tissue-
dependent, the expression level of the reporter gene inserted in 68A was tested in 
different tissues, particularly in the larval CNS where it was found to be high compared 
to other phiC31 insertion sites (Markstein et al, 2008). 
 
In this study, several Drosophila lines were created using the phiC31-mediated 
transgenesis carrying the same human 2N4R tau gene. The chromosomal sites of 
transgene insertion were chosen in non-coding areas of the Drosophila genome and 
were reproducible. Upon 2N4R tau expression in the fly eye, the phiC31 Drosophila 
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lines exhibit very weak eye degeneration compared to the transgenic lines created with 
standard methods. Following a biochemical characterisation, the levels of tau transcript 
were shown to be significantly lower compared to that seen in lines generated by 
standard transgenesis. Moreover, soluble and insoluble tau isoforms were produced with 
increased levels of soluble tau over the insoluble form. Additionally, the lines carrying 
the tau transgene insertion in the cytological locations 51C or 68E do not show eye 
degeneration compared to control. A reason for this might be due to a particularly low 
level of tau expressed in the eye, therefore these lines were not considered for my 
investigation. Taken together these results show that the phiC31-mediated transgenesis 
can be used to generate fly models of tauopathy that exhibit weak eye degeneration, but 
more importantly, this transgenesis system overcomes the phenotypic variations due to 
positional effect of the transgenes. Using this method, different transgenic construct 
carrying mutated forms of human tau can be inserted in the same genomic loci in 
different Drosophila lines leading to a standardised level of expression and genetic 
background. Ultimately tau-mediated toxicity in the fly eye would be affected only by 
the mutation on human tau avoiding any positional effect of the transgene. Since my 
thesis aims to identify the human kinases that produce toxic forms of tau, another 
advantage in using this model is the initial low level of degeneration that allows a more 
easily identification of enhancers of the tau-mediated toxicity. 
 
 
3.3.3 Human tau does not cause photoreceptor neurodegeneration in 
adult Drosophila 
 
I further examined whether the eye phenotype caused by tau represents 
neurodegeneration of differentiated neuronal cells, the photoreceptors, or a toxic effect 
of tau during development. Previous studies show that human tau expression throughout 
development leads to photoreceptor neurodegeneration as well as progressive 
vacuolisation and degeneration of cells in the cortex (Chatterjee et al, 2009; Jackson et 
al, 2002; Nishimura et al, 2004; Wittmann et al, 2001). Here, human 2N4R tau was 
expressed in the fly eye only during adulthood to see whether the photoreceptor neurons 
would undergo age-dependent neurodegeneration. Upon ageing the transgenic flies 
expressing human 2N4R tau did not exhibit photoreceptor loss. However, when 
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expressed at high levels during development, human tau causes an alteration of the 
external structure of the eye although the number of photoreceptor does not change 
when tau is expressed only during adulthood. In conclusion, the tau-mediated 
phenotypes observed during the previous experiments are not due to neurodegeneration 
but rather to developmental defects. In the tauopathy model here created the eye 
phenotype is intended to use as readout for the interaction between human tau and 
human kinases. Thus, the causes underlying the eye degeneration should not affect the 
readout of protein interaction. 
 
In conclusion, these data show that in Drosophila models of tauopathy, the genomic 
position and the transcript level of the human tau gene affect the intensity of tau 
mediated-toxicity in the fly eye. The phiC31-mediated transgenesis of the human tau 
gene leads to the creation of a more standardised animal model where the level of 
transgene expression is controlled and the insertion event can be reproduced. The 
transgenic lines created with the site-specific integration are characterised by a very low 
level of transgene expression and tau-mediated toxicity. This might be an advantage in 
the identification of enhancers of the phenotype, for example kinases that might 
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4.1.1 Tau hyperphosphorylation in tauopathies 
 
There is growing evidence that hyperphosphorylation of tau triggers its aggregation into 
tangles (Alonso et al, 2001; Ballatore et al, 2007; Lauckner et al, 2003). Another 
possibility is that after aggregation, tau becomes hyperphosphorylated, adopting an 
altered conformation and thereby inhibiting the action of protein phosphatases. 
Ultimately, phosphorylation of tau plays a critical role in the development of AD 
pathogenesis because it alters the microtubule-binding affinity of tau (Amniai et al, 
2009; Ballatore et al, 2007; Iqbal et al, 2009). Potential therapeutic strategies against 
tauopathies have focused on reducing tau phosphorylation through inhibition of specific 
protein kinases (Lau et al, 2002). This approach aims to reduce tau aggregation and 
associated neuronal loss hopefully slowing neurodegeneration in patients (Churcher, 
2006). Recently, the validity of this approach has been demonstrated by successful in 
vivo experiments using transgenic animals. In fact, it has been shown that tau kinase 
inhibitors can reduce tau hyperphosphorylation and disease-associated phenotypic 
defects (Hung et al, 2005; Lewis et al, 2000; Munoz-Montano et al, 1997; Nakashima et 
al, 2005; Noble et al, 2005). Therefore, it is crucial to identify the full range of protein 
kinases and phosphatases that regulate tau phosphorylation in order to find the full 
complement of therapeutic targets. 
 
There is no in vivo evidence of the kinases that are specifically involved in the 
production of pathogenic tau hyperphosphorylation in tauopathies. However, many 
kinases have been shown to phosphorylate tau in vitro (Anderton et al, 2001; Cruz & 
Tsai, 2004; Feijoo et al, 2005; Hanger et al, 2009; Hanger et al, 2007; Mandelkow et al, 
2004). The potentially major protein kinases for pathological phosphorylation of tau 
include glycogen synthase kinase-3β (GSK3β), cAMP-dependent protein kinase (PKA) 
and casein kinase 1δ (CK1δ). The phosphorylation sites that are crucial for the 
physiological and pathological tau role in vivo remain unknown. The sequence of tau 
contains 85 potential phosphorylation sites, including 45 serines, 35 threonines and 5 
tyrosines. However, in post-mortem control brains only 17 of them have been found to 
be phosphorylated. On the other hand, in AD brains recent studies have identified 39 
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phosphorylated sites via mass spectrometry and 6 via phospho-antibody 
immunoreactivity (Hanger et al, 2009; Hanger et al, 2007; Lebouvier et al, 2009; 
Morishima-Kawashima et al, 1995). 
 
GSK3β has been shown to phosphorylate tau both in vitro and in cultured cells at 
epitopes known to be phosphorylated in post-mortem AD brain tissue (Hanger et al, 
2007; Hanger et al, 1992; Jicha et al, 1999; Lovestone et al, 1994b). Tau extracted from 
transgenic mice over-expressing an inducible form of GSK3β has a higher level of 
phosphorylation than control brain tau. Moreover, transgenic mice exhibiting tangle 
pathology treated with lithium, an inhibitor of GSK3β, show a reduction of tangle load 
(Noble et al, 2005). Several pharmaceutical companies now have inhibitors of GSK3β 
under development as therapeutic agents for AD. However, it is not clear whether 
inhibition of GSK3β alone would be sufficient to alleviate disease and it is necessary to 
identify whether further kinases contribute to tau pathology since they may be potential 
additional therapeutic candidates. In vitro phosphorylation studies with purified protein 
kinases and recombinant tau has shown that GSK3β can phosphorylate at least 26 but 
not all of the identified tau phosphorylation sites from post-mortem AD brains (Hanger 
et al, 2009; Hanger et al, 2007). 
 
It has been shown that PKA can phosphorylate tau on up to 19 sites causing a reduction 
of microtubule assembly in vitro (Hanger et al, 2009; Pierre & Nunez, 1983; Scott et al, 
1993; Singh et al, 1994). PKA phosphorylation sites reside on the microtubule-binding 
C-terminal region comprising residues 187-430 (Steiner et al, 1990). (Jicha et al, 1999) 
demonstrated that PKA is tightly associated with the neurofibrillary pathology, 
positioning PKA to participate directly in tau hyperphosphorylation. In particular, PKA-
dependent phosphorylation of S214 and S409 is increased in PHF-tau compared to 
control brains and it may be an early step in the conversion of tau in a pathogenic state. 
Moreover, abnormal phosphorylation of tau by PKA has been suggested to result in a 
protease-resistant tau population which may contribute to the formation of tau 
aggregates in tauopathies (Litersky & Johnson, 1992). 
 
CK1 is a family of kinases highly overexpressed in AD brains and mainly found within 
neurofibrillary lesions in both AD and other tauopathies (Ghoshal et al, 1999; Schwab 
et al, 2000; Yasojima et al, 2000). They appear as major players in tau aggregation and 
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filament formation as well as in Aß processing (Flajolet et al, 2007; Hanger et al, 2007; 
Kuret et al, 1997). CK1δ is a particularly robust marker of granulovacuolar 
degeneration bodies and the major source of basal phosphorylation activity on S202, 
T205, S396 and S404 of tau in vitro (Ghoshal et al, 1999; Hanger et al, 2007; Li et al, 
2004). Expression levels of CK1 has been reported to be elevated more than 20 fold in 
post-mortem AD brain (Yasojima et al, 2000). Upon CK1δ phosphorylation of tau, a 
reduction in tau bound to detergent-insoluble microtubules is present, suggesting that 
CK1δ phosphorylates tau at sites that modulate tau binding to microtubules (Li et al, 
2004). These observations lead to the hypothesis that CK1 enzymes regulate tau 
phosphorylation and that their up-regulation in level or activity contributes to tau 
hyperphosphorylation in disease. CK1δ can phosphorylate tau on at least 22 sites; a 
combination of GSK3β and CK1δ can phosphorylate more than three-quarters of the 
sites that are known to be phosphorylated in PHF-tau (Hanger et al, 2009; Hanger et al, 
2007). 
 
Recently, novel kinases have been suggested to be involved in the pathogenic 
production of toxic forms of hyperphosphorylated tau protein, including DYRK1A (Liu 
et al, 2008; Wegiel et al, 2008). This kinase has been shown to contribute to the aberrant 
brain development underlying mental retardation in DS. Interestingly, the DYRK1A 
locus is localised on human chromosome 21, within the DS critical region (Marti et al, 
2003). In addition, it has been shown that early-onset AD is a feature of DS patients 
(Altafaj et al, 2001; Ryoo et al, 2007). Both DS and AD have common pathological 
hallmarks such as amyloid plaques and NFTs. Higher levels of DYRK1A have been 
found in DS brains and its presence has been detected in NFTs from patients with 
sporadic AD (Liu et al, 2008; Wegiel et al, 2008). Moreover, DYRK1A is able to 
phosphorylate tau in vivo mainly in its proline-rich region. The known phosphorylation 
sites on tau in vitro are S199, S202, T205, T212 and S404, which may be important in 
the loss of microtubule assembly and in the formation of NFTs (Hanger et al, 2009; Liu 
et al, 2008; Ryoo et al, 2007). Thus, DYRK1A could be a kinase able to generate toxic 
forms of tau and maybe a novel potential target for the treatment of the tauopathy in 
both DS and AD patients. 
 
Recent in vitro studies have suggested that multiple kinases are likely to be involved in 
tau phosphorylation and that specific kinases may prime tau for phosphorylation by 
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others, inducing a kinase cascade. For example, CK1δ, DYRK1A and cdk5 have been 
suggested to prime tau for subsequent phosphorylation by GSK3β (Li et al, 2006; 
Woods et al, 2001). Moreover, there is evidence suggesting that phosphorylation of 
T212 by DYRK1A promotes GSK3β-mediated phosphorylation of tau (Woods et al, 
2001). Therefore, targeting the inhibition of a priming kinase may be another promising 
therapeutic strategy to reduce the overall level of tau phosphorylation.  
 
 
4.1.2 Tau hyperphosphorylation in Drosophila models of tauopathy 
 
Most work investigating the phosphorylation of tau has been performed in vitro with 
purified proteins; in vivo validation of these findings is required. Therefore, it is 
essential to understand the importance of the candidate kinases for tau toxicity and their 
activity on the predicted sites in vivo. Drosophila has emerged as an excellent model 
system for studying human neurodegenerative disease (Reiter et al, 2001). Previous 
investigations used the fly models of tauopathy to identify endogenous Drosophila 
genes that can modify human tau toxicity. It has been shown that Drosophila 
endogenous kinases phosphorylate tau and possibly have a major role in generation 
toxic forms of the tau protein in this model (Blard et al, 2006; Chatterjee et al, 2009; 
Chau et al, 2006; Jackson et al, 2002; Nishimura et al, 2004; Shulman & Feany, 2003; 
Steinhilb et al, 2007a; Steinhilb et al, 2007b; Wittmann et al, 2001). It has been 
confirmed that the Drosophila GSK3β (shaggy) and MARK (PAR-1) protein kinases 
are necessary for tau-mediated neurodegeneration in flies (Jackson et al, 2002; Mudher 
et al, 2004; Nishimura et al, 2004). Additional genetic screens have also identified 
further endogenous Drosophila genes, primarily kinases and phosphatases, which 
promote or inhibit human tau toxicity (Shulman & Feany, 2003; Steinhilb et al, 2007b). 
It is likely therefore that Drosophila provides an accurate biosensor to evaluate the 
ability of individual kinases to confer toxicity on tau. 
 
The aim of this chapter is to characterise whether these human kinases can produce 
toxic forms of human tau in vivo. Previous studies using Drosophila focused on the role 
of endogenous Drosophila kinases in human tau phosphorylation, this investigation 
proposes to use the fly model of tauopathy to evaluate the role of specific human 
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kinases in producing toxic forms of tau. Human tau together with human kinases were 
expressed together in the Drosophila eye to identify which kinases increase tau toxicity. 
This in vivo model allows us to rapidly manipulate and test the interaction between 
human tau and human kinases. The selected human kinases described above that are 
relevant to tau pathology are studied, including GSK3β, PKA, CK1δ and DYRK1A. 
Ultimately, I hope to determine which of the selected human kinases are responsible for 
production of toxic forms of tau and would make the most promising candidates for 
therapeutic targets. To gain a greater insight into the role of human kinases in the 
generation of tau toxicity, this in vivo system will also be used to determine the sites on 
tau that are phosphorylated to give rise to more toxic forms of tau that may cause neural 
degeneration. The identification of pathogenic phosphorylation sites might also 
contribute to the detection of potential biomarkers. This is achieved by mutating key 
phosphorylation sites within human tau and by investigating whether this modifies the 




4.2.1 Human kinases in Drosophila 
 
To examine whether active human kinases could be expressed in Drosophila cells, S2 
cells were transfected with 2N4R tau and either GSK3β, PKA, CK1δ or DYRK1A. The 
S2 cell line is the most widely used Drosophila cell line and it was originally derived 
from late embryonic stage Drosophila embryos as a spontaneously immortalised, non-
clonal cell line. These cells exhibit mesodermal characteristics and their cellular 
behaviours and gene expression suggest that they are derived from haemocytes 
(Schneider, 1972). 
 
Expression of human 2N4R tau was controlled by an inducible UAS-GAL4 system. 
Cells were transfected with two plasmids, one containing the UAS-tau sequence and the 
other one containing an inducible GAL4 construct. GAL4 expression was controlled by 
a metallothionein promoter, which can be induced by adding copper sulphate. Human 
kinase expression was driven by a constitutively active actin promoter. In order to easily 
detect their expression on western blots, the kinases carried a tag at the 3’end of their 
cDNA sequences. The full-length human GSK3β sequence was tagged with the myc 
epitope. The human CK1δ construct encodes a constitutively active truncated protein, 
which is tagged at the C-terminus with a flag epitope. This truncation at amino acid 317 
has been shown to increase CK1δ activity (Graves & Roach, 1995; Longenecker et al, 
1996). Similarly, expression of only the α-catalytic domain of human PKA has also 
been shown to be more active (Skalhegg & Tasken, 2000). This human PKA construct 
carried a myc epitope tag at the 3’end of its sequence. Finally, rat DYRK1A was tagged 
at the N-terminus with a flag epitope. Rat DYRK1A is characterised by extremely high 
sequence similarity with the human orthologue, differing only by three amino acids. 
S2 cells were transfected with human tau and a single kinase. Human 2N4R tau 
expression was induced for five hours while kinases were constitutively expressed 
(Chapter 2). Cells transfected with an empty vector were used as negative control. 
Expression of human tau and kinases was successfully detected by western blotting 
(Figure 4.1A). The anti-human tau antibody supplied by Dako recognises an epitope on 
tau independent of its phosphorylation state. Control cells carrying an empty vector 
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show no tau expression, suggesting that the anti-human tau antibody is specific and 
does not cross-react with the Drosophila proteins. Following five-hour expression, 
human tau is detected on the blot as multiple bands at an apparent molecular weight 
ranging from 60 kDa to 65 kDa. This might be due to different levels of basal 
phosphorylation by endogenous kinases leading to the production of stable human tau 
species characterised by different mobility on western blot. The expression of human 
and rat kinases were detected using anti-myc and anti-flag antibodies. All kinases ran on 
western blot at the expected molecular weight: PKA 40 kDa, CK1δ 37 kDa, DYRK1A 
100 kDa and GSK3β 60 kDa. Actin expression was used to normalise for gel loading. 
When human 2N4R tau was co-transfected together with human CK1δ or rat DYRK1A, 
the pattern of tau bands did not change compared to human tau transfected alone. 
However, some differences in the tau bands were observed when PKA or GSK3β were 
co-transfected. Co-expression of human PKA enriched the production of tau forms with 
high molecular weight. Co-expression of GSK3β led to a more dramatic shift in 
mobility of human tau. The shifts observed are probably due to phosphorylation of 
human tau by human PKA or GSK3β in Drosophila cells (Figure 4.1A). 
 
In order to monitor the sites of human tau phosphorylated by the selected human 
kinases, we aimed to perform mass spectrometry on human tau extracted from S2 cells. 
This technique would allow us to map all the phosphorylated sites present on human tau 
before and after co-transfection with human kinases. Unfortunately, we were not able to 
extract enough protein for the mass spectrometry analysis (data not shown). This might 
be due to the fact that the construct for human tau does not carry a tag, which might 
have facilitated the purification of the protein. As a consequence, the protein extract 
derived from S2 cells transfected with human tau and kinases were analysed using 
phospho-specific antibodies for human tau (Figure 4.1B-F). The phospho-specific 
antibodies chosen are widely used to study pathogenic tau phosphorylation in 
tauopathies and they recognise different phosphorylation sites: PHF1 (pS396 and 
pS404), AT8 (pS202 and pT205), AT270 (pT181), AT100 (pS212 and pS214) and 
Tau1 (dephosphorylation at Y197-S208) (Goedert et al, 1994; Goedert et al, 1995b; 
Otvos et al, 1994; Szendrei et al, 1993). Control cells carrying an empty vector show no 
phospho tau expression, suggesting that all anti-phospho human tau antibodies are very 
specific and do not cross-react with endogenous Drosophila proteins. Human 2N4R tau 
showed a basal level of phosphorylation of the PHF1 epitope that is significantly 
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increased only when human GSK3β is expressed (Figure 4.1B). Moreover, the PHF1 
antibody detected specifically the higher molecular bands of human tau in all samples, 
suggesting that the multiple bands representing human tau arise from a differential 
phosphorylation state of the protein. However, phosphorylation of the AT8 epitope on 
human tau is very specific and occurs on the higher molecular weight species of tau 
only when GSK3β is co-expressed (Figure 4.1C). The AT270 antibody reveals a basal 
level of phosphorylation at its epitope on human tau generated by endogenous kinases 
but a shift occurs to the tau forms only when GSK3β is co-expressed, similar to the 
result obtained with the PHF1 antibody (Figure 4.1D). No detection of the AT100 
epitope was seen (Figure 4.1E). The Tau1 antibody recognises tau only when S195, 
S198, S199, S202 and T205 are dephosphorylated. A lower level of dephosphorylation 
was shown by the highest molecular species of tau when GSK3β is expressed (Figure 
4.1F). Together these results lead to the conclusion that human GSK3β is the only 
human kinase that significantly phosphorylates human tau in Drosophila cells at the 
specific sites tested. It is possible that human PKA, CK1δ and rat DYRK1A 
















































































Figure 4.1 Human GSK3β phosphorylates human tau in Drosophila S2 cells. After 
transfection, human 2N4R tau, kinase and actin expression were detected on western 
blot of S2 cell lysates. Recombinant human 2N4R tau (rTau) was loaded as positive 
control for tau and S2 cells transfected with an empty vector were used as negative 
control. Total tau was detected as multiple bands (60-70 kDa) using the 
phospho-independent antibody Dako. β-actin was used as loading control (42 kDa). (A) 
Kinases were detected using anti-flag and anti-myc antibodies: PKA (50 kDa), CK1δ (37 
kDa), DYRK1A (95 kDa), GSK3β (60 kDa). (B-F) Phosphorylated human tau was 
detected using phospho-specific antibodies (B) PHF1 for pS396 and pS404, (C) AT8 for 
pS202 and pT205, (D) AT270 for pT181, (E) AT100 for pT212 and pS214 and (F) the 
dephospho-dependent antibody Tau1 (S198-S208). Human 2N4R tau alone shows a 
basal phosphorylation level at PHF1 and AT270 epitopes. Co-transfection of human 
GSK3β causes a mobility shift of human tau and increased phosphorylation is detected 
with PHF1, AT8 and AT270.
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I aimed to identify whether any of the chosen human kinases could increase the toxicity 
of the human tau beyond that generated by endogenous kinases. I tested this by 
expressing specific human kinases with the human tau in the Drosophila eye. Many 
studies demonstrated that human tau-mediated degeneration is enhanced by 
overexpression of Drosophila shaggy (Chatterjee et al, 2009; Jackson et al, 2002; 
Nishimura et al, 2004). Shaggy is the fly orthologue of GSK3β and it is involved in 
many processes, including notch and wingless signalling pathways (Cadigan & Nusse, 
1997; Foltz et al, 2002). In order to see whether this result could be reproduced using 
the phiC31 transgenic tau line created in this study, the phenotype of flies co-expressing 
human 2N4R tau and Drosophila shaggy were observed. The transgenic tau line chosen 
for the experiment was line 2N4Rtau#68A with the human 2N4R tau gene inserted via 
phiC31-specific transgenesis in position 68A. 
 
Human 2N4R tau and Drosophila shaggy was expressed in the fly eye using the 
GMRGAL4 driver. Gene expression was induced throughout development at 25ºC and 
flies were collected between 0 to 5 days post-eclosion. The eye phenotypes were 
examined by light microscopy (Figure 4.2). Control flies express GMRGAL4 alone in 
order to monitor the background phenotype caused by the expression of the genetic 
driver. Control eyes are characterised by an oval optic lobe and a regular arrangement of 
ommatidia (Figure 4.2A). In contrast, when either human 2N4R tau or Drosophila 
shaggy is expressed in the eye, a disruption of the eye architecture is present. Line 
2N4Rtau#68A is characterised by a weak disarrangement of the ommatidial pattern 
compared to control, but no alteration of eye shape or necrotic tissue is present (Figure 
4.2B). Over-expression of endogenous shaggy leads to a disruption of the central 
ommatidia arrangement (Figure 4.2C), as previous studies reported (Chatterjee et al, 
2009; Jackson et al, 2002; Nishimura et al, 2004). When human 2N4R tau is co-
expressed together with shaggy, an enhancement of eye degeneration is observed 
(Figure 4.2D). The area of the eye showing ommatidial disarrangement is larger 
compared to that seen when human tau and shaggy are expressed alone. Moreover, 
depigmentation is observable in the central area of the eye due to the degeneration of 
the pigmented cells, part of each ommatidium. Examination of the phenotypes caused in 
the eye by expression of human 2N4R tau and Drosophila shaggy reveals an 
enhancement of eye degeneration compared to human tau and shaggy expressed alone. 
Thus, the human tau-mediated degeneration observed in the fly model of tauopathy 
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created in this study can be enhanced by over-expression of a kinase, in this case the 
endogenous shaggy. It is possible that this phenotype is due to an addictive 
developmental toxicity of human tau and shaggy, however the intensity of eye 
degeneration correlates with previous studies that demonstrate an enhancement of tau 
toxicity upon shaggy over-expression (Chatterjee et al, 2009; Jackson et al, 2002; 
Nishimura et al, 2004; Steinhilb et al, 2007b). Line 2N4Rtau#68A can reproduce results 
previously seen with other fly models of tauopathy and therefore it can be used for 





Figure 4.2 Human tau-mediated degeneration is enhanced by co-expression of 
shaggy in the Drosophila eye. Light micrographs of eyes from 0-5 days old flies. (A) 
Control eyes carrying the eye specific GMRGAL4 driver show a regular array of 
ommatidia. (B) Expression of human tau from 2N4Rtau#68A causes weak ommatidial 
disruption. (C) A weak disarrangement of ommatidia is also observed when Drosophila 
shaggy is expressed. (D) Co-expression of human 2N4R tau and Drosophila shaggy 
enhances the degenerative phenotype in the eye causing depigmentation and increased 
roughness. Scale bar: 100 µm. Dorsal is top and anterior is left.
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The specific human kinases responsible for the hyperphosphorylation of tau in AD 
brains are still not known. I used the 2N4Rtau#68A line to test the ability of specific 
human kinases to increase toxicity. Drosophila transgenic lines were created carrying 
genes for human kinases, including GSK3β, PKA, CK1δ and DYRK1A. The kinase 
transgenes were inserted in different genomic positions at random and most of them 
carried a tag to detect their expression on western blot. The constructs encoding for 
human and rat kinases contained the same features as described above. The kinases 
were expressed in the Drosophila eye using the GMRGAL4 driver. Expression was 
induced throughout development at 25ºC and flies were collected between 0 to 5 days 
post-eclosion. The effect of co-expression of the above human kinases in Drosophila 
photoreceptor neurons were analysed by light microscopy and western blotting. Control 
flies expressing GMRGAL4 alone are characterised by an oval optic lobe and a regular 
arrangement of ommatidia (Figure 4.3A). When GSK3β, PKA, CK1δ and DYRK1A 
were individually expressed in the fly eye, no ommatidial disarrangement was 
observable compared to control (Figure 4.3B-E). Western blot analysis confirmed that 
expression of the kinases was driven in the eyes. Proteins were extracted from fly heads 
using standard protocols (Chapter 2). Human GSK3β and CK1δ were detected using 
anti-myc and anti-flag antibodies respectively. An antibody specific for the α-catalytic 
domain of PKA was used for the flies expressing human PKA. Finally, tagged rat 
DYRK1A was detected using an anti-flag antibody. Actin or tubulin expression were 
used to monitor protein loading. All the kinases were expressed and represented on the 
blots by a single band of expected molecular weight. 
 
Transgenic lines for GSK3β, CK1δ and DYRK1A express considerable amount of 
kinases, in contrast the line for human PKA shows a weak kinase expression. Levels of 
expression varied as different insertion sites of the transgenes were used. Fly lines 
expressing the highest levels of human and rat kinases were selected to use in this study 
(data not shown). The above characterisation of Drosophila lines expressing human and 
rat kinases demonstrates that no alteration on the regular structure of ommatidia is 
caused by the transgene expression compared to control and that the fly lines have 
reproducible levels of transgene expression. 
In conclusion, expression of human and rat kinases in Drosophila photoreceptor 
neurons does not affect any endogenous developmental pathway necessary for eye 
development.













































Figure 4.3 Expression of human kinases in the developing Drosophila eye does 
not alter the ommatidial architecture. (A-E) Light micrographs of eyes from 0-5 days 
old flies. (A) Control eyes carrying the eye specific GMRGAL4 driver show a regular 
array of ommatidia. (B-F) Drosophila transgenic lines expressing the human kinases (B) 
GSK3β, (C) PKA, (D) CK1δ and (E) the rat kinase DYRK1A does not cause ommatidial 
disarrangement compared to control. (F-H) Kinase expression in the Drosophila eye was 
detected by western blotting. β-actin or α-tubulin were used as loading controls (42 and 
50 kDa respectively). Flies carrying the GMRGAL4 driver only were used as negative 
control. (F) Expression of human GSK3β and CK1δ were detected using anti-myc and 
anti-flag antibodies (60 kDa and 37 kDa respectively). (G) Human PKA expression was 
detected using a specific antibody against the α chain (40 kDa). (H) Rat DYRK1A 
expression was detected using an anti-flag antibody (95 kDa). Scale bar: 100 µm. Dorsal 
is top and anterior is left.
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Many studies have focused on the interaction of human tau and human kinases in vitro, 
however there is no in vivo evidence of which human kinases are involved in tau 
hyperphosphorylation or whether specific phosphorylation sites mediate toxicity 
(Anderton et al, 2001; Cruz & Tsai, 2004; Feijoo et al, 2005; Hanger et al, 2009; 
Hanger et al, 2007; Mandelkow et al, 2004). This study aims to identify the human 
kinases producing the most pathogenic tau species in vivo. To examine whether the 
introduced kinases can increase the 2N4R tau-mediated toxicity, they were co-expressed 
together with tau and the effect on the eye phenotype characterised. 
 
Human 2N4R tau and kinases (GSK3β, PKA, CK1δ and DYRK1A) were expressed 
using GMRGAL4 that drives the expression of the transgenes in the fly eye. Gene 
expression was induced throughout development at 25ºC and flies were collected 
between 0 to 5 days post-eclosion. The eye phenotypes were examined by light 
microscopy. Control flies express GMRGAL4 alone in order to monitor the background 
phenotype caused by the expression of the genetic driver. Control eyes are characterised 
by an oval optic lobe and a regular arrangement of ommatidia (Figure 4.4A). Expression 
of tau alone from line 2N4Rtau#68A causes a weak disarrangement of the ommatidial 
pattern compared to control (Figure 4.4B). The Drosophila lines expressing human and 
rat kinases were demonstrated to present an unaltered eye structure compare to control 
(Figure 4.3A-E). Human 2N4R tau was co-expressed with each individual kinase in 
order to see whether the eye degeneration would increase upon interaction of human tau 
and kinases. When human GSK3β is co-expressed with human 2N4R tau, the eye 
degeneration phenotype is enhanced compared to human tau alone. The disarrangement 
of ommatidia is increased in the anterior part of the eye and the characteristic oval shape 
of the eye is altered compared to control (Figure 4.4C). However, human PKA and 
human CK1δ co-expression with tau does not lead to an enhancement of eye 
degeneration. Unexpectedly, the level of degeneration caused by the interaction of 
2N4R tau and PKA appears to be lower compared to tau alone and more similar to 
control (Figure 4.4D). Moreover, co-expression of 2N4R tau and CK1δ does not affect 
the basal human tau-mediated eye degeneration caused by line 2N4Rtau#68A (Figure 
4.4E). Finally, rat DYRK1A co-expression causes a minor enhancement of human tau-
mediated degeneration shown by increased ommatidial disarrangement in the anterior 
part of the eye (Figure 4.4F). 
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Surprisingly, not all the kinases increase tau toxicity in this model. Human GSK3β and 
rat DYRK1A produced an increased degeneration indicating increased tau toxicity in 
the fly eye. The kinase showing the greatest enhancement of human tau-mediated eye 
degeneration was GSK3β, while DYRK1A produced a very mild phenotypic 
enhancement. In contrast, PKA and CK1δ did not increase the eye degeneration 












Figure 4.4 Human tau-mediated degeneration is enhanced by co-expression of 
human and rat kinases. Light micrographs of eyes from 0-5 days old flies. (A) Control 
eyes carrying the eye specific GMRGAL4 driver show a regular array of ommatidia. (B) 
Expression of human tau from 2N4Rtau#68A causes weak ommatidial disruption. (C) 
Co-expression of human 2N4R tau and human GSK3β enhances the tau-mediated 
degeneration in the eye. (D) No ommatidial disruption is shown when PKA is 
co-expressed with human tau. (E) Co-expression of human 2N4R tau and CK1δ causes 
a weak disruption of ommatidia. (F) Eye degeneration is slightly enhanced when 




4.2.2 Human tau and GSK3β in the fly eye 
 
The previous section revealed an enhancement of tau-mediated degeneration when 
GSK3β is also expressed alongside the human 2N4R tau. In order to confirm the human 
GSK3β enhancement, the expression of the kinase was modulated and the resulting 
phenotype observed. Several fly lines carrying the same human GSK3β transgene were 
generated using standard P-element insertion with the transgene inserted in different 
genomic positions. 
 
Transgene expression was controlled by the eye specific GMRGAL4 driver and was 
induced throughout development at 25ºC. Flies were collected between 0 to 5 days post-
eclosion and they were analysed by light microscopy and western blotting. Control flies 
express GMRGAL4 alone and exhibit an oval optic lobe and a regular arrangement of 
ommatidia (Figure 4.5A). All lines expressing human GSK3β alone (lines GSK3β#1-4) 
showed an eye phenotype similar to control revealing that the expression of the human 
kinase does not interfere with the fly eye development (Figure 4.5B-E). As shown 
before, line 2N4Rtau#68A is characterised by a weak disarrangement of the ommatidial 
pattern compared to control (Figure 4.5F). When line 2N4Rtau#68A was combined 
with the lines expressing human GSK3β, the tau-mediated eye degeneration was 
enhanced (Figure 4.5G-J). Interestingly, the level of enhancement of the degenerative 
phenotype was different in the four lines co-expressing human tau and GSK3β. The fly 
line producing the greatest level of degeneration was GSK3β#1, as shown in figure 
4.4C. Mild enhancement was observed when human tau was expressed together with 
GSK3β#2 and GSK3β#3. Finally, expression of GSK3β#4 did not enhance the eye 
degeneration shown when human tau is expressed alone. 
 
The transgenic lines for GSK3β carry the human kinase gene inserted in different 
genomic positions, therefore, its expression level is different in each line (as 
demonstrated in Chapter 3). The protein levels for GSK3β were tested in all transgenic 
lines by western blotting (Figure 4.5K). Human GSK3β was detected using an anti-myc 
antibody. Control flies show no GSK3β expression. Following expression using the 
GMRGAL4 driver, human GSK3β is detected in all transgenic lines (GSK3β#1-4) as 
single band at the expected molecular shift. Phosphorylation of GSK3β on S9 has been 
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used as marker to monitor its activity; when S9 is phosphorylated GSK3β is not active. 
In order to see whether human GSK3β was active when expressed in the Drosophila 
eye, the level of phosphorylation of S9 was tested by western blotting. A phospho-
specific antibody for human GSK3β-pS9 detected a single band at the same molecular 
shift of total GSK3β. The blot revealed a very low level of phosphorylation of S9 
compared to the amount of total GSK3β expressed, suggesting that the human kinase is 
not inactivated in fly cells (Figure 4.5K). Expression levels of GSK3β were quantified 
using actin to normalise for gel loading. To enable a better comparison between the 
different lines, the protein levels were expressed in percentage relative to the highest 
mean. Line GSK3β#1 expresses a significantly higher amount of human kinase 
compared to the other lines, while GSK3β#4 the lowest amount (Figure 4.5L). 
 
In conclusion, the level of increased tau toxicity correlates to the amount of GSK3β 
expressed. This evidence shows that human 2N4R tau and GSK3β interacts together 
leading to a greater degeneration in the Drosophila eye. Moreover, human GSK3β is 
not inactivated by phosphorylation of S9 in a Drosophila background. Line GSK3β#1 
was used in the following experiments because of its high level of human kinase 
expressed. 
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Figure 4.5 Human GSK3β enhances tau-mediated degeneration in the Drosophila 
eye proportionally to its expression level. Light micrographs of eyes from 0-5 days 
old flies. (A) Control eyes carrying the eye specific GMRGAL4 driver show a regular 
array of ommatidia. (B-E) Expression of human GSK3β from three different insertion 
sites in the Drosophila eye using GMRGAL4 causes no change in regular ommatidial 
arrangement. (F) Expression in the eye of the human tau transgene in the 2N4Rtau#68A 
transgenic line causes a weak ommatidial disruption. (G-J) Co-expression of human 
2N4R tau and human GSK3β enhances the tau-mediated degenerative phenotype in the 
eye. (K) Human GSK3β and actin expression were detected by western blotting from 
head homogenates. flies carrying GMRGAL4 alone were analysed as negative control. 
Human GSK3β was detected as a single band (60 kDa) using an anti-myc antibody (total 
GSK3β) and a phospho-specific antibody for S9 (GSK3β-pS9) which reveals inactivation 
of the kinase. β-actin was used as loading control (42 kDa). (L) GSK3β protein levels for 
each transgenic line were normalised to actin. Values correspond to the mean and SEM 
of 3 replicates of independent experiments. To enable comparison between samples, the 
protein levels were expressed as relative numbers to the highest mean. Asterisks 
indicate statistically significant differences of protein expression. The levels of human 
GSK3β expression are proportional to the enhancement of eye degeneration caused 
when co-expressed with human tau. The levels of S9 phosphorylation on GSK3β are 




Co-expression of human GSK3β with human 2N4R tau causes an enhancement of tau 
toxicity in the Drosophila eye. I next examined the toxic modifications on tau caused by 
GSK3β expression. Alterations in the solubility properties of tau has been shown to be 
associated with increased toxicity in disease and one of the major factors contributing to 
this alteration is tau phosphorylation (Hirata-Fukae et al, 2009; Ishihara et al, 2001; 
Lewis et al, 2000; Zhukareva et al, 2002). In Chapter 3 of this study, the Drosophila 
lines over-expressing human 2N4R tau were shown to produce Sarcosyl-soluble and 
insoluble tau species. 
 
I examined whether the levels of Sarcosyl-soluble and insoluble human tau change upon 
human GSK3β expression in the fly eye. Protein homogenate obtained from fly heads 
was resuspended in 1% Sarcosyl and insoluble tau separated by centrifuging at 
100,000g (Chapter 2). Human 2N4R tau (line 2N4Rtau#68A) and human GSK3β (line 
GSK3β#1) were expressed throughout development at 25ºC with the eye-specific 
GMRGAL4 driver. Protein extracts were prepared from heads of flies collected 0 to 5 
days post-eclosion. Sarcosyl-soluble and insoluble human tau was successfully detected 
on western blot and the expression levels were quantified using actin to normalise for 
protein loading (Figure 4.6). The quantification reveals that the levels of soluble and 
insoluble tau do not change when GSK3β is co-expressed compared to human tau alone. 
However, the levels of insoluble tau produced are significantly lower than the levels of 
soluble tau, as previously shown in figure 3.9. This result shows that the 
phosphorylation by Drosophila endogenous kinases does induce the formation of 
Sarcosyl-insoluble tau species, however these do not appear to be enriched after 
expression of human GSK3β. More importantly, here I show that tau-mediated 
degeneration induced by human GSK3β occurs without a shift in human tau solubility 
in flies. This does not exclude the possibility that GSK3β phosphorylates tau on key 
sites that increase its toxicity in the fly eye. 
 
In section 4.2.1 I demonstrated that in S2 cells human GSK3β increases the 
phosphorylation of 2N4R tau at specific sites. Therefore, I examined whether the same 
sites are phosphorylated in vivo and whether these forms distribute equally in the 
soluble and insoluble fractions of tau. As for the experiment conducted in S2 cells, I 
initially planned to map the phosphorylated sites on human tau extracted from fly heads 
via mass spectrometry. Due to the impossibility of extracting enough protein to perform 
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the analysis, only a limited number of phosphorylation sites were examined using the 
same phospho-specific antibodies as for section 4.2.1: PHF1 (pS396 and pS404), AT8 
(pS202 and pT205), AT270 (pT181) and AT100 (pS212 and pS214). The tau antibody 
supplied by Dako was used to detect the total level of human tau. Expression of human 
tau was successfully detected on western blot (Figure 4.7). Control flies carrying the 
GMRGAL4 driver only show no tau expression in the soluble or insoluble fractions. 
Following expression using GMRGAL4, human 2N4R tau was detected as single band 
in all samples at an apparent molecular weight of 65 kDa corresponding to recombinant 
2N4R tau. The tau mobility does not change when GSK3β is co-expressed. Previous 
studies have shown that hyperphosphorylated tau is insoluble and characterised by a 
higher shift weight compared normal tau (Ishihara et al, 2001; Lewis et al, 2000; 
Zhukareva et al, 2002). This result confirms that the activity of only one kinase is not 
enough to generate hyperphosphorylated forms of human tau in the cell. Moreover, 
human tau is differently represented on western blot when extracted from S2 cells 
compared to fly eyes. In S2 cells transfected 2N4R tau is found in multiple bands 
suggesting a differential phosphorylation by endogenous Drosophila kinases (Figure 
4.1), while, when expressed in fly eyes, it appears as a single band. A different set of 
endogenous kinases might be active in S2 cells compared to the eye possibly leading to 
a different pattern of phosphorylation of human tau. 
 
The phosphorylation of human tau by GSK3β was examined on disease-relevant 
epitopes as follows. Phosphorylation at PHF1 epitopes is specifically detected in the 
soluble and insoluble tau fractions of flies over-expressing human 2N4R tau and 
GSK3β (Figure 4.7A), while the AT8 epitope is phosphorylated also when human tau is 
expressed alone in the eye but not in S2 cells (Figure 4.7B). Also AT270 detects 
phosphorylation of soluble and insoluble tau in all samples but it appears to be 
increased in flies co-expressing human tau and GSK3β (Figure 4.7C). In contrast, 
phosphorylation at AT100 epitopes is very low in the soluble tau fraction and is not 
present in the insoluble fraction (Figure 4.7D). The increase in phosphorylation in the 
soluble and insoluble tau fractions was measured when GSK3β was co-expressed 
together with tau in the fly eye. The phosphorylation levels for PHF1, AT8 and AT270 
were quantified using total tau and actin to monitor gel loading (Figure 4.7E and F). In 
the soluble fraction of tau the levels of phosphorylation at PHF1 and AT270 epitopes 
are significantly increased upon human GSK3β expression. In particular, the PHF1 
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epitope is not phosphorylated in flies expressing human tau only, while it shows a basal 
level of phosphorylation in S2 cells transfected with human tau only (Figure 4.1B). A 
basal level of phosphorylation by endogenous kinases contributes to phosphorylation at 
the AT270 epitope in the fly eyes as seen previously in S2 cells (Figure 4.1D). In 
contrast, the AT8 epitope shows a non-significant increase in phosphorylation when 
GSK3β is co-expressed, differently from the result obtained in S2 cells where 
phosphorylation of this epitope was specific for GSK3β (Figure 4.1C). The insoluble 
fraction of tau appears to be characterised by the same phosphorylation pattern. PHF1 
and AT270 epitopes are characterised by a significant increase in phosphorylation when 
GSK3β is expressed, while phosphorylation at the AT8 epitope does not show a 
significant change. 
 
Thus, the proportions of Sarcosyl-soluble and insoluble human tau do not change upon 
GSK3β expression. The increased tau toxicity caused by human GSK3β in the fly eye is 
not due to a shift in solubility of tau. Moreover, human GSK3β can phosphorylate 
2N4R tau in Drosophila. In particular, phosphorylation at PHF1 and AT270 epitopes 
are significantly increased when GSK3β is expressed in the eye differs to that seen in 
S2 cells. In conclusion, human tau is unlikely to undergo hyperphosphorylation via 
GSK3β in flies since its solubility is unaltered. However, more specific phosphorylation 
events might be responsible for the increased level of toxicity seen in the fly eye when 
human GSK3β is co-expressed with human 2N4R tau. 
Figure 4.6 The amount of soluble and insoluble tau does not vary upon human 
GSK3β expression in Drosophila. Human tau and human GSK3β were expressed in 
the fly eye using the GMRGAL4 driver. Human tau and actin were detected on western 
blot. Protein levels were normalised to actin. Values correspond to the mean and SEM 
of 3 replicates of independent experiments. Asterisks indicate statistically significant 
differences of protein expression. The histogram shows the amount of Sarcosyl-soluble 
and insoluble human tau expressed with or without GSK3β co-expression. The levels of 
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Figure 4.7. Human GSK3β increase the phosphorylation level of human tau in 
Drosophila. Human tau and human GSK3β were expressed in the fly eye using the 
GMRGAL4 driver. Human tau and actin expression were detected by western blotting. 
Recombinant human 2N4R tau (rTau) was loaded as positive control and flies carrying 
GMRGAL4 alone were analysed as negative control. Sarcosyl-soluble and insoluble 
tau fractions were analysed. Human tau was detected as a single band (60 kDa) using 
the phospho-independent antibody supplied by Dako. β-actin was used as loading 
control (42 kDa). Phosphorylated tau was also detected using (A) PHF1 (B) AT8 (C) 
AT270 (D) AT100. (E-F) Levels of phospho-tau in the Sarcosyl-soluble and insoluble 
fractions. Protein levels were normalised to actin. Values correspond to the mean and 
SEM of 3 replicates of independent experiments. Asterisks indicate statistically 
significant differences of protein expression. Co-expression of GSK3β together with 
human tau increases the phosphorylation levels of PHF1 and AT270 epitopes in both 
tau fractions. The AT8 epitope remains unchanged, while no phosphorylation is seen at 
the AT100 epitope. 
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Recent studies have suggested that specific kinases may prime tau for phosphorylation 
by other kinases in vitro. For example, phosphorylation by GSK3β on tau might be 
primed by phosphorylation via CK1δ or DYRK1A (Li et al, 2006; Woods et al, 2001). I 
tested whether multiple kinases have an additive or synergistic effect on human tau 
toxicity. The Drosophila model created in this study was used to assess whether 
GSK3β-mediated eye degeneration could be enhanced by co-expression of CK1δ or 
DYRK1A. 
 
Human 2N4R tau and pairs of kinases were expressed in the fly eye using the 
GMRGAL4 driver. Gene expression was induced throughout development at 25ºC and 
flies were collected between 0 to 5 days post-eclosion. The eye phenotypes were 
examined by light microscopy. Control flies express GMRGAL4 alone in order to 
monitor the background phenotype caused by the expression of the genetic driver. 
Control eyes are characterised by an oval optic lobe and a regular arrangement of 
ommatidia (Figure 4.8A). As shown before, line 2N4Rtau#68A is characterised by a 
weak disarrangement of the ommatidial pattern compared to control (Figure 4.8B). 
When human GSK3β is co-expressed with human 2N4R tau, the eye degeneration 
phenotype is enhanced compared to human tau alone (Figure 4.8C). Moreover, human 
CK1δ co-expression with tau does not lead to an enhancement of eye degeneration, 
while rat DYRK1A co-expression causes a minor enhancement of human tau-mediated 
degeneration (Figure 4.8E). When human 2N4R tau was co-expressed with GSK3β and 
CK1δ, the eye degeneration phenotype was increased compared to human tau and CK1δ 
expression. Moreover, the intensity of the degeneration was also mildly enhanced 
compared to human tau and GSK3β expression. The disarrangement of the ommatidia 
spread to the whole surface of the eye, while it is concentrated to the anterior part of the 
eye upon tau and GSK3β expression. In contrast, the eye phenotype caused by 
expression of human tau, GSK3β and DYRK1A was very similar to the phenotype 
caused by human tau and DYRK1A alone but milder compared to the one cause by 
GSK3β alone. 
 
In conclusion, GSK3β and CK1δ or DYRK1A do not have a synergistic effect in 
enhancing human tau-mediated toxicity. In fact, the eye phenotype resulting from the 
co-expression of GSK3β and CK1δ or DYRK1A together with human tau did not show 
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a very significant exacerbation of tau toxicity that would be expected if those kinases 
would have a priming effect on one another. 
BA CGMR>2N4Rtau#68AControl GMR>2N4Rtau#68A+ GSK3β#1





Figure 4.8 Co-expression of additional kinases does not enhance the human 
tau-mediated degeneration produced by GSK3β. Light micrographs of eyes from 0-5 
days old flies. (A) Control eyes carrying the eye specific GMRGAL4 driver show a regular 
array of ommatidia. (B) Expression of human 2N4R tau causes weak ommatidial 
disruption. (C) Co-expression of human 2N4R tau and human GSK3β enhances the 
tau-mediated degeneration in the eye. (D) Co-expression of human 2N4R tau and CK1
δ causes a weak disruption of ommatidia. (E) Eye degeneration is slightly enhanced 
when DYRK1A is co-expressed together with human tau. The tau-mediated 
degeneration is not further enhanced by the co-expression of (F) CK1δ or (G) DYRK1A 
together with 2N4R tau and GSK3β. Scale bar: 100 µm. Dorsal is top and anterior is left.
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4.2.3 Effect of tau point mutations on GSK3β-mediated toxicity 
 
To investigate the role of individual phosphorylated residues in the production of toxic 
tau, several constructs for mutated tau were generated. As seen above, human GSK3β 
increased tau-mediated toxicity in flies and potential phosphorylation sites involved in 
conferring toxicity were identified on human tau via western blotting. Phosphorylation 
of S396 and S404, corresponding to the PHF1 epitope, was confirmed to be increased 
by GSK3β in both S2 cells and fly eyes. However, the AT8 epitope at pS202 and pT205 
showed opposite results in S2 cells compared to the in vivo experiments. Thus, it is still 
unclear whether these sites are important in increasing tau toxicity via GSK3β. 
Moreover, T181 phosphorylation recognised by AT270 has been shown to occur by 
GSK3β and also endogenous kinases in both S2 cells and fly eye. Finally, previous 
studies have identified T212 on tau as one of the major phosphorylation site targeted by 
the novel kinase DYRK1A. Furthermore, phosphorylation of this site might influence 
phosphorylation by GSK3β on human tau (Woods et al, 2001). In light of my previous 
experiments looking at the effect of concurrent phosphorylation by GSK3β and 
DYRK1A on human tau, T212 appears to be an important site to further examine. 
 
Four tau constructs were created carrying point mutations substituting serine or 
threonine sites with alanines in order to inhibit phosphorylation of these sites. The 
mutations generated by in vitro mutagenesis are S202A, T205A, T212A and S404A. 
Another construct was created carrying all four of those mutations, including 202, 205, 
212 and 404 (4xA). Unfortunately, due to time constraints, I was not able to examine 
the effect of the mutation T181A. In section 4.2.1 it was shown that in Drosophila S2 
cells the interaction of human tau with human GSK3β causes a shift in mobility of tau 
probably due to phosphorylation. In order to see whether the mutated constructs of 
human tau were modified differently by human GSK3β, S2 cells were transfected with 
wild type and mutated 2N4R tau with or without GSK3β. As previous experiments in 
S2 cells, expression of human 2N4R tau was controlled by an inducible UAS-GAL4 
system and expression of human GSK3β by an actin promoter. GSK3β carried a 3’ end 
tag made by a myc epitope. Protein expression occurred at 25ºC. Expression of wild 
type and mutated human 2N4R tau was induced for five hours while human GSK3β was 
constitutively expressed. Expression of human tau and GSK3β was successfully 
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detected by western blotting (Figure 4.9A). The phospho-independent tau antibody 
recognises the total level of tau expressed. Human GSK3β was detected using an anti-
myc antibody and it migrated at the expected molecular weight (60 kDa). Actin 
expression was used to monitor protein loading. Control cells carrying an empty vector 
show only actin expression. Due to different levels of basal phosphorylation by 
endogenous kinases in S2 cells, wild type human tau is detected on the blot as multiple 
bands ranging from 60 kDa to 65 kDa. Moreover, human tau carrying S202A, T205A 
and T212A also exhibit a multiple band pattern on western blot similar to wild type tau. 
In contrast, human tau with the S404A mutation and 4xA tau were detected on the blot 
as single bands of low molecular weight (60 kDa). When wild type and mutated 2N4R 
tau were co-transfected together with human GSK3β, a molecular shift was observed 
for wild type 2N4R tau, tau S202A, tau T205A and tau T212A as revealed using the a 
phospho-independent tau antibody (Figure 4.9A). One additional species of human tau 
S404A was produced at higher molecular weight upon GSK3β expression. In contrast, 
4xA tau did not show any molecular shift when GSK3β is expressed. 
 
In order to monitor the phosphorylation level of wild type and mutated 2N4R tau, the 
same samples were analysed with phospho-specific antibodies for human tau including 
PHF1 (pS396 and pS404), AT8 (pS202 and pT205), AT270 (pT181), AT100 (pS212 
and pS214) (Figure 4.9B-E). Control cells carrying an empty vector show no phospho-
tau expression. Phosphorylation at the PHF1 epitope only occurred in the samples 
where GSK3β was co-expressed (Figure 4.9B). The antibody did not recognise human 
tau mutated with S404A since phosphorylation is now inhibited at that site. Moreover, 
the AT8 antibody detected a very mild phosphorylation of wild type, S212A and S404A 
tau upon GSK3β expression. Human tau with S202A and T205A mutations were not 
detected indicating that phosphorylation at these sites is inhibited. However, the AT270 
antibody recognises a baseline phosphorylation level on human tau by endogenous 
kinases. Its level of detection is increased when GSK3β is co-expressed, except for 4xA 
tau (Figure 4.1D). The AT100 antibody shows no detection as seen in previous 
experiments using in S2 cells (Figure 4.1E).  
 
These results, particularly figure 4.9A, suggest that mutating S404 on 2N4R tau inhibits 
the basal level of phosphorylation by endogenous kinases and human GSK3β in fly 
cells. The individual mutations S202A, T205A and T212A do not affect 
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phosphorylation by GSK3β on other sites. However, when mutated all together S202, 
T295, T212 and S404 appear to affect phosphorylation of the AT270 epitope. All 
together these results lead to the conclusion that phosphorylation of S404 might play a 
key role in favouring the phosphorylation of other sites on human tau by endogenous 





































































Figure 4.9 Point mutations on human tau reveals a key role for S404 in the tau 
phosphorylation generated by GSK3β in Drosophila S2 cells. Constructs bearing 
the single mutations S202A, T205A, T212A, and S404A or all four mutations (4xA) were 
co-transfected with GSK3β into S2 cells. Recombinant human 2N4R tau (rTau) was 
loaded as positive control for tau and S2 cells transfected with an empty vector were 
used as negative control. Total tau was detected as multiple bands (60-70 kDa) using the 
phospho-independent antibody Dako. β-actin was used as loading control (42 kDa). (A) 
GSK3β was detected using an anti-myc antibody (60 kDa). (B-E) Human tau was 
detected using phospho-specific antibodies (B) PHF1 for pS396 and pS404, (C) AT8 for 
pS202 and pT205, (D) AT270 for pT181 and (E) AT100 for pT212 and pS214. Human tau 
S404A and 4xA do not show a significant mobility shift when co-transfected with GSK3β 
compared to wild type tau.
139
 140 
In order to assess whether the point mutations previously generated affect the human 
tau-mediated degeneration in the fly eye, transgenic Drosophila lines were created 
carrying the mutated forms of human tau. Using the phiC31-mediated transgenesis, five 
constructs carrying mutated forms of human tau were inserted in the same genomic 
locus used by line 2N4Rtau#68A resulting in fly lines with the same genetic 
background and expression level of tau. Therefore, the tau-mediated toxicity in the fly 
eye is affected only by the mutation on human tau avoiding any positional effect of the 
transgene. The aim of this experiment is to assess whether the point mutations in human 
tau influence its interaction with the kinases thought to play a role in 
hyperphosphorylation of tau during disease. 
 
The transgenes were expressed using GMRGAL4 that drives the expression of the 
transgenes in the fly eye. Gene expression was induced throughout development at 25ºC 
and flies were collected between 0 to 5 days post-eclosion. The eye phenotypes were 
examined by light microscopy. As shown before, line 2N4Rtau#68A is characterised by 
a weak disarrangement of the ommatidial pattern compared to control (Figure 4.10A1). 
When mutated forms of human tau are expressed in the fly eye, the phenotype exhibits 
comparable characteristics to those of 2N4Rtau#68A (Figure 4.10B1, C1, D1 and E1). 
The individual point mutations S202A, T205A, T212A and S404A on 2N4R tau cause a 
mild alteration of the eye architecture. The transgenic lines over-expressing human 
GSK3β, PKA, CK1δ and rat DYRK1A were crossed to the tau lines carrying the point 
mutations.  When human GSK3β is co-expressed with human 2N4R tau, the eye 
degeneration phenotype is enhanced compared to human tau alone (Figure 4.10A2). 
Also, the eye degeneration of flies expressing mutated tau and human GSK3β is 
enhanced. The degree of enhancement of eye degeneration in flies carrying the S202A, 
T205A and T212A mutations is comparable to the enhancement seen in the line 
expressing wild type tau. The disarrangement of ommatidia is increased in the anterior 
part of the eye and the characteristic oval shape of the eye is altered compared to control 
(Figure 4.10 B2, C2 and D2). Surprisingly, the mutation S404A on tau appears to show 
a greater enhancement when human GSK3β is co-expressed. In fact, the ommatidial 
disarrangement extends to the central part of the eye and a significant depigmentation is 
observed (Figure 4.10E2). As in previous experiments human PKA co-expression with 
2N4R tau does not lead to an enhancement of eye degeneration (Figure 4.10A3). 
Moreover, the tau lines carrying the individual mutations S202A, T205A and T212A 
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show no enhancement in eye phenotype when PKA is co-expressed (Figure 4.10B3, C3, 
D3). S404 is not a known site targeted by PKA phosphorylation, therefore it was not 
analysed (Figure 4.10E3). Subsequently, co-expression of wild type, T212A and S404A 
tau together with CK1δ does not affect the basal human tau-mediated eye degeneration 
caused by line 2N4Rtau#68A (Figure 4.10, panel A4, D4 and E4). Human CK1δ does 
not phosphorylate S202A and T205A, therefore these sites were not analysed (Figure 
4.10B4 and C4). It has been shown before in this study that rat DYRK1A co-expression 
with 2N4R tau causes a minor enhancement of human tau-mediated degeneration 
(Figure 4.10A5). None of the individual mutations analysed alters the tau interaction 
with DYRK1A. The eye phenotypes are characterised by a minor enhancement of 
human tau-mediated degeneration comparable to that seen for line 2N4Rtau#68A 
(Figure 4.10 B5, C5, D5 and E5). The point mutations in 2N4R tau were also tested to 
alter the possible priming interaction of GSK3β by CK1δ or DYRK1A. Mutation on 
T212A appears not to change the enhancement of tau-mediated degeneration in flies 
expressing GSK3β and CK1δ in a 2N4Rtau#68A background (Figure 4.10A6 and D6). 
However, S404A tau exhibit a stronger enhancement in eye phenotype compared to 
wild type tau (Figure 4.10E6). Moreover, when wild type and mutated tau are expressed 
together with GSK3β and DYRK1A, the eye degeneration was similar to the phenotype 
caused in the wild type tau background, with exception for mutation S404A that shows 
a greater enhancement compared to the others (Figure 4.10, column 7). 
 
These results show that single point mutations in 2N4R tau such as S202A, T205A and 
T212A do not affect the ability of human GSK3β, PKA, CK1δ and rat DYRK1A to 
generate toxic forms of human tau in Drosophila. Inhibiting phosphorylation of those 
sites does not change the eye degeneration enhancement caused by the kinases studied 
in this chapter. However, the mutation S404A appears to exacerbate the enhancement of 
phenotype generated by co-expression of human GSK3β and wild type 2N4R tau. The 
eye degeneration of flies expressing S404A tau and GSK3β is enhanced compared to 
the one shown by wild type tau and the same human kinase. 
 
The use of single point mutations in tau did not alter the interaction between tau and 
endogenous kinases in flies, as previously shown by Steinhilb et al (2007a). Therefore, 
the effect of the four point mutations together on human tau was tested. Transgenic flies 
were generated expressing the human 2N4R tau carrying the following mutations: 
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S202A, T205A, T212A and S404A (4xA). The ability of the mutations to modulate tau 
toxicity via the expression of human kinases was also analysed. Transgene expression 
was controlled by the eye-specific GMRGAL4 driver at 25ºC. Flies were collected 
between 0 to 5 days post-eclosion. When tau 4xA is expressed in the fly eye alone, the 
phenotype is comparable to line 2N4Rtau#68A expressed alone. The eye is 
characterised by weak eye degeneration in the anterior part of the eye (Figure 4.11A1 
and B1). Expression of tau 4xA together with human kinases showed a variation in 
degeneration phenotype only with GSK3β (Figure 4.11B1-7). The phenotype caused by 
human GSK3β in flies expressing human tau 4xA shows an increased level of 
degeneration compared to the one caused by line 2N4Rtau#68A (Figure 4.11B2). 
However, when human PKA, CK1δ and rat DYRK1A are expressed with tau 4xA the 
phenotype is identical to that seen when they are co-expressed with line 2N4Rtau#68A 
(Figure 4.11B3-5). When testing the combined action of CK1δ and DYRK1A with 
GSK3β, the degenerative phenotype generated using tau 4xA is enhanced over that 
caused by wild type tau (Figure 4.11B6 and B7). However, these enhancements are 
similar to that seen for tau 4xA and GSK3β alone suggesting that toxicity does not 
increase when other kinases are co-expressed with GSK3β. Interestingly, the 
degenerative enhancements obtained from the co-expression of human tau 4xA and 
human kinases are equivalent to those seen using human tau carrying the S404A 
mutation. Thus, this result leads to the conclusion that the enhancement of tau toxicity is 
only due to inhibiting phosphorylation or mutation of S404. 
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Figure 4.10. Effect of single tau point mutations on the degeneration caused by 
co-expression of human kinases. Light micrographs of eyes from 0-5 days old flies. 
All transgenes were expressed in the fly eye using the GMRGAL4 driver. (A1,B1,C1,D1 
and E1) Expression of wild type and mutated 2N4R tau cause weak ommatidial 
disruption. (B2-D7) No alleviation of degeneration was observed when the single point 
mutations S202A, T205A and T212A were separately introduced on tau compared to 
wild type tau (A2-A7). (E2-E7) The single point mutation S404A increases the eye 
degeneration phenotype caused by GSK3β. Grey panels are located where the 
muatated site is not targeted by the kinase. Scale bar: 100 µm. Dorsal is top and 
anterior is left. 
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Figure 4.11 Multiple point mutations on human tau increase the eye degeneration generated by GSK3β. Light micrographs of eyes 
from 0-5 days old flies. All transgenes were expressed in the fly eye using the GMRGAL4 driver. (A1 and B1) Expression of wild type 2N4R 
tau or mutated tau carrying four point mutations (S202A, T205A, T212A and S404A) causes weak ommatidial disruption. (B2-B7) When tau 
4xA is expressed together with individual kinases the degeneration is greater than that seen when wild type tau is expressed with the kinase 





Neurofibrillary tangles are one of the main pathological features that contribute to the 
neurodegenerative process in AD. They are composed of hyperphosphorylated tau 
protein and the major kinases involved in the abnormal phosphorylation in vivo are 
unknown. Currently therapeutic strategies for AD are based upon preventing tau 
hyperphosphorylation by inhibiting the pathological kinases. Drosophila is now a well-
established model for tauopathies in order to investigate tau hyperphosphorylation 
(Bonini & Fortini, 2003; Lau et al, 2002; Lewis et al, 2000; Muqit & Feany, 2002; 
Wittmann et al, 2001). 
 
The aim of this chapter was to investigate the contribution made by individual human 
kinases to the degenerative phenotypes produced by human tau using the Drosophila 
eye as a measure to toxicity. The human kinases studied were selected from those that 
potentially contribute to tau pathology in humans, including GSK3β, PKA, CK1δ and 
DYRK1A. Fly lines over-expressing human tau and these kinases were characterised to 
assess any enhancement of tau-mediated eye degeneration. The kinase conferring 
increased toxicity was further analysed to examine the phosphorylation state of human 
tau. Finally, several tau point mutations on pathological S/T sites were tested for their 
ability to alter tau toxicity induced by the kinases. 
 
 
4.3.1 Human tau and kinases co-expression in the Drosophila eye 
 
Identifying the contribution of individual kinases to generate tau toxicity and their 
activity on the predicted sites in vivo is of crucial importance to develop new 
therapeutic strategies and identify biomarkers. Meaningful fly models of tauopathy have 
been created over-expressing human tau in the Drosophila photoreceptor neurons 
together with endogenous kinases (Bonini & Fortini, 2003; Jackson et al, 2002; Muqit 
& Feany, 2002; Wittmann et al, 2001). No evidence has been produced on the 
interaction of human tau and human kinases in Drosophila before. 
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In this study Drosophila transgenic lines over-expressing kinases including human 
GSK3β, PKA, CK1δ and rat DYRK1A were generated. When the human and rat 
kinases were over-expressed in the Drosophila eye, no toxicity was observed suggesting 
that those transgenes do not interact with any endogenous pathway in the developing 
eye. To confirm that tau toxicity can be enhanced in the tauopathy model created in this 
study, the level of the Drosophila orthologue of GSK3β, shaggy, were increased in the 
fly eye as previously done in other studies (Chatterjee et al, 2009; Jackson et al, 2002; 
Nishimura et al, 2004). As a result, the degeneration caused by human tau in the fly eye 
could be enhanced following hyperphosphorylation by an endogenous kinase. More 
importantly, the level of eye degeneration achieved overexpressing an endogenous 
kinase is not maximal, suggesting that the phosphorylation of tau by fly kinases does 
not saturate all sites available. Thus, it could be enhanced further by the introduction of 
other kinases. The ability of individual human kinases to increase tau toxicity was 
tested. The kinases PKA, CK1δ and DYRK1A did not show any considerable 
enhancement of eye phenotype. However, the only kinase able to enhance tau toxicity in 
the fly eye was human GSK3β. Co-expression of 2N4R tau with human GSK3β showed 
a considerable enhancement of eye degeneration. This result is perhaps not surprising 
considering that GSK3β is one of the best known kinases to play a crucial role in tau 
hyperphosphorylation during disease in humans (Hanger et al, 1992; Lovestone et al, 
1994a; Lucas et al, 2001). In summary, GSK3β was the only human kinase conferring 
an increased toxicity to human tau in the Drosophila model of tauopathy created in this 
study. Therefore, further studies investigated any change in the biochemistry of human 
tau when GSK3β is co-expressed. 
 
 
4.3.2 Phosphorylation and solubility of tau by GSK3β in Drosophila 
 
Tau hyperphosphorylation and insoluble aggregates are two cellular features of 
tauopathies. It has already been demonstrated that expression of human tau in the 
Drosophila eye is toxic and causes neuronal degeneration (Chatterjee et al, 2009; 
Jackson et al, 2002; Steinhilb et al, 2007a; Steinhilb et al, 2007b; Wittmann et al, 2001). 
Moreover, it has been shown that kinase activity is important to generate tau toxicity 
since it causes hyperphosphorylation and alters tau solubility properties in mammals 
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and fly models (Chau et al, 2006; Hirata-Fukae et al, 2009; Jackson et al, 2002; 
Shulman & Feany, 2003). 
 
Wittmann et al (2001) have shown that neurodegeneration occurs in flies expressing 
human tau without the formation of neurofibrillary tangles characteristic of human 
pathologies. However, tau aggregates have been found in the retina of transgenic 
Drosophila over-expressing human tau, suggesting the possible presence of pre-tangle 
tau forms. Moreover, human tau hyperphosphorylation by fly kinases has been shown to 
correlate with an alteration of tau protein solubility (Chau et al, 2006). In my model of 
tauopathy, human tau is predominantly found in a soluble state, while insoluble tau is 
produced in smaller amounts. The alteration in tau solubility is probably due to 
phosphorylation by endogenous kinases on human tau (Chatterjee et al, 2009; Chau et 
al, 2006). Moreover, in my thesis, changes in the proportion of soluble to insoluble 
human tau were measured upon co-expression of human GSK3β. Following western 
blot analysis, the levels of soluble and insoluble tau did not change when GSK3β was 
co-expressed compared to human tau expressed alone. As expected, the additional 
activity of only one kinase on tau does not alter its solubility confirming that the 
aberrant phosphorylation events leading to the formation of insoluble and aggregated 
tau forms in pathology are driven by the activity of several kinases. However, despite 
the absence of an alteration of tau solubility, human GSK3β increased the tau-mediated 
toxicity in the fly eye. Thus, this result suggests that a change in tau solubility is not 
needed to induce a greater level of tau toxicity in flies. It is possible that GSK3β 
phosphorylates tau on specific sites that increase tau toxicity without altering its 
solubility. 
 
In Drosophila tauopathy models, human tau has already been demonstrated to be 
phosphorylated by endogenous kinases. The role of phosphorylation at serine-
proline/threonine-proline (SP/TP) sites on human tau by Drosophila kinases has been 
proved to play a critical role in tau neurotoxicity in flies, but no-single phosphorylation 
residue seems to play a dominant role in controlling tau toxicity. Therefore, it could be 
likely that SP/TP sites cooperate to mediate neurodegeneration in the Drosophila eye 
when phosphorylated by endogenous kinases (Steinhilb et al, 2007a; Steinhilb et al, 
2007b). In this thesis, human GSK3β is found to enhance tau toxicity beyond the level 
achieved by endogenous kinases. In this case there might be a possibility of identifying 
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single phosphorylated sites targeted by human GSK3β and contributing to the increase 
in toxicity driven by endogenous kinases. In this chapter, the phosphorylation of human 
tau on several residues was examined in the transgenic fly line expressing human tau 
and human GSK3β. I initially aimed to map the whole spectrum of phosphorylation 
sites on human tau via mass spectrometry. Unfortunately, due to technical reasons, I 
was not able to purify enough protein to perform the analysis. One of the reasons for 
this is that the construct with human tau did not carry any tag, which could have 
facilitated the protein extraction and purification. Therefore, the phosphorylated sites on 
human tau were mapped by western blotting using phospho-specific antibodies. The 
choice of the epitopes to examine was driven by the pathological relevance and 
availability of the antibodies. The antibodies PHF1 (pS396 and pS404), AT8 (pS202 
and pT205) and AT270 (pT181) are widely used in the field of tauopathy research 
because phosphorylation of their epitopes is increased in human patients (Hasegawa et 
al, 1992; Lovestone & Reynolds, 1997).  Phosphorylation of human tau by GSK3β was 
mapped in vitro and in vivo Drosophila systems. Interestingly, the phosphorylation 
pattern of human tau was different in S2 cells compared to the fly eye. This tissue-
dependent phosphorylation is probably due to the activation of different sets of 
endogenous kinases in different fly cell types. In vitro in S2 cells, tau phosphorylation 
of the PHF1, AT8 and AT270 epitopes is increased upon GSK3β expression. However, 
endogenous fly kinases produce a basal level of tau phosphorylation of the PHF1 and 
AT270 epitopes. Phosphorylation of the AT8 epitope appears to be very specific for 
human GSK3β in the eye. Moreover, phosphorylation of the soluble and insoluble tau 
fraction was measured in vivo in the fly line co-expressing human tau and GSK3β. 
Upon GSK3β expression, an increased phosphorylation was observed at PHF1 and 
AT270 epitopes in the soluble and insoluble fractions of tau, as seen in S2 cells. In 
particular, phosphorylation of S396 and S404 underwent a very large increase of about 
40 fold in the soluble fraction and about 20 fold in the insoluble fraction. On the other 
hand, the increase of phosphorylation of T181 was measured to be around 3 fold in the 
soluble fraction and 4 fold in the insoluble fraction. In contrast, phosphorylation of the 
AT8 epitope does not change significantly upon GSK3β expression, differently from the 
data obtained from the in vitro experiments. 
 
These results lead to the conclusion that the enhancement in tau-mediated eye 
degeneration caused by GSK3β in vivo might be due to increased phosphorylation of 
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human tau in the soluble and insoluble forms. More importantly, S396, S404 and T181 
appears to be key sites to be targeted for GSK3β phosphorylation of tau and they might 
be involved in generating more toxic forms of human tau in the fly eye. Interestingly, 
previous in vitro evidence show that phosphorylation of S396 and S404 is primarily 
responsible for the functional loss of tau-mediated tubulin polymerisation, suggesting a 
possible role in initiating the destabilisation of microtubules (Evans et al, 2000). These 
results possibly suggest that detachment of human tau from microtubules due to 
phosphorylation by human GSK3β causes toxicity in the fly eye. 
 
 
4.3.3 Effects of tau point mutations on GSK3β-mediated toxicity 
 
Multiple phosphorylation or dephosphorylation events located in functionally regions of 
tau could cause the protein to alter its physiological function and become toxic. In order 
to modulate the toxicity generated by human kinases in the fly eye, some S/T residues 
on human tau were mutated in alanines to inhibit phosphorylation. In Drosophila 
tauopathy models, the role of phosphorylation by endogenous kinases at SP/TP sites on 
human tau has been proved to play a critical role in tau toxicity in flies. However, no-
single phosphorylation residue seems to play a dominant role in controlling tau toxicity 
generated by endogenous kinases (Steinhilb et al, 2007a; Steinhilb et al, 2007b). Since 
my thesis focuses on the ability of human kinases to enhance human tau-mediated 
degeneration in flies, single phospho-residues were mutated to alanines to see whether 
additional toxicity generated by the introduction of human kinases could be modulated 
and mapped to individual sites.  
 
The choice of the residues to mutate was driven by the results obtained from previous in 
vitro and in vivo experiments in this thesis and by the pathological relevance of the 
phosphorylation of those sites. Moreover, all mutated sites are phosphorylation targets 
of DYRK1A, a novel kinase found to be involved in tau hyperphosphorylation and 
suggested to prime GSK3β phosphorylation of tau (Liu et al, 2008; Woods et al, 2001). 
The mutations studied were S202A, T205A, T212A and S404A. In this study, 
phosphorylation of S202 and T205 of human tau was shown to increase in S2 cells 
transfected with human GSK3β, while no increase was seen in fly eyes expressing 
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human tau together with human GSK3β. Interestingly, S202 and T205 were also 
demonstrated to be substrates for phosphorylation of endogenous kinases in the eye but 
not in S2 cells. The inhibition of phosphorylation of S202 and T205 did not affect the 
eye phenotypic enhancement generated by GSK3β, PKA and DYRK1A. 
 
Moreover, the novel kinase DYRK1A has been suggested to prime the activity of 
GSK3β on tau via phosphorylation of T212. In the course of this thesis not enough 
evidence was obtained to demonstrate an increase of tau phosphorylation of T212 by 
human GSK3β. However, in fly eyes a low level of phosphorylation of this site occurs 
by endogenous kinases. Not surprisingly, when T212 was mutated to alanine, the 
enhancement in degeneration generated by GSK3β, PKA, CK1δ or DYRK1A on wild 
type tau was not affected. The same effects occurred when human tau T212A was 
expressed together with GSK3β and DYRK1A. As a result, individual phosphorylation 
of human tau on S202, T205 and T212 by human kinases does not appear to contribute 
to the tau-mediated degeneration caused by human GSK3β in this fly model of 
tauopathy. 
 
Tau phosphorylation was also inhibited on S404, which is consistently 
hyperphosphorylated in neurofibrillary tangles together with S396 and widely believed 
to be important players in pathological tau action (Goedert et al, 1994). Moreover, in 
this thesis, phosphorylation of S396 and S404 has also been shown to significantly 
increase upon human GSK3β expression compared to other epitopes and, therefore, 
they are thought to be important in conferring tau toxicity. Surprisingly, inhibiting 
phosphorylation of S404 increased the degeneration generated by human GSK3β on 
wild type tau. In addition, when phosphorylation was inhibited on S202, T205, T212 
and S404 at the same time, the eye degeneration increased upon human GSK3β 
expression, as for the mutation of S404 alone. These results suggest that 
dephosphorylation or mutation of S404 plays a crucial role in increasing tau toxicity. 
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4.3.4 S404 of human tau contributes to confer toxicity via GSK3β 
 
In physiological conditions, tau binds directly to microtubules promoting their assembly 
and regulating microtubule dynamic instability essential for many cellular functions, 
including neuronal axonal transport (Lindwall & Cole, 1984; Mandelkow et al, 2003). 
Indeed, tau phosphorylation plays a physiological role in regulating the affinity of tau 
for microtubules: tau binding to microtubules is promoted by dephosphorylation of tau, 
while tau detachment is promoted by phosphorylation of tau (Buee et al, 2000). In 
tauopathies the main pathogenic event responsible for neuronal loss is tau 
hyperphosphorylation, although the molecular mechanisms by which tau mediates cell 
death remain elusive (Ballatore et al, 2007). Two widely accepted hypotheses consider 
tau hyperphosphorylation to cause gain-of-function and loss-of-function pathogenic 
effects for neurons. Firstly, abnormal phosphorylation increases tau propensity to 
aggregate into oligomers or tangles gaining a toxic function and leading to cytotoxicity 
(Ballatore et al, 2007). However, it has also been suggested that tau tangles may not be 
necessary for tau-mediated cell death since neurodegeneration can occur in the absence 
of tau aggregation in vitro and in vivo (Kambe et al, 2011; Wittmann et al, 2001). 
Alternatively, the tau-mediated neuronal cell death in tauopathies might be caused by a 
tau loss-of-function in the regulation of microtubule dynamic instability (Iqbal et al, 
2009). Indeed, an abnormal regulation of tau phsophorylation might compromise its 
ability to promote microtubule assembly and therefore, to regulate microtubule dynamic 
instability (Amniai et al, 2009). Axonal transport mechanisms rely on microtubules as 
tracks for the transport of mitochondria and organelles to the synapse. Thus, the 
misregulation of microtubule dynamic instability disrupts axonal transport and can lead 
to cell cycle arrest followed by cell death (Morfini et al, 2009). In this case the 
misregulation of tau can occur due to pathogenic phosphorylation or dephosphorylation 
events that lead to aberrant microtubule detachment or attachment of tau respectively. 
 
In this thesis, phosphorylation and dephosphorylation events of the S404 site alone were 
demonstrated to generate human tau toxicity in the Drosophila eye. Firstly, 
phosphorylation of the PHF1 epitope (which includes the S404 site) largely increases 
after human GSK3β expression and it is thought to be responsible for the eye 
degeneration caused in vivo. At the same time, inhibition of phosphorylation or 
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mutation of S404 enhances the eye degeneration caused by human GSK3β only. These 
results lead to the conclusion that S404 might be a crucial site mediating human tau 
toxicity in flies. Thus, a tight regulation of phosphorylation and dephosphoryaltion on 
this site might be required to maintain the physiological function of tau. 
 
The model here proposed has been confirmed also by other in vitro and in vivo studies. 
Indeed, tau phosphorylation at S396 and S404 has been shown to be responsible for the 
impairment of microtubule assembly and dissociation of tau from microtubules leading 
to the disruption of the microtubule transport system in vitro (Evans et al, 2000; Kiris et 
al, 2011). Finally, in the cerebral cortex and hippocampus of transgenic mice with 
increased phosphorylation of S396 and S404 of human tau has been suggested to detach 
tau from microtubules and disturb the synaptic function leading to synapse loss (Kambe 
et al, 2011). Interestingly, phosphorylation of S404 in vitro has been shown to have a 
dominant effect on microtubule stability among the multiple phosphorylated sites (Kiris 
et al, 2011). On the other hand, cell culture studies have shown that inhibition of 
GSK3β leads to a decrease of phosphorylation of several proline-dependent sites, 
including S404. Tau dephosphorylation resulted in the inhibition of anterograde 
transport, while the mitochondrial and organelle transport was largely intact in cells 
containing phosphorylated tau (Tatebayashi et al, 2004). As a result, tau 
phosphorylation by GSK3β has been shown to regulate the anterograde transport of 
organelles and mitochondria (Tatebayashi et al, 2004). In vivo studies using Drosophila 
have also demonstrated that multiple mutations in human tau, including S404A, lead to 
increased tau toxicity upon shaggy expression. This increased toxicity was attributed to 
a pathogenic detachment of human tau from microtubules which altered the regulation 
of microtubule assembly leading to increased toxicity (Chatterjee et al, 2009). 
 
In conclusion, it is possible that phosphorylation or dephosphorylation of tau at defined 
single sites cause phosphorylation-dependent conformational changes of tau or toxic 
effects on the dynamics of microtubule assembly that generate toxicity. In particular, 
the regulation of phosphorylation of S404 might play a crucial role in maintaining the 









Investigating the toxicity of 




5.1.1 Tau isoforms and tau mutations in disease  
 
Tau exists in a variety of isoforms and a number of mutations in tau are associated with 
disease. In adult human brains alternative splicing generates six tau isoforms ranging 
from 352 and 441 amino acids in length. These tau isoforms differ by the presence of 
none, one or two N-terminal inserts and 3 or 4 C-terminal repeats (Figure 1.1). The N-
terminal inserts mediate the interaction between tau and the neural plasma membrane, 
other cytoskeletal elements and cytoplasmic organelles, while the C-terminal repeats are 
involved in tau binding to microtubules (Andreadis, 2005; Buee et al, 2000). During 
adulthood the majority of tau isoforms contain a single N-terminal insert (1N), while the 
ratio of 3R:4R isoforms is approximately 1 (Buee et al, 2000). In the previous chapters, 
I investigated the toxicity of the full-length tau protein (2N4R) containing two N-
terminal domains and four C-terminal repeats. However, it is possible that different tau 
isoforms contribute differently to toxicity. Thus, I extended the assay presented in this 
thesis to see whether different tau isoforms exhibit different ability to confer toxicity. 
 
Tauopathies are a collection of neurodegenerative diseases characterised by the 
deposition of insoluble intra-neuronal aggregates of tau, including AD, Pick’s disease, 
FTDP-17, PSP and CBD (Dickson, 1997; van Slegtenhorst et al, 2000). In a minority of 
cases, genetic mutations have been identified in the tau gene that are responsible for the 
formation of toxic variants of tau responsible for the neurodegeneration underlying the 
tauopathies. Mutations in the tau gene can have multiple effects including alteration of 
microtubule assembly, promotion of tau filament formation, alteration of tau mRNA 
splicing and isoform expression (Hutton et al, 1998; Poorkaj et al, 1998; Spillantini et 
al, 1998). In particular, FTDP-17 patients carry autosomal-dominant mutations in the 
tau gene responsible for the formation of abundant tau inclusions in neurons (Hutton, 
2001; Hutton et al, 1998). The types of mutations found in the coding region of tau 
include missense, deletion and silent mutations. These are mostly located in the 
microtubule-binding region, these mutations lead to a reduction in the affinity of tau for 
microtubules (Dayanandan et al, 1999). In contrast, five mutations are present in the 
intronic regions and they mainly affect the mRNA splicing of exon 10. As a 
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consequence, an increased expression of tau carrying four C-terminal repeats occurs 
together with the formation of more tau deposits (Hong et al, 1998). Moreover, genome-
wide association analysis of PSP and CBD patients have shown that mutations in the tau 
gene also constitute a genetic risk factor for the development of these pathologies, in 
particular the MAPT H1 haplotype (Di Maria et al, 2000). 
 
The majority of FTDP-17 missense mutations disrupt tau affinity and binding capacity 
to microtubules as well as reducing the ability of tau to polymerise tubulin (Dayanandan 
et al, 1999; Hasegawa et al, 1998; Hong et al, 1998; Spillantini & Goedert, 1998). 
Moreover, since the interaction between tau and microtubules is disrupted, the level of 
unbound tau in neurons increases, accelerating the formation of tau aggregates (Goedert 
et al, 1999; Nacharaju et al, 1999). In addition in some cases, missense mutations also 
decrease tau degradation by calpain resulting in an increased level of tau available for 
aggregation (Yen et al, 1999). Among the missense mutations leading to FTDP-17, only 
three affect all tau isoforms and are localised outside exon 10: G272V in exon 9, 
V337M in exon 12 and R406W in exon 13. These three mutations cause a neuronal 
pathology characterised by straight filaments composed of all six human tau isoforms, 
similar to the PHFs and straight filaments observed in AD (Barghorn et al, 2000; 
Crowther & Goedert, 2000). 
 
Cell culture studies have demonstrated that the R406W mutation markedly reduces the 
ability of tau to bind microtubules and to promote their assembly when compared with 
other tau mutations or wild type tau proteins (Dayanandan et al, 1999; Hong et al, 1998; 
Pérez et al, 2000). Also, in vivo experiments showed that the R406W mutation on tau 
might induce a conformational change of the microtubule-binding domain leading to a 
reduction of microtubule-binding and assembly (Delobel et al, 2002; Zhang et al, 2004). 
Moreover, the tau gene mutation R406W alters the phosphorylation state of tau 
contributing to the formation of tau aggregates. Indeed, tau isoforms carrying this 
mutation exhibit a low level of phosphorylation in cells compared to the other variants 
(Dayanandan et al, 1999; Miyasaka et al, 2001; Sahara et al, 2000; Vogelsberg-Ragaglia 
et al, 2000). In particular, R406W decreases phosphorylation by GSK3β on S/T sites, 
including S195, S199, T231, S235, S396, S400 and S404 (Connell et al, 2001; Pérez et 
al, 2000). All together these defects cause an impaired axonal transport and tau 
accumulation into filamentous inclusions that eventually lead to axonal degeneration 
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(Zhang et al, 2004). The R406W mutation on tau has occurred as an independent event 
in several families leading to a slow rate of disease progression lasting up to 25 years, 
compared to an expected duration of illness of 10 years (Rademakers et al, 2003). 
 
 
5.1.2 Using Drosophila to model the toxicity of different tau isoforms 
and to study the R406W tau mutation 
 
Several Drosophila models of tauopathy have been created in the past decade 
recapitulating the progressive accumulation of insoluble tau and extensive 
neurodegeneration of human tauopathies. However, the discrepancy among these 
transgenic models is the use of different human tau isoforms and mutated forms of these 
that might behave differently in the fly as well as during disease in humans. There is a 
preference in using the 4R tau isoforms in Drosophila, especially 0N4R and 2N4R tau, 
for their completeness in the number of microtubule-binding repeats present. Moreover, 
Drosophila models of tauopathy have previously addressed the role of the FTDP-17 
associated mutation R406W, which appears to confer high toxicity to human tau in flies 
(Nishimura et al, 2004; Wittmann et al, 2001). 
 
Wittmann et al (2001) showed that human tau expression in the Drosophila CNS causes 
neurodegeneration and lifespan reduction without aggregate formation. In particular, 
this study demonstrated that the R406W and V337M mutations confer more toxicity 
compared to wild type human tau in flies. Moreover, tau phosphorylation in the CNS 
increased as the fly aged and accumulated in areas of degeneration. Additionally, it has 
been demonstrated that human tau carrying the R406W mutation confers more toxicity 
in the fly eye compared to wild type tau (Chau et al, 2006; Nishimura et al, 2004). No 
evidence of NFT-like aggregates has been shown, however phosphorylation of R406W 
tau was increased at S202, S262, S396 and S404 compared to wild-type tau. Moreover, 
the toxicity generated by R406W tau can be enhanced by Drosophila kinases via 
increased phosphorylation (Chau et al, 2006; Nishimura et al, 2004). PAR-1 kinase, the 
Drosophila orthologue of MARK, was identified as an early player in tau 
phosphorylation, initiating a temporally ordered series of additional tau phosphorylation 
events by downstream fly kinases, including cdk5 and GSK3β (Nishimura et al, 2004). 
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The human tau model described in the previous chapters expresses the 2N4R tau 
isoform and showed a considerably low level of toxicity in the fly eye compared to 
other published fly models (Chatterjee et al, 2009; Chau et al, 2006; Jackson et al, 2002; 
Shulman & Feany, 2003; Steinhilb et al, 2007a; Steinhilb et al, 2007b; Wittmann et al, 
2001). This chapter aims to investigate the different toxicity levels of wild type and 
R406W tau and their differential interaction with human kinases. The Drosophila 
models previously reported were created via P-element mediated transgenesis, however 
in this study transgenic fly lines were generated using the phiC31-mediated 
transgenesis. This system allows the reproducibility of the genomic position of the 
transgene ensuring a standardised level of expression and genetic background. Different 
tau isoforms are compared for their ability to generate toxicity and to interact with 




5.2.1 Exploiting the phiC31-mediated transgenesis to study the toxicity 
of different tau forms 
 
The reported fly models of tauopathy aim to recapitulate the tau pathology by 
expressing different human tau isoforms. The tau isoform shown to confer more 
degeneration when expressed in the fly is the 0N4R tau carrying the R406W mutation 
(Nishimura et al, 2004; Wittmann et al, 2001). However, these fly models have been 
created using the P-element meditated transgenesis, which generates variability in 
expression levels and phenotype depending on the insertion site of the transgene 
(Chapter 3). Different human tau isoforms carrying the R406W mutation were tested for 
their ability to induce degeneration in the fly eye. Transgenic Drosophila lines were 
generated expressing human 2N4R tau R406W, 0N4R tau and 0N4R tau R406W. Using 
the phiC31-mediated transgenesis, the three human tau isoforms were inserted at the 
same genomic locus used by line 2N4Rtau#68A resulting in fly lines with the same 
genetic background and expression level of tau. Therefore, the tau-mediated toxicity in 
the fly eye is affected only by the tau isoform inserted avoiding any positional effect of 
the transgene. The aim of this experiment is to compare the ability of human 2N4R tau, 
2N4R tau R406W, 0N4R tau and 0N4R tau R406W to generate eye toxicity and to 
assess whether their interaction with the human kinases varies. 
 
The transgenes were expressed in the eye using GMRGAL4. Gene expression was 
induced throughout development at 25°C and flies were collected between 0 to 5 days 
post-eclosion. The eye phenotypes were examined by light microscopy (Figure 5.1). As 
shown before, line 2N4Rtau#68A is characterised by a weak disarrangement of the 
ommatidial pattern compared to control (Figure 5.1A). When different isoforms of 
human tau are expressed in the fly eye, their resultant phenotypes exhibit similar 
characteristics to that of 2N4Rtau#68A (Figure 5.1B-D). The mutation R406W does not 
enhance the toxicity of tau in the fly eye compared to wild type human tau. Fly lines 
expressing human 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W are 
characterised by a comparable weak disarrangement of the ommatidial pattern in the 
anterior part of the eye. 
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This result shows that tau isoforms differing for the number of N-terminal domains, 
including 2N4R tau and 0N4R tau, generate the same degree of degeneration when 
expressed at the same level and in the same genetic background in the fly eye. 
Moreover, in contrast with previous studies, the mutation R406W does not alter the 
toxicity conferred by either wild type 2N4R or 0N4R tau. Therefore, in a Drosophila 
context, the N-terminal domains of tau and the R406W mutation do not appear to 




Figure 5.1 Expression of different tau isoforms from a phiC31-specific site causes 
similar levels of eye degeneration. Light micrographs of eyes from 0-5 days old flies. 
All transgenes were expressed in the fly eye using the GMRGAL4 driver. (A-D) 
Expression of the same low level of 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R 
tau R406W cause the same level of weak ommatidial disruption. Scale bar: 100 µm. 
Dorsal is top and anterior is left.
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The previous experiment shows that the fly lines expressing different tau isoforms do 
not differ in their ability to generate toxicity. The transcript levels of human tau were 
quantified via qPCR in order to confirm that they are equal in the lines created by 
phiC31-mediated transgenesis. The experimental design was planned as in previous 
experiments (Chapter 2 and 3). The results were standardised in order to ensure they 
could be compared with the values obtained in previous experiments. Human tau 
expression was controlled by the eye-specific driver GMRGAL4. Flies were raised at 
18°C and after eclosion they were aged for three days at 25°C. The human tau 
transgenes were expressed alongside a UAS-CD8::GFP reporter gene using the same 
genetic driver. The spatial and temporal control of the reporter gene overlaps with that 
of the human tau transgene. The transcript level of human 2N4R tau in each transgenic 
Drosophila line was quantified using actin, GAPDH and the transcriptional factor eIF-
4a as reference genes. The copy number of CD8::GFP was used to normalise for the 
actual number of eye cells expressing human tau. Flies carrying only the eye specific 
driver GMRGAL4 and reporter UAS-CD8::GFP were used as negative control (Figure 
5.2). The P-element transgenic Drosophila lines carry different isoforms of the human 
tau transgene which are inserted at different genomic positions. Upon tau expression, 
the transgenic fly lines produce different levels of human tau transcript. To enable a 
better comparison between the different lines, the transcript levels were expressed in 
percentage relative to the highest mean. The fly lines expressing human 2N4R tau, 
2N4R tau R406W, 0N4R tau and 0N4R tau R406W inserted in position 68A using the 
phiC31-mediated transgenesis exhibit a statistically non-significant difference in the 
levels of transgene expressed. This result is expected since the transgenes are inserted in 
the same genomic locus and the experimental conditions were equal for all lines. The 
transcript expression for human tau was measured also for a widely used fly model of 
tauopathy, originally created by Wittmann et al (2001). This fly line carries the 0N4R 
tau R406W transgene (line MF_0N4RtauR406W) inserted in a random genomic 
position and it is characterised by an increased tau-mediated toxicity in the eye 
compared to that seen in the lines created in this study (Wittmann et al, 2001). The 
qPCR result shows that line MF_0N4RtauR406W expresses a statistically significant 
higher level of human tau compared to the lines created in this study via phiC31-
mediated transgenesis. In particular, the level of tau expression for line 
MF_0N4RtauR406W is approximately the double that seen for line 0N4RtauR406W. 
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The tau transcript levels seen for lines 2N4Rtau#1 and 3 (Chapter 3) were compared to 
the tau isoforms measured here. Interestingly, line MF_0N4RtauR406W expresses the 
same level of tau transcript as line 2N4Rtau#1 expressing the 2N4R tau transgene 
inserted in genome at random. Finally, as in figure 3.5 and 3.7, line 2N4Rtau#3 is 
characterised by a level of tau transcript that is statistically much higher than the other 
Drosophila tau lines examined here. 
 
This evidence suggests that at the expression level generated by tau transgene insertions 
in 68A, Drosophila lines expressing 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R 
tau R406W show weak tau toxicity. To examine whether the different isoforms behave 
similarly at higher expression levels, the line generated by Wittmann et al (2001) was 
examined. This line has been reported to exhibit stronger tau-mediated eye degeneration 
and it is characterised by a higher level of human tau transcript compare with the lines 
generated via phiC31-mediated transgenesis. 
Figure 5.2 Variation of transcript levels of human tau in different Drosophila 
models of tauopathy. The transcript level of human tau was examined in flies 
expressing tau together with UAS-CD8::GFP using GMRGAL4. To enable comparison 
between samples, the transcript levels were expressed as relative copy number to the 
highest mean. Tau copy numbers were normalised to 3 reference genes and to 
UAS-CD8::GFP. Values correspond to the mean and SEM of 3 to 5 replicates from 
independent experiments. Asterisks indicate statistically significant differences of tau 
transcript. Control flies carrying the eye specific GMRGAL4,UAS-CD8::GFP driver show 
no human tau transcript expression. Transgenic flies carrying 2N4R tau, 2N4R tau 
R406W, 0N4R tau and 0N4R tau R406W transgenes inserted in the same genomic 
position show no significant difference in the tau transcript levels upon expression. The 
P-element inserted transgenes MF_0N4RtauR406W and 2N4Rtau#1 show the same 
high level of tau transcript levels. Transcript levels driven from 2N4Rtau#3 are 
significantly higher than that driven from all the other transgenes (p<0.001).
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To examine the interaction between the different tau isoforms and human kinases, 
transgenic flies expressing human 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R 
tau R406W were combined with human GSK3β, PKA, CK1δ and rat DYRK1A in the 
fly eye. The eye degeneration is similar in flies expressing the different tau isoforms 
alone (Figure 5.3). When human GSK3β is co-expressed with human 2N4R tau, the eye 
degeneration phenotype is enhanced compared to human tau alone (Figure 5.3A2). 
Also, the eye degeneration of flies expressing other tau isoforms with human GSK3β is 
enhanced. The disarrangement of ommatidia is increased in the anterior part of the eye 
and the characteristic oval shape of the eye is altered compared to control. The degree 
of phenotypic enhancement via human GSK3β is comparable in flies expressing human 
2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W (Figure 5.3A2, B2, C2 
and D2). As in previous experiments shown in this study, human PKA co-expression 
with 2N4R tau does not lead to an enhancement of eye degeneration (Figure 5.3A3). 
Moreover, the tau lines carrying the different tau isoforms show no enhancement in eye 
phenotype when PKA is co-expressed (Figure 5.3B3, C3 and D3). Subsequently, co-
expression of 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W together 
with human CK1δ does not affect the basal human tau-mediated eye degeneration 
caused in each line (Figure 5.3A4, B4, C4 and D4). It has been shown before in this 
study that rat DYRK1A co-expression with 2N4R tau causes a minor enhancement of 
human tau-mediated degeneration (Figure 5.3A5). Also, the tau-mediated eye 
degeneration caused by the different tau isoforms is mildly enhanced by expression of 
rat DYRK1A. The eye phenotypes are characterised by a minor enhancement of human 
tau-mediated degeneration comparable to the one seen for line 2N4Rtau#68A (Figure 
5.3, panel B5, C5 and D5). 
 
Human 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W were also tested 
in their ability to alter the possible priming interaction of GSK3β by CK1δ or 
DYRK1A. The expression of different tau isoforms and the introduction of the R406W 
mutation appears not to change the enhancement of tau-mediated degeneration in flies 
expressing GSK3β and CK1δ or DYRK1A compared to that seen in the 2N4Rtau#68A 
background (Figure 5.3A6-7, B6-7, C6-7 and D6-7).  
 
In conclusion, these results show that the human 2N4R tau, 2N4R tau R406W, 0N4R 
tau and 0N4R tau R406W have a similar interaction with human kinases in flies. 
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Neither the N-terminal domains of tau or the R406W mutations appears to mediate the 
interaction of the individual human kinases GSK3β, PKA, CK1δ, and rat DYRK1A. In 
particular, the only human kinase showing an enhancement of tau-mediated toxicity in 
all lines is GSK3β. 























A1 A2 A3 A4 A5 A6 A7
D1 D2 D3 D4 D5 D6 D7
C1 C2 C3 C4 C5 C6 C7
B1 B2 B3 B4 B5 B6 B7
Figure 5.3 Different tau isoforms expressed at similar levels cause equal eye degeneration upon human kinase expression. Light 
micrographs of eyes from 0-5 days old flies. All transgenes were expressed in the fly eye using the GMRGAL4 driver. (A1, B1, C1 and D1) 
Expression of 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W cause weak ommatidial disruption. (B2-D7) The level of 
degeneration caused when the tau isoforms are expressed with human kinases is similar to that seen for 2N4R tau (A2-A7). Scale bar: 100 
µm. Dorsal is top and anterior is left.
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5.2.2 Understanding the importance of tau expression level in 
transgenic Drosophila models of tauopathy 
 
In section 3.2.1 it has been shown that fly lines expressing a higher level of the 
transgene confer an increased tau-mediated toxicity. The ability of 2N4R tau and 0N4R 
tau R406W to induce eye degeneration was tested in fly lines with comparable 
expression of the transgenes. Lines 2N4Rtau#68A and 0N4RtauR406W express an 
equal amount of human 2N4R tau and 0N4R tau R406W respectively. In contrast, lines 
2N4Rtau#1 and MF_0N4RtauR406W express approximately double the amount of 
transcript for human tau compared with the lines above. I investigated whether the 
interaction of the different tau isoforms with the human kinases varies when they are 
expressed at different levels in the fly eye. 
 
The different tau constructs were expressed using the GMRGAL4 that drives the 
expression of the transgenes in the fly eye. Gene expression was induced throughout 
development at 25°C and flies were collected between 0 to 5 days post-eclosion. The 
eye phenotypes were examined by light microscopy (Figure 5.4). As shown above, line 
2N4Rtau#68A and line 0N4RtauR406W are characterised by a weak disarrangement of 
the ommatidial pattern, which is enhanced by co-expression of human GSK3β (Figure 
5.3A1-2 and D1-2). Line 2N4Rtau#1 expresses double the amount of 2N4R tau 
compared to line 2N4Rtau#68A. The eye phenotype caused by expression of human tau 
alone shows greater degeneration when 2N4Rtau is expressed from the insertion 
2N4Rtau#1 (Figure 5.4B1). When expression is driven from 2N4Rtau#1 together with 
the kinases the degree of enhancement is similar to that seen when expression is driven 
from 2N4Rtau#68A with the same kinases. Human GSK3β and rat DYRK1A enhances 
the tau-mediated phenotype, while PKA and CK1δ do not have any effect (Figure 
5.4B2-5). Interestingly, when co-expressed with 2N4Rtau#1, rat DYRK1A appears to 
cause a greater enhancement of eye degeneration compared to when expressed with tau 
from line 2N4Rtau#68A. In fact, after co-expression of high levels of 2N4R tau and rat 
DYRK1A the eye is characterised by the presence of several necrotic ommatidia not 
seen when driving tau from line 2N4Rtau#68A (Figure 5.4B5). In flies expressing tau 
from the transgene of line MF_0N4RtauR406W, the eye degeneration is greater 
compared to that seen for line 2N4Rtau#68A, 2N4Rtau#1 and 0N4RtauR406W (Figure 
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5.4D1). This result is similar to that seen in previous findings (Chau et al, 2006; 
Nishimura et al, 2004). Line MF_0N4RtauR406W was combined with the human 
kinases in order to see how they affect the toxicity of 0N4R tau R406W when 
expression is driven at higher levels. All kinases produced a greater enhancement of eye 
degeneration compared to that seen in previous experiments (Figure 5.4D2-7). Co-
expression of human GSK3β together with MF_0N4RtauR406W causes a severe 
enhancement of eye degeneration characterised by the presence of large patches of 
necrotic ommatidia (Figure 5.4D2). Moreover, the human kinase PKA, that did not 
cause an increase in tau toxicity with other tau fly lines, enhances the human tau-
mediated degeneration caused by MF_0N4RtauR406W in the eye. The eye is 
characterised by an extended disarrangement of ommatidia and the presence of several 
necrotic ommatidia (Figure5.4D3). However, the expression of human 
MF_0N4RtauR406W and CK1δ did not produce any enhancement of eye degeneration 
(Figure 5.4D4). Finally, rat DYRK1A strongly increased the eye degeneration caused 
by MF_0N4RtauR406W alone. In this case, the eye size is slightly reduced and large 
necrotic patches of ommatidia are present. The different tau isoforms were also tested 
for changes in toxicity when expressed with GSK3β together with CK1δ or DYRK1A. 
When human tau expression is driven at low levels in lines 2N4Rtau#68A and 
0N4RtauR406W, CK1δ or DYRK1A do not appear to have a synergistic activity on tau 
with human GSK3β (Figure 5.4A6-7, C6-7). However, when human tau is expressed at 
higher levels, a synergistic interaction might be present between human GSK3β and rat 
DYRK1A. When 2N4R tau is expressed from line 2N4Rtau#1, GSK3β and DYRK1A 
together enhance the eye degeneration phenotype as revealed by an increase of necrotic 
ommatidia and eye depigmentation (Figure 5.4B6-7). Moreover, when these two 
kinases are co-expressed in line MF_0N4RtauR406W, the eye exhibits a high number 
of necrotic ommatidia, a strong depigmentation and a reduction in size (Figure 5.4D6-
7).  
 
In conclusion, when expressed at a higher and equal level, the 0N4R tau R406W 
appears to generate more toxicity in the fly eye compared to 2N4R tau. In contrast, at 
low levels of expression 0N4R tau R406W and 2N4R tau exhibit the same weak level 
of toxicity. Interestingly, the fly lines expressing higher tau levels were both generated 
through P-element mediated transgenesis, therefore it might be possible that 
endogenous genes are affected by the insertion of the transgene and affect the eye 
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toxicity. Moreover, this evidence shows that in fly models where human tau is highly 
expressed, the interaction with human kinases results in a more evident phenotypic 
enhancement of eye degeneration. In particular, tau-mediated toxicity was enhanced by 
human kinases, which did not show an interaction with human tau at low expression 
levels. 
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Figure 5.4 0N4R tau R406W exhibits a greater toxicity than 2N4R when expressed at higher expression levels. Light micrographs of 
eyes from 0-5 days old flies. All transgenes were expressed in the fly eye using the GMRGAL4 driver. (A1-D8) Expression of different levels 
of 2N4R tau and 0N4R tau R406W cause a variation in enhancement of eye degeneration when kinases are co-expressed. 




Increased expression levels of tau isoforms reveal differences in their ability to confer 
toxicity in the fly eye. To test whether an increased amount of tau isoforms or the 
mutant forms expressed from the phiC31-mediated insertions can generate a different 
level of toxicity I increased the level of expression in the lines by doubling the copy 
number. 
 
Human 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W were driven in 
flies carrying one or two copies of the transgene in position 68A. The aim of this 
experiment is to compare the eye degeneration caused by fly line expressing low or 
increased levels of human tau to determine whether the presence of the N-terminal 
domains or the R406W mutation contribute to more toxic forms of tau. Human tau was 
expressed in the fly eye using the GMRGAL4 driver. Gene expression was induced 
throughout development at 25°C and flies were collected between 0 to 5 days post-
eclosion. The eye phenotypes were examined by light microscopy (Figure 5.5). As 
shown before, when one copy of human 2N4R tau, 2N4R tau R406W, 0N4R tau and 
0N4R tau R406W is expressed, the resulting eye phenotype is comparable. It is 
characterised by a weak disarrangement of the ommatidial pattern in the anterior part of 
the eye (Figure 5.5A-D). Subsequently, human tau expression was increased doubling 
the number of copies of transgenes present. At higher expression levels, the different tau 
isoforms cause a greater level of degeneration in the fly eye compared to the same 
isoforms expressed at lower levels. Indeed, the ommatidia disarrangement is increased 
and extends on the whole eye surface in the flies with a high tau level. Moreover, flies 
expressing the 0N4R tau and 0N4R tau R406W are characterised by a mild loss of 
tissue on the bottom anterior part of the eye (Figure 5.5E-H). However, when compared 
between each other, these transgenic lines expressing different tau isoforms generate the 
same degree of eye phenotype at high expression levels.  
 
In conclusion, human 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W 
were demonstrated to confer the same level of toxicity in the fly eye when expressed 
from a conserved site. This result is in contrast with previous studies showing a higher 
toxicity of 0N4R tau R406W compared to the wild type form in the fly eye (Nishimura 
et al, 2004; Wittmann et al, 2001). The fly models previously reported were created via 
standard P-element transgenesis allowing a random insertion of the transgene insertion 
in the fly genome. For this reason, an alteration of the degenerative phenotype due to 
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the genomic position of the transgene cannot be excluded and subtle differences in 
expression level. In this study, using the phiC31-mediated transgenesis, the toxicity of 
different tau isoforms was compared avoiding any positional effect of the transgene. 
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Figure 5.5 Tau isoforms do not exhibit a different level of toxicity when inserted in 
the same genetic background in Drosophila. Light micrographs of eyes from 0-5 days 
old flies. All transgenes were expressed in the fly eye using the GMRGAL4 driver. (A-D) 
One copy of 2N4R tau , 2N4R tau R406W, 0N4R tau and 0N4R tau R406W tau is 
expressed. (E-H) The tau-mediated eye degeneration is enhanced when the two copies 
of the transgenes are expressed. The tau isoforms do not display different levels of 
toxicity. Scale bar: 100 µm. Dorsal is top and anterior is left.
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The toxicity generated by 0N4R tau R406W appeared to be increased by human kinases 
compared to 2N4R tau expressed at the same level (Figure 5.4). Thus, I investigated 
whether the tau isoforms and their mutated forms show different phosphorylation by 
human kinases in Drosophila. 
 
In Drosophila S2 cells the interaction of human tau with human GSK3β causes a 
mobility shift of tau probably due to phosphorylation. To investigate the 
phosphorylation pattern of different tau isoforms, human GSK3β was transfected in S2 
cells together with human 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau 
R406W. Expression of human tau was driven using an inducible UAS-GAL4 system 
activated by adding copper sulphate. Full-length human GSK3β, carrying a C-terminus 
myc-tag, was expressed using an actin promoter. Protein expression occurred at 25°C. 
Expression of wild type and mutated human 2N4R tau was induced for five hours while 
human GSK3β was constitutively expressed. Expression of human tau and GSK3β was 
successfully detected by western blot (Figure 5.6A). The phospho-independent tau 
antibody recognises the total level of tau expressed. Human GSK3β was detected using 
an anti-myc antibody and its mobility appeared to be at the expected molecular weight 
(60 kDa). Actin expression was used to control for protein loading. Control cells 
carrying an empty vector show only actin expression. Due to different levels of basal 
phosphorylation by endogenous kinases, wild type and mutated human tau were 
detected on the blot as multiple bands ranging from 60 kDa to 65 kDa for 2N4R tau and 
from 55 kDa to 60 kDa for 0N4R tau. The tau isoforms carrying the R406W mutation 
exhibit a multiple band pattern similar to wild type tau. When wild type and mutated tau 
was co-transfected together with human GSK3β, the mobility of all isoforms was 
reduced (Figure 5.6A). In order to monitor the phosphorylation level of wild type and 
mutated tau, the same samples were analysed with phospho-specific antibodies for 
human tau (Figure 5.6B). The phospho-specific antibodies chosen are PHF1 (pS396 and 
pS404), AT8 (pS202 and pT205) and AT270 (pT181). Control cells carrying an empty 
vector show no phospho tau expression. Phosphorylation at the PHF1 and AT8 epitopes 
was detected only in the samples where GSK3β was co-expressed together with tau. In 
contrast, the AT270 antibody recognises a basal level of phosphorylation of human tau 
by endogenous kinases. The amount of this epitope is strongly increased only when 
GSK3β is co-expressed.  
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These results suggest that 2N4R and 0N4R tau exhibit the same phosphorylation pattern 
on T181, S202, T205, S396 and S404. Moreover, the R406W mutation does not affect 
phosphorylation by endogenous kinases or human GSK3β on 2N4R and 0N4R tau as 



































Figure 5.6 The phosphorylation pattern of GSK3β on human tau in Drosophila S2 
cells does not vary with the tau isoform expressed. After transfection, human tau, 
GSK3β and actin expression were detected on western blot of S2 cells lysates. 2N4R 
tau, 2N4R tau R406W, 0N4R, 0N4R tau R406W where co-transfected with or without 
GSK3β. Recombinant human 2N4R tau (rTau) was loaded as positive control for tau and 
S2 cells transfected with an empty vector were used as negative control. Total tau was 
detected as multiple bands (60-70 kDa) using the phospho-independent antibody Dako. 
β-actin was used as loading control (42 kDa). (A) GSK3β was detected using an 
anti-myc antibody (60 kDa). (B) Phosphorylated human tau was detected using 
phospho-specific antibodies PHF1 (pS396 and pS404), AT8 (pS202 and pT205) and 






Drosophila has been extensively used to model human tauopathies and investigate the 
interaction between human tau and endogenous fly kinases. The models have been 
created by driving expression of different tau isoforms and their mutated forms from 
sites inserted in the fly genome at random positions via P-element mediated 
transgenesis. The majority of the fly models created to date use the tau isoforms 
containing four C-terminal repeats, however some tau mutations have been shown to 
generate more toxicity. In particular, previous studies have been shown that human 
0N4R tau carrying the FTDP-17 associated R406W mutation is characterised by an 
increased toxicity compared to wild type tau in Drosophila (Nishimura et al, 2004; 
Wittmann et al, 2001). The different tau isoforms used, levels of transgene expression 
and genetic background pose several difficulties in comparing results obtained in 
different research studies using the previous fly models of tauopathy. The phiC31-
mediated transgenesis in Drosophila allows the insertion of transgenes in specific 
genomic loci (Bischof et al, 2007; Groth et al, 2004). Several transgenic Drosophila 
lines can be created carrying transgenes inserted in the same genomic position ensuring 
the same transgene expression levels and genetic background. This technique is useful 
to solve the issue related to variations of eye degeneration due to positional effect and 
expression levels of the human tau transgene. 
 
This chapter proposed to use the phiC31-mediated transgenesis system to study the 
toxicity levels of different human tau isoforms and their mutated forms in Drosophila. 
In particular, tau isoforms containing none or two N-terminal domains and all four C-
terminal repeats were tested. Moreover, the role of the FTDP-17 associated mutation 
R406W was also examined. Thus, transgenic fly lines were generated carrying human 
2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W inserted in the same 
genomic position (68A). These lines are characterised by the same genetic background 
and expression level of the transgene. When the toxicity of the tau isoforms and mutants 
was tested in the fly eye, a weak degeneration was observed in all lines. In contrast with 
the study by Wittmann et al (2001), the R406W mutation did not confer more toxicity to 
wild type tau when expressed in the fly eye. Moreover, the N-terminal domains did not 
appear to contribute to the tau-mediated degeneration either. 
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In addition, the different tau isoforms and their mutated forms were also tested for their 
ability to interact with human kinases in flies. The human kinase that confers greater 
toxicity to all tau forms is GSK3β. Human CK1δ and DYRK1A also weakly enhance 
the eye degeneration caused by tau, while PKA does not. The effect that these human 
kinases produced on the tau-mediated eye degeneration was comparable in flies 
expressing wild type and mutated human tau. Moreover, the ability of GSK3β to 
phosphorylate 2N4R tau, 2N4R tau R406W, 0N4R tau and 0N4R tau R406W was 
compared in Drosophila cell culture. The phosphorylation pattern on T181, S202, T205, 
S396 and S404 was equal in all tau isoforms and their mutant forms. Thus, the presence 
of N-terminal domains or of the R406W mutation on tau does not affect tau toxicity 
when these human kinases are also present. The effect of human kinases on tau-toxicity 
was also tested using the 0N4R tau R406W insertion line used in Wittmann et al (2001). 
In this case, human GSK3β, CK1δ, PKA and DYRK1A all cause a greater degeneration 
phenotype when combined to 0N4R tau R406W in flies. 
 
The analysis of the tau transcript level confirmed that the expression level of human tau 
in the flies created with the phiC31 system is significantly lower compared to the fly 
line used in the publication by Wittmann et al (2001). In chapter 3, many Drosophila 
lines expressing wild type human 2N4R tau were generated expressing different levels 
of the transgene. One of these fly lines (2N4Rtau#1) exhibit the same level of tau 
expression compared to the line used in the report by Wittmann et al (2001). The 
toxicity generated by 0N4R tau R406W alone and combined with human kinases was 
higher than wild type 2N4R tau in fly lines expressing the same increased amount of tau 
transcript. This chapter shows that the N-terminal domains and the R406W mutation do 
not contribute to generate tau-toxicity in flies when tau is expressed at low levels. In 
contrast, at higher levels of expression, the absence of N-terminal domains and the 
presence of the R406W mutation on tau were shown to produce more toxicity than wild 
type tau containing two N-terminal domains. The reason for this difference might be 
related to the expression level of the transgene. A minimum level of transgene 
expression might be needed in order for changes in toxicity to be identified. In addition, 
the transcript analysis also revealed that the fly lines created via phiC31-mediated 
transgenesis express approximately half of the tau transcript expressed by the R406W 
created by Wittmann et al (2001). When the transgene level was increased by 
expressing two copies of the tau gene, the degenerative phenotype observed in the eye 
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was enhanced compared to when tau was in single copy. However, also using these 
conditions, the R406W mutation did not appear to confer an increased toxicity 
compared to wild type tau. Interestingly, the R406W mutation on tau in FTDP-17 
patients leads to a late onset and long duration of the disease compared to patients that 
carry other mutations (Rademakers et al, 2003). On the basis of this observation, a 
Drosophila model of FTDP-17 carrying the R406W mutation might be expected to 
present a low level of tau toxicity and increased viability compared to flies expressing 
wild type tau. 
 
In conclusion, using the phiC31-mediated transgenesis it is possible to generate 
Drosophila lines carrying transgenes inserted in the same genomic position. One of the 
major advantages of this system is the equal genetic background of the transgenic flies 
created and the absence of positional effects of the insertion on toxicity. When 
comparing transgenic fly lines generated via phiC31-mediated transgenesis, the only 
difference is in the transgenic insertion carried in the genome. Although the phiC31-
mediated transgenesis allows a reproducible method of transgene insertion in 
Drosophila, the expression level of the transgene is low compared to flies generated via 
P-element mediated transgenesis. Using this system, the FTDP-relevant mutation 
R406W on tau was demonstrated to confer a similar level of toxicity as wild-type tau in 
the fly eye. These findings are in contrast with previous studies and the reason for this 
discrepancy may lie on the different methods used to produce the transgenic fly models. 
The fly line generated by Wittmann et al (2001) might present an increased tau-
mediated toxicity because of positional effects caused by the random insertion of the 












Tauopathies are a collection of neurodegenerative diseases that include Alzheimer’s 
disease, FTDP-17, Pick’s disease, PSP and CBD. AD is the common type of senile 
dementia whose symptoms include decline in memory, confusion, disorientation, 
impaired communication and loss of motor function (Walsh and Selkoe, 2004). The 
other disorders are grouped in the FTLDs-tau because of a progressive degeneration 
affecting mainly the frontal and temporal lobes of the brain. Typical symptoms include 
changes in personality and behaviour as well as difficulty with language (Josephs et al, 
2011; Neary et al, 1998). The main pathological feature that contributes to the 
neurodegenerative process in tauopathies is the formation of tau aggregates containing 
high levels of hyperphosphorylated tau (Alonso et al, 2001; Ballatore et al, 2007; 
Lauckner et al, 2003). Indeed, the normal physiological role of phosphorylation 
regulating tau function may be disrupted during disease by a series of aberrant 
phosphorylation events. This contributes to the formation of tau aggregates precipitating 
in neurons and leading to toxicity (Alonso et al, 2001; Ballatore et al, 2007; Lauckner et 
al, 2003). Tau aggregation reduces the normal microtubule-binding activity of tau 
resulting in the depolymerisation of microtubules (Amniai et al, 2009; Ballatore et al, 
2007; Iqbal et al, 2009). The destruction of the microtubule network affects axonal 
transport and synaptic integrity (Morfini et al, 2009; Terry et al, 1991). These 
alterations, together with the impairment of cellular functions due to the formation of 
insoluble tau aggregates, lead to cell death (Ballatore et al, 2007; Iqbal et al, 2009). 
 
The human kinases responsible for tau hyperphosphorylation in vivo have not been fully 
identified yet and little is known about their individual importance to tau 
phosphorylation during tauopathies. It is still debated whether the pathological tau 
kinases correspond to those that normally regulate the physiological function of tau or 
whether new kinases participate to generate the aberrant tau phosphorylation in disease. 
When identified, the pathological tau kinases can be used as targets for therapies to slow 
the degenerative process during disease. Reducing tau phosphorylation through 
inhibition of specific protein kinases is a promising approach to reduce tau aggregation 
and associated neuronal loss (Lau et al, 2002). 
 
My thesis aimed to establish a Drosophila model of tauopathy in order to monitor tau 
toxicity and to identify the most pathogenic tau kinases. Drosophila is a widely used 
animal model to study tauopathies as it shows key features of the human disorders 
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including human tau-driven neurotoxicity. Previous work has investigated the 
interaction of human tau with endogenous Drosophila kinases (Jackson et al, 2002; 
Khurana et al, 2010; Shulman & Feany, 2003; Steinhilb et al, 2007a; Steinhilb et al, 
2007b; Wittmann et al, 2001). Importantly and in contrast with previous studies, the 
model created here allows the study of the contribution of individual human kinases and 
their phosphorylation sites to human tau toxicity in Drosophila. I believe this approach 
is more disease relevant since the transgenic fly model is used to study the interaction 
between human proteins in contrast with studies where human tau and endogenous 
Drosophila kinases were used. Moreover, human kinases may confer toxic 
phosphorylation sites in human tau that are not targeted by endogenous kinases. 
Therefore, this system can reveal additional phosphorylation sites on tau that confer 
greater toxicity when human kinases are expressed. 
 
 
6.1 Transgenesis methods to establish Drosophila models of 
tauopathy 
 
Another aspect that diversifies the Drosophila model created in this thesis with those 
previously used concerns the method of transgenesis used to generate the transgenic fly 
lines. Previous fly models of tauopathy were created using standard P-element mediated 
transgenesis that allows the integration of the transgene in random chromosomal sites of 
the Drosophila genome (Rubin & Spradling, 1982; Spradling & Rubin, 1982). This 
method leads to the generation of transgenic fly lines characterised by different genetic 
backgrounds and by a variable expression level of the transgene that cannot be 
reproduced. This feature poses difficulties when comparing the toxicity of different tau 
constructs since the phenotype can be significantly affected by the site of P-element 
insertion. In this thesis I investigated the level of human tau toxicity in several fly lines 
produced with this method of transgenesis. I found that the same 2N4R tau transgene 
inserted in different chromosomal sites can be expressed at significantly different levels 
and ultimately lead to variations in phenotype intensity in the Drosophila eye. The 
human tau-mediated toxicity corresponds to the level of transcription expression of the 
human transgene. In conclusion, the genomic position of the transgene has a strong 
influence on the intensity of phenotype produced since it affects its transcription levels 
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in Drosophila. When investigating the phenotypic effects of constructs carrying 
different tau isoforms or mutated forms of those, it is ideal to standardise the transgene 
expression level and the genetic background of the fly models created to allow a better 
comparison. For this reason a novel method of transgenesis, the phiC31-mediated 
transgenesis, was used in this thesis to allow the integration of transgenes in specific 
and reproducible genomic loci (Bischof et al, 2007; Groth et al, 2004). In this way, the 
Drosophila lines created here carry the human transgenes inserted in the same genomic 
locus and so have the same genetic background and a reproducible expression level. 
The phiC31 system overcomes the phenotypic variations due to positional effect of the 
transgenes, thus the resulting phenotype is affected only by the type of transgene 
inserted. 
 
The Drosophila lines expressing human 2N4R tau produced a degenerative phenotype 
in the eye as previously demonstrated (Jackson et al, 2002; Nishimura et al, 2004; 
Wittmann et al, 2001). Unexpectedly, the lines created using the phiC31-mediated 
transgenesis exhibited a weak eye phenotype and a lower transgene expression 
compared to the lines created using the P-element mediated transgenesis. One of the 
reasons for the weaker expression could be related to the chromosomal sites of 
transgene insertion chosen for the phiC31-mediated system. The fly lines available for 
site-specific transgenesis have the attP attachment sites located in non-coding genomic 
positions that might be refractory to high levels of transcription due to repressive effect 
of the surrounding chromatin (Groth et al, 2004; Markstein et al, 2008). It has been 
shown that the positional effect can also cause a large variation in level of transgene 
expression from tissue to tissue. In light of this, I chose a site of insertion that has been 
characterised by high expression levels in the CNS (Markstein et al, 2008). The lower 
level of expression was unexpected but allowed the opportunity to identify factors that 
could increase the level of degeneration. 
 
It would be useful to improve the Drosophila model of tauopathy created here using the 
phiC31-mediated transgenesis and increasing the expression level of the transgene and 
therefore the phenotype generated. One possible remedy would be to engineer the 
transgenes to include insulators, stretches of DNA that block the effects of neighbouring 
enhancers and silencers of transcription as well as encroaching heterochromatin 
(Gaszner & Felsenfeld, 2006). Recently Markstein et al (2008) found that in transgenic 
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Drosophila the insertion of a gypsy retrovirus insulator flanking the transgene increases 
the transcriptional activity of many attP sites using the GAL4 system. With this 
technique, the expression of human tau in the model presented here could be expressed 
at high levels and produce a greater phenotype in the eye. 
 
 
6.2 Human GSK3β enhances tau toxicity in Drosophila via 
site-specific phosphorylation 
 
My thesis aimed to establish a Drosophila model of tauopathy and to identify the 
human kinases that produce toxic forms of tau. An advantage of using a fly line 
expressing human tau with an initial low level of degeneration is the possibility that 
identification of enhancers of the tau-mediated toxicity could be easier. In contrast with 
previous studies in flies, human kinases were tested for their ability to enhance the 
human tau toxicity generated in the transgenic phiC31 Drosophila lines. Selected 
human kinases relevant to tau pathology were studied, including GSK3β, PKA, CK1δ 
and DYRK1A. Human GSK3β was found to generate the strongest enhancement of 
human tau toxicity, while the results for the other kinases did not lead to significant 
conclusions. This observation is confirmed by previous findings showing that GSK3β is 
thought to be one of the major pathogenic tau kinases involved during disease (Hanger 
et al, 1992; Lovestone et al, 1994a; Lucas et al, 2001). 
 
The toxicity of human tau in flies can be enhanced by endogenous Drosophila kinase 
activity, which causes an increased phosphorylation of tau and alters its solubility 
properties (Chau et al, 2006; Jackson et al, 2002; Shulman & Feany, 2003). However, it 
has been shown that human tau-mediated neurodegeneration in flies occurs without 
neurofibrillary tangles characteristic of AD, but with the formation of insoluble pre-
tangle tau aggregates (Chatterjee et al, 2009; Jackson et al, 2002; Wittmann et al, 2001). 
The human 2N4R tau expressed in the phiC31 fly line created in this study was found in 
the soluble and insoluble form probably due to phosphorylation by endogenous kinases 
on human tau as previously shown (Chatterjee et al, 2009; Chau et al, 2006). However, 
no correlation was found between the solubility levels of human tau and the degree of 
toxicity in the eye. Moreover, the additional activity of GSK3β did not alter tau 
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solubility although it enhanced its toxicity in the fly eye. An important observation from 
my thesis is that a change in tau solubility is not needed to increase its toxicity in flies. 
This result suggests that GSK3β might enhance tau toxicity via phosphorylation of 
specific sites that are not usually phosphorylated by endogenous fly kinases. It is 
possible the activity of multiple kinases could be required in order to alter tau solubility 
leading to the formation of the insoluble and aggregated tau forms found during human 
disease. 
 
Since human GSK3β is found to enhance tau toxicity beyond the level achieved by 
endogenous kinases, this thesis attempted to identify whether single sites targeted by 
human GSK3β are responsible for the increased toxicity. I found that phosphorylation 
of tau on S396 and S404 is consistently increased by human GSK3β in Drosophila cell 
culture and in the eye compared to other epitopes. The increase in phosphorylation of 
these sites was of about 40 fold in the soluble fraction and about 20 fold in the insoluble 
fraction of tau extracted from fly eyes. Moreover, phosphorylation of T181 was found 
to be moderately increased by GSK3β, however it is also a substrate for endogenous 
kinases as well. Despite previous studies suggesting that no single phosphorylation 
residue seem to play a dominant role in controlling human tau mediated degeneration 
via phosphorylation by endogenous kinases, this thesis suggests that it is possible to 
identify a single site that contributes to tau toxicity mediated by a human kinase 
(Steinhilb et al, 2007a; Steinhilb et al, 2007b). In conclusion, S396, S404 and T181 
appear to be key sites to be targeted by GSK3β phosphorylation and they might be 
involved in generating more toxic forms of human tau in the fly eye. 
 
Further investigations would be needed to test the toxicity generated by human tau and 
GSK3β in Drosophila under conditions that more resemble human pathology. With the 
development of more sophisticated genetic tools for temporal control of gene 
expression, Drosophila is rapidly becoming a useful model organism for aging studies. 
For example, using the temperature-sensitive inhibitor of GAL4, GAL80TS, transgene 
expression could be initiated only during adulthood in the fly eye to investigate the 
degeneration of photoreceptor neurons. In this thesis it was already shown that 
expression of human tau only during adulthood does not lead to neurodegeneration in 
the eye. However, it would be useful to investigate whether the increased tau toxicity 
generated by GSK3β could result in the degeneration of differentiated neurons in the 
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eye. In addition, to confirm the interaction between human tau and GSK3β in flies, the 
effect of the expression of these transgenes should be tested in another cell type, for 
example in motor neurons. The toxicity of tau can be assessed by using a climbing 
assay that measures the locomotor ability of flies. The loss of motor neuron function 
leads to a decline in climbing activity. Novel approaches have been recently developed 
to allow a quantitative description of fly trajectories (Kohlhoff et al, 2011). This assay 
could be utilised to see whether human GSK3β affects the motor neuron function and 
the climbing ability of aged flies expressing human tau. Finally, as firstly attempted in 
this study, mass spectrometry could be used to map each phosphorylated site produced 
by GSK3β on tau. This could help to clarify the role that specific phosphorylation sites 
play in generating tau toxicity during disease. 
 
 
6.3 Mutation of S404 contributes to human tau toxicity in 
Drosophila 
 
Phosphorylation of tau is highly complex with currently 45 identified phosphorylated 
residues and little information on the importance of each to tau toxicity (Hanger et al, 
2007). The role of aberrant phosphorylation at SP/TP sites on human tau by Drosophila 
kinases has been proved to play a critical role in tau neurotoxicity in flies causing the 
protein to alter its physiological function and become toxic (Chatterjee et al, 2009; Chau 
et al, 2006; Jackson et al, 2002; Steinhilb et al, 2007b). The tau toxicity generated by 
endogenous kinases has been modulated using mutated forms of the tau gene that 
inhibit phosphorylation of single sites (Steinhilb et al, 2007a). These studies have 
shown that only the loss of all SP/TP phosphorylation sites on tau can block the toxicity 
produced by endogenous fly kinases. It has not been possible to identify the importance 
of individual phosphorylation sites to confer tau toxicity. Moreover, the transgenic 
Drosophila lines generated for this purpose have been using P-element mediated 
transgenesis. To overcome the variability of phenotype and of expression level of the 
transgene from P-element insertions, I created a model of tauopathy where the transgene 
insertion can be reproduced ensuring a standardised genetic background and expression 
level of the transgene. Using the phiC31 method, this thesis shows that S404 is an 
important site to mediate toxicity via human GSK3β in the fly eye. In particular, GSK3β 
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was able to generate greater eye degeneration when S404 was mutated compared to 
wild type tau. These results suggest that mutation of S404 increase tau toxicity possibly 
through inhibiting phosphorylation or through a conformational change that alters the 
ability of GSK3β to phosphorylate tau. 
 
Based on these observations, I propose a model where a tight regulation of the 
phosphorylation and dephosphorylation events on S404 of human tau might be required 
to maintain the physiological function of tau. An increase in phosphorylation of S404 
by human GSK3β was shown to correlate with an increase in tau-mediated toxicity. 
Indeed, increased phosphorylation of S404 has consistently been found in 
neurofibrillary tangles from AD brains and in vitro evidence shows that it is primarily 
responsible for the loss of tau-mediated tubulin polymerisation, suggesting a possible 
role in initiating the destabilisation of microtubules (Evans et al, 2000; Goedert et al, 
1994; Kiris et al, 2011). This evidence supports the hypothesis that the detachment of 
human tau from microtubules due to phosphorylation by human GSK3β causes toxicity 
in the fly eye. At the same time, this thesis found that mutating S404 in a non-
phosphorylatable form also increased the toxicity mediated by human GSK3β on wild 
type tau in flies. S404 dephosphorylation has been shown to result in the inhibition of 
anterograde transport in vitro (Tatebayashi et al, 2004). Moreover, in agreement with 
my study, mutation of S404 on human tau expressed in Drosophila has also been found 
to lead to increased toxicity upon shaggy expression. This increase toxicity could be due 
to a pathogenic detachment of human tau from microtubules which altered the 
regulation of their assembly leading to increased toxicity (Chatterjee et al, 2009). 
 
Further experiments would be needed to investigate whether mutation of S404 in human 
tau leads to increased toxicity through conformational changes of tau or through toxic 
effects on the regulation of phosphorylation causing changes in the dynamics of 
microtubule assembly. The microtubule-binding activity of the mutated form of human 
tau could be studied in vitro on tau extracted from flies. The amount of tau bound to 
microtubules would be quantified by western blot as previously done (Chatterjee et al, 
2009). Moreover, another approach could focus on investigating the consequences of 
the mutation on vesicle transport that relies on a strong network of microtubules. This 
could be performed in Drosophila as the translucent appearance of the larvae allows the 
transport of vesicles to be visualised in living animals. Using this technique, it would be 
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possible to see whether the mutation of the S404 residue affects the microtubule 
stability and therefore the vesicle transport in flies. 
 
 
6.4 The N-terminal domains and the R406W mutation do not 
alter human tau-mediated degeneration in Drosophila 
 
Tau exists in a number of isoforms and different mutated forms are associated with 
disease. Previous investigations studying human tau toxicity in Drosophila have used 
various tau isoforms and mutated forms of those. As explained above, the fly models of 
tauopathy established to date have been created using P-element mediated transgenesis. 
The use of different tau isoforms and the positional effect of the transgenes cause 
difficulties in the comparison between the different fly models. For this reason I 
exploited the phiC31-mediated transgenesis to generate Drosophila lines expressing 
different forms of the tau gene at the same level from the same genetic background. In 
contrast with previous studies, here I show that the FDTP-17 associated mutation 
R406W confers a similar level of toxicity as wild-type tau at low and high expression 
levels in the fly eye. Whereas, human 0N4R tau carrying the R406W mutation was 
demonstrated to be more toxic compared to wild type tau at higher expression levels in 
Drosophila (Nishimura et al, 2004; Wittmann et al, 2001). In previous work the 
positional effects caused by the random insertion of the R406W tau transgene in the fly 
genome are unknown, but they might affect the resulting phenotype. Using the site-
specific method of insertion, the transgene expression level is lower and the genetic 
background of the fly lines is controlled. I found that the toxicity generated by the 
presence of none or two N-terminal domains was demonstrated to be very similar in fly 
lines generated using the phiC31-specific method of transgenesis. The fly models 
generated in this study suggest that the R406W mutation and the N-terminal domains do 
not appear to contribute to the tau-mediated degeneration in flies. 
 
However, I found that the toxicity of the tau forms combined with the human kinases 
was shown to be different when tau was expressed at low and high levels in different 
genetic backgrounds. At low expression levels using the phiC31 lines, the kinase that 
confers greater toxicity to the all tau forms tested is human GSK3β. At higher 
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expression levels using the fly lines made with standard methods, many human kinases 
had a greater effect on the toxicity generated by 0N4R tau R406W rather then by the 
2N4R isoform expressed at an equal level. The N-terminal domains and the R406W 
mutation do not contribute to generate tau-toxicity in flies when tau is expressed at low 
levels with or without human kinases. In contrast, at higher levels of expression, the 
absence of N-terminal domains and the presence of the R406W mutation on tau are 
more toxic than wild type tau containing two N-terminal domains in conferring toxicity 
with and without human kinases. It is possible that a considerably high level of 
transgene expression is needed in order for changes in toxicity to be identified. Once 
again these results show the importance of the expression level of the transgene the 
genetic background of the transgenic flies to be able to identify changes in toxicity of 
different tau isoforms. 
 
As suggested above it would be useful to expand this study in an attempt to increase the 
transgene expression in flies created with the phiC31-mediated transgenesis. The 
introduction of insulators in the site of transgene insertion would possibly improve the 
system leading to a greater level of expression of tau and phenotype generated 
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